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An Investigation of the Response of Irish Food Firms to the 
Technological D iscontinuity Caused by the Emergence of N ew  
Biotechnological Techniques.
Clare Kavanagh.
Abstract.
N ew  biotechnological techniques have been identified as a factor 
determ ining the fu ture  success of industries as d iverse as healthcare 
and  agriculture. They have the potential to revolutionise p rim ary  food 
production  and food processing activities. The p rim ary  objective of this 
research w as to investigate the response of the Irish  food industry  to 
the technological discontinuity  caused by the em ergence of new  
biotechnological techniques.
A three phase m ethodology was developed to achieve this objective. 
Phase one involved exploratory research of expert opin ion  to assist the 
developm ent of a research design specifically tailored to the unique 
features of the Irish  food industry  in  the context of the applications of 
new  biotechnological techniques. The second phase involved 
extensive p rim ary  research of identified potential early adopters of new  
biotechnological techniques. Pivotal response factors investigated  were: 
firms' technological capacity to apply the techniques, strategies used  for 
involvem ent in  R&D and attitudes to the em ergence of the techniques. 
In  phase three food firm s' response to the technological d iscontinuity  
caused by the em ergence of new  biotechnological techniques w as 
inferred th rough  an appreciation of their perform ance w ith  regard  to 
the three factors exam ined in  unison. In  addition, a scoring system  w as 
developed that allows quantification of firm s' responses to one of the 
topics at issue, technological capacity. The scoring system  also allows 
com parison w ith  in ternational findings.
Findings indicated  responses w ere twofold. M ost firm s w ere non- 
responsive to the em ergence of new  biotechnological techniques or 
w ere involved in a m onitoring strategy only. The sole group for w hich  
possible fu ture direct use w as indicated  w ere h igh  value low volum e 
ingredient supply  firms.
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Introduction.
"In recent years scientific advances have transform ed th a t group of 
technologies referred to as biotechnology into a set of increasingly 
pow erfu l tools for m any industries. Biotechnology is identified by 
m any  as an  im portan t factor determ ining the fu tu re  success of
industries as diverse as healthcare and  agriculture"1 W ith reference to 
developm ents overseas this study  aims to investigate the response of 
the Irish  food and  drink  industry  to this new  technological paradigm . 
The s tudy  is based in  the food and  drink  industry  (henceforth food 
industry) for tw o reasons:
1. The food industry  is of significant strategic im portance to Irish 
econom ic life.
2. N ew  biotechnological techniques have the potential to im prove bo th  
p rim ary  food production  and  food processing activities. To illustrate: 
Use of new  biotechnological techniques can p rov ide  im proved  crop 
varieties and  also aid in  their processing.
The s tudy  is of a p ioneering nature as little is know n of Irish  food 
firm s' response to the technological d iscontinuity  caused by the 
em ergence of new  biotechnological techniques. A reas identified  as 
im p o rtan t for investigation of Irish food firm s' response to the 
techniques are:
1. G eneral patterns of adop tion  and  diffusion no ted  w ith  new  
technologies in  general and  in  particu lar patterns of adop tion  and  
diffusion  no ted  w ith  new  biotechnoogical techniques in  other 
industria l sectors and  countries.
2. Characteristics of the techniques and  their po ten tia l specific to the 
food industry .
3. The im pact of public perception  issues.
4. The existing Irish food industry  and  in  particular the p a rt new  
biotechnological techniques m ight p lay  in  this sector's strategies for 
fu tu re  developm ent.
1
References.
1. Ui Ghallachoir K. and K avanagh C. (1993), "Biotechnology-Beauty or 
Beast," Irish Marketing Review , vol.6, p p .70-77.
2
Chapter 1 N ew  Technology Adoption and D iffusion  in Industry.
1.0 Introduction.
Technology and the innovative process have been  identified  as 
im portan t determ inants of economic success. It is assum ed that 
technological leads and  lags are major determ inants of the relative
efficiencies, com petitiveness and incomes of firm s and  countries.1 The 
em ergence of new  industria l technologies can have significant 
im plications for ind iv idual firms and  indeed  entire industria l sectors. 
Schum pter has term ed radical technological change as a "force of 
creative destruction" because the em ergence of revo lu tionary  new  
technologies can destroy com panies using existing ou tda ted  
technologies w hile concom itantly breath ing  life in to  new  com panies 
based  on em erging technologies.2
In recent years the unprecedented  instability caused by the em ergence 
of rap id ly  changing technologies in  the env ironm ent has afforded 
technology m anagem ent a new  im portance in industria l life. In  1981 
Booz, A llen and H am ilton  show ed that m ost senior executives 
expected their organisations fu ture grow th  and profits to come largely 
from  new  technology based  products.3 Also, of the 43 com panies w hich 
Peters and  W aterm an, jr. judged  to be excellent in  "In Search of 
Excellence", alm ost half w ere classified as "high technology" or as
containing a substantial h igh  technology com ponent.4 It w ou ld  seem 
thus that in the w ords of C apon and Glazer,
"the avoidance of technological risk today m ay lead to 
considerable m arket risk tom orrow "5
In this chapter the focus of the literature accessed is h igh  technology 
innovation, adoption  and  diffusion in  the industria l sector. The w ork  
is organised as follows: The first section is concerned w ith  theories
3
relating  to industria l innovation, adoption  and  d iffusion  in  general. 
P resen tation  is m ade of: A lternative conceptualisations of the nature  
of and  the procedures associated w ith  technological change, a detailed 
analysis of the agents of technical change and  the processes of diffusion 
associated w ith  new  technologies adopted  in  an  industria l sector. The 
next section explores patterns of adoption  and diffusion specifically 
associated w ith  the technological discontinuity  caused by the 
em ergence of new  biotechnological techniques.
1.1 Technology and K now ledge
In advance of m aking a detailed review  of the natu re  and  evolution of 
h igh  technologies it is necessary to d istinguish  technology from  science 
or the general notion of know ledge. C apon and G lazer defined 
technology as a subset of know ledge and  is unlike all know ledge in  
th a t it is in tended for use. They proposed that technology could be 
defined broadly  as "know-how", or m ore specifically w ith  respect to a 
firm  as the inform ation required  to produce a n d /o r  sell a p roduct or
service.6 A m ore im pressionistic definition is offered by  Dosi w ho 
defines technology as a set of pieces of know ledge,{both directly 
"practical" (related to concrete problem s and devices) and  
"theoretical"(but practically applicable a lthough  no t necessarily already 
applied)}, know  how , m ethods, procedures, experience of successes and  
failures and  also, of course physical devices and  equipm ent.7
Technology as described by  these definitions is m uch  less well 
articulated than  is scientific know ledge; m uch of it is no t w ritten  dow n  
and  is im plicit in  experience, skills, etc. As the industria lised  w orld  has 
been  shifting from  a labour and  capital intensive to a know ledge or 
inform ation based  econom y it now  seem s reasonable to regard  
know ledge as a p rim ary  com m odity and  know ledge capitalised as
4
know -how  or technology as an asset for m ost firm s.8
1.1.1 Technological Change.
As noted  the relationship betw een econom ic g row th  and change on 
the one hand  and technical progress on  the other is a rather evident 
and  w ell recognised fact in  economic thought. The nature  of the 
relationship  betw een the two, how ever, has been  a m uch m ore 
controversial issue of economic theory. The theoretical problem  
concerns the direction of the causal relationship. In  general, theories 
of technical change have been  classified into tw o m ain  categories, 
nam ely  'technology push ' and 'dem and puli'. D ifficulties are 
associated w ith  extrem e forms of both  theories. In terpretations based 
o n  'dem and puli' theories present a ra ther crude conception of 
technical change, as an essentially reactive m echanism  based on a 
'black-box' of readily available technological possibilities. On the other 
hand , extrem e forms of 'technology push ' approaches, allow ing for a 
one-w ay causal determ ination  (from science to technology to the 
econom y) fail to take in to  account the in tu itive im portance of
econom ic factors in  shaping the direction of technical change.9
A lternative conceptualisations of the process of technical change seek 
to  avoid these difficulties. A rrow  in  1962 conceptualised technology as 
inform ation  about the m ethods of p roduction  of any  one good. As 
such  technology, like inform ation, is a durable public good. In this 
context the rate of innovation in any industry  can be analysed as the 
equilibrium  outcom e of a race for the  acquisition of valuable 
in form ation  am ong profit m axim ising com peting agents. The p rim ary  
failing of this conceptualisation is th a t technology, far from  being a 
public good, also involves im portan t private aspects w hich are related 
no t only to the protection provided  by  patents and  secrecy b u t also to its
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tacit and  specific nature. A lthough some portions of technological 
know ledge m ay be available in universities and  research institutes, 
technology also depends on  the developm ent of the internal, specific
and tacit capabilities of any one company. 10
Dosi on the other hand  proposed an in terp re ta tion  of technological 
change using technological paradigm s and technological trajectories. 
U sing Dosi's m odel it is proposed that the procedures and the nature of 
technologies are broadly  similar to those w hich characterise science. In  
particu lar it is proposed  th a t 'technological parad igm s' or research 
program s perform  a sim ilar role to 'scientific parad igm s' or research 
program s. A technological paradigm  is defined by Dosi as a,
"...model or pa tte rn  of solution of selected technological 
problem s based on  selected principles derived  from  natural 
sciences and on  selected m aterial technologies".11
In o ther w ords a technological parad igm  em bodies strong prescriptions 
on  the directions of technical change to pursue and  those to neglect. A 
technological trajectory is defined as the p a tte rn  of 'norm al' problem  
solving activity on the grounds of a technological paradigm . Thus, 
continuous changes are related to progress along a technological 
trajectory defined by a technological paradigm , w hile discontinuities 
are associated w ith  the em ergence of a new  paradigm .
Technological discontinuities are also discussed by  Richard Foster in 
'Innovation - the A ttackers A dvantage.'12 Foster recom m ends 
graphical representation  of progress along a technological trajectory 
defined by a technological paradigm  to aid m anagem ent of the R&D 
function. He calls these graphs 'S Curves'. (Figure 1.0)
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Figure 1.0 The S Curve
Effort (funds)
Source: Foster R. (1986), Innovation-the Attackers Advantage,
M acm illan Ltd., London.p.31.
They show ,
"...the relationship  betw een the effort p u t in to  im proving a 
p roduct or process and  the results one gets back for that 
in v es tm en t" .13
If a technological parad igm  is conceptualised as an  S Curve it is easy to 
track progress along a trajectory defined by  that paradigm . As Foster 
explains;
"...initially as funds are p u t in to  developing  a new  product or 
process progress is very  slow. Then all hell breaks loose as the 
key know ledge necessary to m ake advances is p u t in  place. 
Finally, as m ore dollars are p u t in to  the developm ent of a 
p roduct or process, it becom es m ore and  m ore difficult and 
expensive to m ake technical progress. Ships don 't sail m uch 
faster, cash registers don 't w ork  m uch better and  clothes don 't 
get m uch cleaner. A nd that is because of the lim its of the S 
C urve ."14
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These limits are w hat lead to the developm ent of a new  S Curve or a 
new  paradigm . W hile one com petitor is nearing  it's lim its on an  S 
Curve (technological paradigm ) another perhaps less experienced is 
exploring alternative technologies w ith  h igher lim its. There is a break 
betw een S Curves and a new  one begins to form , no t from  the same 
know ledge th a t underlays the old one b u t from  an  entirely new  and 
different know ledge base. One technology replaces another. It is for 
this reason tha t S Curves in  periods of technological change or 
discontinuity occur in  pairs. (Figure 1.1)
Figure 1.1 S Curves and  Technological D iscon tinu ities
Effort (funds)
Source: Foster R. (1986), Innovation-the Attackers Advantage,
M acm illan Ltd., London.p.102.
Examples of technological discontinuities offered by  Foster include the 
follow ing,
"...the sw itch from  propeller d riven  planes to jets, the sw itch 
from  n atu ra l to synthetic detergents or fibers, the sw itch from  
cloth to paper diapers, the sw itch from  records to tapes to 
com pact disks..."15
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The em ergence of new  biotechnological techniques w hich are the focus 
of this study  have also caused a technological discontinuity. Use of 
these techniques w ill transform  the m anner in  w hich scientists 
p roduce p lan t and  anim al species, the pharm aceutical in d u stry  and 
m any other industries. They represent a new  technological parad igm , 
a new  S Curve and  a unique challenge to firm s involved w ith  their 
use.
1.1.2 Agents of Technical Change.
A gents of technical change m ust be concerned w ith  their 'technological 
capacity'. The term  'technological capacity' is used  to describe a 
num ber of different aspects of technology necessary to effect technical
change.16 The p a tte rn  of technical change outlined in  Figure 1.2 show s 
clearly the prim acy of technological capacity as a determ inant of 
technical change. Effective agents of technical change need to possess 
strong technological capacity. This poin t w as highlighted by the report 
of Central A dvisory Council for Science and  Technology as far back as 
1968 w hen  they stated,
"any firm  or indeed any country engaged in  w orld  trade  in 
advanced industria l products m ust repeatedly  m odernise its 
m anufacturing  processes and  introduce new  or u p d a ted  
products if it is not to lose m arkets and  go ou t of business 
because of com petition from  advances elsew here. H ence the 
constant need  for m arket aw areness and  for technological 
in n o v a tio n ."17
Figure 1.3 show s the resources associated w ith  the average p ro d u ct life 
over tim e and  identifies the key technological functions th a t relate to 
the indiv idual stages in  this cycle. Key functions such as R&D and 
process technology are often used  as a m easure of the technological 
capacity of ind iv idual firms and a m edium  to h igh  level of com petence
in  each is needed for com petitive su c c e ss .18
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Figure 1.2 Pattern of Technical Change.
Innovation
A '
Producing -----------  and ----------- ^  Technical
Activ ities T rain ing Services
Source: C otter A. (1979), Science and Technology in the Irish Food 
Processing Industry, NBST, Dublin, p .32.
O n a nation-w ide scale Schmookler asserts that the rate of g row th  of a 
country's technological capacity sets w h at is probably the m ost 
im portan t ceiling on a nation 's longterm  rate  of economic grow th. 
A ccording to Schmookler the rate of g row th  of technological capacity is 
jointly determ ined  by the rate of technological progress w hich  is the 
p roduction  of new  know ledge and  the rate of replication, w hich  is the
Imitation
Technical Change
A
♦
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rate at w hich the existing technology is d issem inated.19
The purpose of increasing a nation's technological capacity thus is 
clearly to increase the potential for technological change. Activities 
w hich increase the rate of technological progress and  the rate of 
replication (the determ inants of technological capacity) are research 
and  developm ent, education and  training and general technical 
specialist services.
Figure 1.3 Product Lifecycle and Technology focus.
Source: O hm ae K. (1982), The M ind of the Srategist - Business 
Planning for Competitive Advantage. M cG raw H ill, England, p .115.
In 1959 C arter and  W illiams developed a classification for firm s 
according to  the degree of technical progressiveness attained  by  them . 
These were:
1. Those w hich  are in the forefront of discovery in  applied  science and 
technology, quick to m aster new  ideas and  to perceive the relevance of 
w ork  in  neighbouring  fields.
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2. Those w hich are quite unin terested  in  science and  technology and 
are perfectly content to continue w ith  trad itional m ethods w ithou t 
even  exam ining alternatives.
3. A large m iddle group, neither ou tstand ing  leaders in  technology nor
w holly  unin terested  in it.20 It m ay be assum ed that those firms 
com m anding significant technological capacity to effect technical 
change w ould  be represented  in  the first group of the W illiams and  
C arter classification.
1.1.3 Industrial D iffusion of N ew  Technologies.
Innovation  occurs w ith  the in troduction  by the first enterprise of a 
given technical change and  im itation  w h en  other enterprises follow
suit, bo th  factors jointly determ ining the rate of technical change.21 
T ushm an and A nderson  have show n that com petitive conditions after 
a technological b reak through  are often sharply  different from  those 
th a t prevailed  before the discontinuity. They poin ted  ou t that dram atic 
shifts in  industry  structures and com petitive positions can follow as 
the traditional advantages of established firms are eroded under 
revised com petition rules. O ther characteristics of a m arketplace 
follow ing a technological b reak th rough  are increased levels of 
technical and  m arket uncertainty, changed term s and  sources of 
com petition and new  strategic choices and  options available.22
In this section discussion is focussed u p o n  the im itative process w hich  
results in  diffusion of a new  innovation  th ro u g h o u t an industria l 
sector. Diffusion as defined by Everett Rogers,
"...is the process by w hich an  innovation  is com m unicated 
th ro u g h  certain channels over tim e am ong the m em bers of a 
social system ."23
Rate of adoption  is the relative speed  w ith  w hich an  innovation is
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adop ted  by m em bers of a social system . Research has show n that the 
m ost im portan t factor in explaining the rate of adop tion  are the 
innovations perceived attributes. Studies indicate th a t betw een 49% 
and  87% of the variance in rate of adoption  is explained by the five 
a ttributes; Relative A dvantage, Com patibility , Com plexibility, 
Trialability and  O bservability .24
In  the diffusion of industrial innovations relative advantage m ay be 
experienced in  a num ber of ways. To illustrate: A dvantage m ay be 
created th rough  a change in either a p roduct or a process leading to a 
reduction  in the average total cost of production  per un it or 
alternatively advantage m ay be the resu lt of increased dem and for 
fin ished products because of im proved quality or variety or price.25 Size 
of investm ent is an im portan t factor governing perceived relative 
advantage and  M ansfield notes th a t the probability of diffusion and 
adop tion  of an innovation is a decreasing function of the size of
investm en t requ ired .26
C om patibility  and com plexity of innovations are also im portan t 
indicators of diffusion rates. W ebster identified these factors as 
obstacles claiming,
"Factors w hich tend  to re tard  diffusion include the degree to 
w hich  an innovation is incom patible w ith  existing processes 
and  requires major process change, the degree to w hich 
increased technical skills are requ ired  to use the innovation and  
the probability that m ajor im provem ents will rap id ly  alter the 
innovation  m aking delay in  adop tion  advantageous"27
All of these factors cause increased uncertain ty  for the potential 
adop ter w hich m ay in  tu rn  resu lt in  an  assessm ent of greater risk. A 
s tu d y  u n d ertak en  am ong a C olum bian  farm ing com m unity illustrates 
w ell how  incom patibility w ith  existing processes m ay result in  a
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negative evaluation of an innovation. Farm ers p resen ted  for the first 
tim e w ith  a chemical fertiliser applied  the substance on  top of their 
potato  seed, as they had  previously done w ith  m anure, thereby 
dam aging their seed. As a result they w ere loathe to adop t the new  
innovation  In general Rogers postulates that the com patibility  of an 
innovation  w ith  existing m ethods, as perceived b y  m em bers of a social 
system , is positively related to its rate of adoption  and  com plexity is
negatively  related.29
The im portance of trialability and  observability in  d ictating diffusion 
rates stem s from  their role in  com m unication of ideas. Trialability is 
m ore im portan t for earlier adopters th an  those w ho  adop t later. The 
m ore innovative individuals have no precedent to follow  w hen  they 
adopt, w hile the later adopters are su rrounded  by  peers w ho have
already adopted  the innovation.30 Thus, later adopters are likely to 
learn  about the innovation  th ro u g h  observation ra ther th an  th ro u g h  
first h and  experience.
Q uite ap art from  these innovation  attributes other factors also 
influence the rate adoption  of innovations. One im portan t factor is 
term ed  by  M ansfield as the 'bandw agon ' or 'contigon' effect. He 
postu lates that the probability tha t a given firm  w ill ad o p t a p roduct or 
process is an increasing function of the p roportion  of firm s in  the 
industry  already using it and  of the probability of their doing so.
"As the num ber of firm s in  an  industry  using  an  innovation  
increases, the probability  of it's adoption  by  a non-user increases. 
This is because, as experience and inform ation regard ing  an 
innovation  accum ulate, the risks associated w ith  it's 
in troduction  grow  less and  com petitive p ressures m ount. 
M oreover in cases w here the profitability  of an  innovation  is 
difficult to assess, the m ere fact that a large proportion  of a firm s 
com petitors have adop ted  the innovation  m ay  p ro m p t the firm  
to consider it m ore seriously". 31
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Rogers calls this the 'diffusion effect' and  explain it as,
"The cum ulatively increasing degree of influence u p o n  an 
ind iv idual to adop t or reject an  innovation  resu lting  from  the 
activation of peer netw orks about an innovation  in a social 
system ".32
It is because of the diffusion effect that the S shape diffusion curve 
takes off at about 10-25% adoption. (Figure 1.4)
Figure 1.4 Bell Shaped Frequency Curve and S shaped Cumulative 
Curve of an Adopter Distribution.
Source: Rogers E.M. (1971), Diffusion of Innovations, 3 rd
Edition,The Free Press, N ew  York.p.243.
Interestingly, researchers have no t found  a relationship  betw een  firm  
size and  ability to innovate, nor has a relationship  been  found  betw een
firm  size and speed of adoption  of innovations.33 W ebster contends 
th a t larger firm s m ore able to afford investm ent requ ired  for adoption
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and  the associated risk will adop t innovations earlier.34 H ow ever, 
sm aller firm s w ith  less com plex decision-m aking processes m ight also
be am ong the earliest adopters of new  innovations.35 
It is clear how ever that for any innovation there exists a significant 
tim e lag betw een  its in troduction  and any w ide econom ic and social 
im pact of use. M ansfield estim ated that diffusion of a major new  
technique could often take tw enty  years or m ore before all m ajor firm s
adop ted  and  seldom  took less than  ten years.36
1.1.4 A dopter Categories
A n Innovation  spreads th rough  a social system , w hether that be an 
industry  or com m unity or neighbourhood, because indiv iduals adop t 
it. H ow ever no t all ind ividuals in  a social system  will adop t an 
innovation  at the same time. Rather they adop t in  a tim e sequence 
and  they m ay be classified into adopter categories on the basis of w hen  
they first began  using a new  idea. The adopter categorisation of Rogers 
(1962) has gained w idespread  prom inence. It is based  on  the S shape 
curve of adoption  show n in  Figure 1.4. Note th a t b o th  these curves are 
for the sam e data, the adop tion  of an innovation over tim e by  the 
m em bers of a social system. The bell-shaped curve show s these data in  
term s of the num ber of individuals adopting each year, w hereas the s- 
shaped  curve show s the data on a cum ulative basis. The shaded area 
m arks the tim e period  du ring  w hich the s-curve of diffusion "takes 
off".3?
The five adopter categories p u t forw ard  by Rogers are, innovators, early 
adopters, early m ajority, late m ajority and  laggards. D om inant 
attributes of each category are as follows:
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"Innova to rs  
Early A dopters 
Early M ajority 
Late M ajority 
Laggards
v en tu reso m en ess
respectable
deliberate
skeptical
trad itiona l"38
U se of new  biotechnological techniques is still quite  lim ited, for this 
reason  focus in  this s tudy  w ill be on possible innovators and  early 
adopters the first 15% of those w ho m ay use the techniques. (Figure 1.5)
Figure 1.5 A dop ter C ategorisation  on the Basis of Innovativeness.
Source: Rogers E.M. (1971), Diffusion of Innovations, 3 rd
Edition,The Free Press, N ew  York.p.247.
1.2 Patterns of A doption  and  D iffusion  no ted  in  R esponse to  the  
Em ergence of N ew  Biotechnological Techniques.
The em ergence of new  biotechnological techniques has been  hera lded  
as a new  technological paradigm . U sing the w ords of R ichard Foster 
they  represent a new  S curve. The rem ainder of this chapter focuses on  
pa tterns of adoption  and  diffusion noted  follow ing the em ergence of 
these techniques. The techniques are initially described and  then  the 
response of em erging and  established firms discussed.
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1.2.1 N ew  Biotechnological Techniques.
"It is m ore th an  a decade since the in ternational fascination w ith  
biotechnology began. From 1979 to 1981 eighteen  official reports 
across the industria lised  w orld  announced th a t biotechnology 
w ould  be the new  technological base for our civilisation."39
'Biotechnology' is not in  itself a science, an  industry , a p roduct or a 
'thing'. It is a pow erful set of tools w hich m ay be used  to develop and  
produce m edicines, agricultural products and  foods and  m any other
goods for everyday personal consum ption and  industria l use.40 
Biotechnology is not new . It represents a developing series of 
technologies w ith  roots established (in m ay cases) thousands of years 
ago. It includes m any trad itional processes such as baking, 
w inem aking and cheesem aking. H ow ever, it is new  or m odern  aspects 
of biotechnology, founded  in  recent advances in  m olecular biology, 
genetic engineering and  ferm entation  process technology w hich has 
cap tu red  the im agination  of scientists, financiers and  the public. N ew  
biotechnological techniques have applications in  m any  industries.
They have the potential to treat previously  incurable genetic diseases, 
provide us w ith  better and  healthier food products and  afford us a
reduction  in  use of toxic pesticides.41
1.2.2 D efining Biotechnology.
Biotechnology has been defined in  m any form s b u t as yet no dictionary 
definition  has achieved un iversal acclaim.
"While in  practice the w ord  often refers vaguely  to technologies 
associated w ith  genetic engineering, form al definitions give it 
w ider scope. C onsequent problem s of definition have 
som etim es ren d ered  m eaningless com parisons betw een 
expenditures of different nations or even different agencies 
w ith in  a single governm ent."42
Perhaps the m ost popu lar definition is that offered by the UK A dvisory
council for Science and  Technology. Biotechnology is defined as a,
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"broad term  used  to describe the p roduction  of innovative 
products, devices and organism s by exploitation of biological 
processes. Traditional biotechnology w as based  on  enrichm ent 
and  purification, m odern  biotechnology o n  the m anipulation  of 
genes and  on  the genetic structure of cells. M uch of its 
im portance stem s from  recent advances in  genetics and 
biochem istry and  from  the em ergence of m olecular biology."43
1.2.3 A doption  and  D iffusion  of N ew  B iotechnological Techniques.
It has been estim ated that the com panies, institu tes an d  universities 
involved  in  biotechnology num ber in  the thousands w orldw ide.44 T he 
techniques have been adopted  by tw o m ain types of firms, startup  and 
established firms. The m ost dynam ic adopters are the small, 
p ioneering  biotechnology firm s w hich  have em erged  since the early 
1970's w ith  the support of venture capital and  corporate investors. In  
the early 1980's the US saw an  explosive grow th  in  the num ber of these 
sm all companies. Cetus and G enentech are generally considered
am ong the leaders in  this group.45 M ore th an  350 such firms appeared  
in  the US betw een 1971 and  1987.46 Established firm s have m oved 
m ore slow ly in to  biotechnology, b u t their com m itm ents are grow ing as 
po ten tial applications becom e m ore apparent.
The distinction betw een  em erging and  established firm s is an 
im portan t one in  the developm ent of a new  technology. H am ilton  has 
defined an em erging firm  as,
"one created to exploit a new  technology" w hereas "established 
firms are, in  contrast, those w ith  positions in  existing 
technologies and  m arkets at the tim e a new  technology 
appears "47
Em erging firms created to exploit new  biotechnological techniques are 
popularly  referred to as new  biotechnology firms. Established firm s
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can be d iv ided  into two groups: those w ith  established positions in  a 
particu lar m arket or industry  to w hich applications of the new 
technology m ay be directed, w hich are term ed incum bents, and  new  
entrants w hich are those firms w ith  established positions in other 
industries w ho a ttem pt to enter new  m arkets or businesses th rough  
applications of the new  technology.
Established and  em erging firms have different core technical and 
com plem entary assets. These assets have a bearing  on  their potential 
for success w ith  technical innovation. Core technical assets are defined 
by H am ilton as the codified and  tacit know ledge associated w ith  
radically new  science and  technology. C om plem entary  assets are 
requ ired  to m ake a technological innovation a com m ercial success and  
m ay be broken dow n into those w hich have specific applicability to the 
technology or m arkets of interest (innovation specific assets) and  those 
w hich  are generally applicable (generic assets). H am ilton 's p roposed  
d istribu tion  of core and  com plem entary assets am ong participants in  
technological innovation is show n in  Table 1.0. This Table indicates 
that follow ing a technological d iscontinuity  established  incum bent 
firm s m ay enjoy some initial advantages over established new  
entrants. H ow ever, bo th  lack the core technical assets w hich the 
em erging new  en tran t enjoys. Strategies for involvem ent w ith  new  
biotechnological techniques differ betw een  established and em erging 
firm s due to their differing core technical and  com plem entary assets. 
Both established and em erging firms experience different types of 
difficulties in  becom ing involved w ith  the techniques.
1.2.4 Emerging Firms Involved w ith N ew  Biotechnological 
Techniques.
Research show s that problem s of new  biotechnological firms or 
em erging new  en tran t firms w orking  to becom e involved w ith  new
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biotechnological techniques tend to stem  from  financial difficulties. A 
study  by  W atson (1992) of smaller EC firm  startups in  the 
biotechnology industry  found tha t few  firm s w ere able to generate 
substantial sources of finance and  w ere d ep en d en t on successive
rounds of equity  for survival. 48 Debt financing is no t a viable 
alternative for these com panies due to the long lead  tim e and  heavy 
expenditu re  requ ired  to develop m ajor new  biotechnological products. 
Steven Burill reporting  from  Ernst and  Young's fifth  biotechnology 
su rvey  "Biotech'91: A C hanging  Environm ent" u n d erlin ed  the 
im portance of this issue as he asserted that sm aller com panies are 
consum ed w ith  finance w orries. This s tudy  ind icated  that sm aller 
firm s w ere suffering due to lack of finance and  US biotechnology 
com panies indicated that they expected increased fu tu re  financing to 
come from  strategic alliances and  public e q u ity .4 9
Table 1.0 D istribu tion  of Core Technical and  C om plem entary
A ssets am ong Participants in  T echnological Innovation .
TYPE OF FIRM
FIRM
POSITION
ESTABLISHED
Innovation-
Specific
IN CU M BEN T Complementary
assets
EMERGING
Generic
NEW  ENTRANT Complementary
assets
Core technical 
assets
Source: H am ilton  W.F.(1990), "The D ynam ics of Technology and 
Strategy", European Journal o f Operational Research, vol.47, pp. 141- 
152.
Strategies u n d ertak en  to overcom e the financing problem  for sm aller 
firm s include the strategy of p roduct p rogression  noted by  Sm ith and
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Fleck. This involves starting  w ith  products th a t requ ire  relatively little 
capital, such as contract research or production, then  m oving on to 
diagnostic products w ith  the production  and  sale of drugs as the m ost
am bitious and  capital dem anding objective.50 Daly has also endorsed  
this evolutionary p a th  for new biotechnological firms. H e highlighted  
the strategic possibilities open to firms in term s of m arket focus and  
tim e fram e of R&D effort. A  focussed strategy  involves concentration 
on  a narrow  m arket to achieve overall p roduct d ifferentiation or cost 
leadership. G enentech is a prim e exam ple of a com pany pu rsu ing  such 
a strategy as it attem pts to become an in tegrated  m arket leader in  
hum an  and  anim al therapeutics. The b road  based strategy is m ore 
readily  illustrated by com panies like A m gen and Cetus w ho attem pted  
to reduce com petitive risk by developing a b road  R&D portfolio. A n 
early products strategy is characterised by  the developm ent of products 
w ith  short R&D tim es and  relatively low entry  barriers. These m arkets 
are extrem ely com petitive and new  biotechnological firm s ru n  the risk
of loosing ou t in  the longer term  w ith  m ore com plex products. 51
1.2.5 Established Firms Involved w ith N ew  Biotechnological 
Techniques.
Follow ing the em ergence of a technological d iscontinuity  such as new  
biotechnological techniques established firm s m ust m ake a decision 
concerning possible fu tu re  involvem ent. Daly has ou tlined  the 
options available to established firms follow ing the em ergence of a 
new  technology. These are:
"1. Do nothing.
2. M onitor only.
3. A ttem pt to prevent the developm ent of the new  technology.
4. Im prove old  technology.
5. Participate in  some m a n n e r ."52
O bviously m any firm s w ill choose no t to becom e involved b u t w ill
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continue to use ou tdated  technologies for as long as they rem ain 
profitable.
Established firm s considering involvem ent m ay decide to becom e 
leaders or followers in  the developm ent of the new  technology. 
A ccording to Porter the choice betw een leadersh ip  and  follow ership is 
a function o f ,
"the technological opportun ity  to influence cost or 
differentiation, the uniqueness of the firm 's technological skills, 
first m over advantages, the continuity of technological change, 
the rate of change in  process technology or custom er purchasing  
behaviour, the irreversibility  of investm ents, uncertain ty  and 
leadersh ip  externalities."53
In the context of the technological discontinuity  caused by the 
em ergence of new  biotechnological techniques a policy of late entry  
leadership is indicated as particularly  im portan t as it w ou ld  allow the 
established firm  to 'leap-frog' ahead of the new  biotechnological firms. 
H ow ever, Daly points ou t that technological follow ership m ay also be a 
w ise strategy in  those m arkets w here there is a h igh  level of p roduct 
and  process uncertain ty  and this w ould  appear to  be the im plied
strategy of some established firm s.54 H ow ever, because of the com plex 
nature of m any established firms and  the range of m arkets in  w hich  
they are involved, firm s m ay pursue alternate strategies in  d ifferent 
m arkets.
Firms m ay also pu rsue  differing strategies as their strategic 
com m itm ent to the techniques increase. These are:
O p en in g  W indow s: M ainly concerned w ith  m onitoring and 
identification of im portan t technologies.
C reating  O ptions: Prim ary tru s t is creation of defined opportunities for 
active partic ipa tion  in  new  technology and  it's com m ercial 
applications.
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Establishing Positions: Firms using this strategy are staking ou t their 
com petitive positions in  selected technologies an d  m arkets w ith  the 
in ten tion  of long-term  com m itm ents in  these or closely related  
com m ercial m arkets. (Figure 1.6)
Figure 1.6 Progression of Technology Strategies.
TIME
Source: H am ilton  W.F.(1990)/ "The Dynam ics of Technology and  
Strategy", European Journal o f Operational Research, vol.47, p p .141- 
152.
These evo lu tionary  strategies h ighlight the logical progression  in  
strategic em phasis from  inform ation gathering  to m ore focussed 
com m itm ents as technologies and m arkets develop. H am ilton  posited  
that increased involvem ent w ou ld  lead  to in ternalisation  of technical
assets over time. 55 Prior to this level of com m itm ent the p rim ary  
problem  of established firm s, bo th  new  en tran ts and  incum bent firm s, 
lies in  their lack of core technical assets. H am ilton  proposed  th a t in  
order to circum vent this problem  established firms should  partic ipate  
w ith  new  biotechnological firms or universities affording access to 
their technical skills. Types of partic ipation  available to established
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firms include:
Equity investm ents in  new  biotechnological firms.
Joint V entures and  licensing w ith  new  biotechnological firm s 
In  house R&D investm ent 
Investm ent in  academ ic In stitu tions56
1.2.6 Strategic Alliances.
As outlined the differing assets enjoyed by em erging and  established, 
(incum bent and  new  en tran t firms) p rov ide  the p rim ary  m otivation  to 
collaborate. As Shan and  V isudtibhan said of the new  biotechnological 
techniques,
"although the technology is revo lu tionary  and  represents in 
Dosi's term s, a new  parad igm  of technology its 
com m ercialisation m ay require u tilisation  of m uch of the 
com m ercial infrastructure of the existing pharm aceutical 
industry , w hich  is ow ned or otherw ise controlled by incum bent 
established firm s."57
The classic view  is th a t the em erging firm s w ho have in  their 
com m and core technical assets collaborate to gain access to m arketing  
distribution  and  finance. Established firm s collaborate to gain access to 
technical skills. C om panies use collaborative arrangem ents to ad d  
com plem entary streng th  to in ternal s treng th .5« The popu larity  of 
collaborative arrangem ents in  the biotechnology field bears testam ent 
to their efficacy. According to Roberts and  M izouchi,
"Collaborations have becom e as popu lar as they are im portan t 
and  an alliance m ap of the biotechnology industry  looks like a 
spiders w eb w here a single com pany is involved in  m any 
d ifferent types of relationships w ith  different partners"59
Research undertaken  by Schwartz an d  Dibner indicates that strategic 
alliances represen t a significant p roportion  of biotechnology firm  R&D 
activities. They found  that in  1992 biotechnology firm s perform ed, on
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average, 24.4% of their research and  17.1% of p roduct developm ent 
externally. This represented over $1 billion in  R&D spending.60 
Similar research undertaken  by Dibner indicated  that the first increase
in  collaboration betw een biotechnology firm s w as no ted  in  1985.61 
Collaborations are increasing in  popu larity  not only am ong dom estic 
com panies. W agner show ed in  her s tudy  of in ternational strategic 
alliances am ong biotechnology firm s, th a t those firm s w ho have not 
undertaken  in ternational R&D are now  the exception to the rule. 47% 
of those in terview ed in 1986 w ere involved in  in ternational strategic 
alliances com pared w ith  67% in  1991.62 Strategies of collaboration 
form ally used to access capital, m arketing and distribution  are now  also 
utilised  to access regulatory expertise, know ledge of foreign culture and
m arkets.63 H owever, m arket access, incom e and technology w ere rated  
the three m ost im portan t objectives to be achieved th rough  strategic 
alliances by  US firms. Interestingly these firms ranked  E uropean and
Japanese objectives in  reverse order.64
Studies undertaken  in  1986 and  1991 to identify com panies m ost likely 
to  becom e involved in  strategic alliances indicated firm  size is 
negatively correlated w ith  the use of cooperative relationships. 
Research also indicated that strategic alliances are p redom inantly  used  
by high tech startup  firm s in  foreign m arkets and  the m ore p roducts a 
firm  has b rough t to com m ercialisation the less likely they are to 
becom e involved in  a cooperative relationship. These studies differed 
how ever, w ith  regard  to the relationship  betw een firm  status and 
propensity  to cooperate. The 1986 results indicated that followers w ere 
m ore likely to cooperate than  leaders. In  1991 how ever, leaders w ere 
show n to be m ost involved w ith  strategic alliances. It is hypothesised 
that the static nature of both  snap-shot studies failed to capture the 
dynam ic nature of firm s involved. If follower firms cooperated to 
im prove their com petitive position  th en  they  w ould  have m oved  u p
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against rivals in the intervening period.65
H am ilton  has identified 5 principal form s of collaborative 
arrangem ents open to firms.
1. Research Contracts
2. R&D Contracts
3. Licences
4. Equity Investm ents
5. Joint V entures.66
Each of these collaborative relationships m ay be use by  a variety  of 
firms w ith  m ultiple partners and different application areas. Roberts 
and  M izouchi in  their survey of 100 Japanese com panies involved 
w ith  biotechnology pointed ou t the suitability of particu lar 
collaboration form s as the firm  increased its com m itm ent to the new  
techniques. They outlined a strategic collaborative pa thw ay  w hich 
begins w ith  research contracts or m inority  investm ents, m oves on  to
licensing to corporate alliances and  term inates w ith  acquisition.67
Research confirms the com plem entarity  of various collaborations. 
A rora and  G am berdella tested the hypothesis that the strategies of 
external linkage of the large firms w ith  o ther parties are 
com plem entary to each other. U sing data from  a sam ple of large US, 
E uropean and  Japanese chemical and  pharm aceutical producers they 
found  th a t these strategies w ere positively correlated even after
controlling for firm  specific characteristics.6»
The research indicates the efficacy and  usefulness of strategic alliances 
in  the evolu tion  of firms follow ing the technological d iscontinuity  
caused by  new  biotechnological techniques. H am ilton  has p roposed  
that as com panies evolve tow ards ultim ate com m ercialisation of 
products and  as m arket and  technical uncertainties decline the
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m otivation  to collaborate will also lessen. As w e reach the 
com m ercialisation stage w ith  new  biotechnological techniques 
how ever, strategic alliances are increasing not decreasing. A h igh 
degree of satisfaction was noted by  those firms in terview ed by Dibner 
and  Schw artz and tw o thirds in tended  to seek m ore alliances in  the 
fu tu re .69 The fu ture of new  biotechnological techniques w ould  seem  to 
involve m ore collaboration. Perhaps the use of alliances is not just a 
'short term  fix' as proposed by  Porter 70 bu t essential to strategy due to 
the effects of globalisation.7!
1.3 Summary.
It is an accepted fact that technology and the innovative process are 
im p o rtan t determ inants of econom ic success. Theories of technical 
change have in  the past been classified as either 'technology push ' or 
'dem and  puli'. Difficulties are associated w ith  extrem e form s of both  
theories. A m ore balanced conceptualisation of technical change is 
offered by Dosi. He proposed th a t continuous technical changes are 
re lated  to progress along a technological trajectory, defined by a 
technological paradigm , w hile discontinuities are associated w ith  the 
em ergence of a new  paradigm . The em ergence of new  biotechnological 
techniques has been heralded as a new  technological paradigm .
Firm s involved  in  technical change m ust have a h igh  level of 
com petence in  the different technological requirem ents of d ifferent 
stages of production  in  order to rem ain  com petitive. This is referred  to 
as firm s' technological capacity.
Follow ing the in troduction of an  innovation  it is often adopted  by 
o ther firms. Diffusion is the process by  w hich an  innovation is 
com m unicated th ro u g h  certain  channels over tim e am ong m em bers 
of a social system. Rate of adoption  is the relative speed w ith  w hich an
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innovation  is adopted  by m em bers of a social system . The m ost 
im portan t factors in  explaining the rate of adoption  are the 
innovations perceived attributes, i.e. relative advantage, com patibility  
w ith  existing processes, complexibility, trialibility, and  observability.
N ot all m em bers of social system  w ill adopt an  innovation  at the same 
tim e ra ther they m ay begin to use the idea in  tim e sequence and  thus 
can be categorised in  term s of their innovativeness. The first 15% of 
those w ho adop t a new  idea are called innovators or early  adopters.
Difficulties of definition have been associated w ith  new  
biotechnological techniques b u t perhaps the m ost po p u la r defin ition is 
that offered by  ACOST. Biotechnology is defined as
"a b ro ad  term  used  to describe the p roduction  of innovative 
products, devices and  organism s by  exploitation of biological 
processes. T raditional biotechnology w as based  on  enrichm ent 
and  purification, m odern  biotechnology on  the m an ipu la tion  of 
genes and  on the genetic structure of cells. M uch of its 
im portance stem s from  recent advances in  genetics and  
biochem istry and  from  the em ergence of m olecular biology."72
N ew  biotechnological techniques have been adop ted  by  tw o m ain  types 
of firm s, s tartups and  established firms. In  the adop tion  of new  
biotechnological techniques the problem s of em erging firm s tend  to 
stem  from  financing w orries w hereas established firm s considering 
involvem ent suffer from  a lack of core technical assets. These 
deficiencies of em erging and  established firms in  the adop tion  of new  
biotechnological techniques are com plem entary and  have lead  to  a 
large num ber of strategic alliances. W hereas em erging firm s are set up  
w ith  the p rim ary  objective of exploiting the new  techniques, 
estab lished  firm s have m any options follow ing the em ergence of the 
technological d iscontinuity  caused by  the in troduction  of new  
biotechnological techniques.
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Chapter 2 N ew  Biotechnological Techniques - Applications and 
Use in the Food industry. 
2.0 Introduction.
Experts are often at pains to highlight the evolu tionary  rather than  
revolu tionary  im pact new  biotechnological techniques m ay have on
the food industry  as o ther industries.1 As a set of, albeit pow erful, tools 
certain conditions are necessary for adoption  and  use by  ind iv idual 
food firms. In this chapter analysis is undertaken  of the applicability of 
new  biotechnological techniques to the food industry . The techniques 
w ill be review ed th ro u g h  use of the m arketing  m ix fram ew ork. The 
m arketing m ix is defined as,
"a set of m arketing  tools that the firm  uses to  pursue it's 
m arketing  objectives in  the target m arket."2
There exists a m yriad  of m arketing mix tools. H ow ever, M cCarthy has 
popularised  a four factor classification of tools called the 'four P.s', -
P roduct, Price, Prom otion, Place.3 In the follow ing review  analysis w ill 
be m ade of w hat new  biotechnological techniques have to offer w ith  
regard  to each of the 'four P.s'. In this w ay the salient aspects affecting 
adoption  and  use of new  biotechnological techniques are exam ined 
from  the perspective of the potential user.
2.1 The 'Four P.s' of N ew  Biotechnological Techniques.
In  the M cCarthy classification of m arketing  m ix tools the first 'P'- for 
product, refers to features/serv ices afforded a potential consum er. In 
the context of new  biotechnological techniques po ten tial users are 
concerned w ith  the functions these techniques m ay  provide them . The 
techniques have applications in  bo th  P rim ary Food Production  and  
Food Processing.
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2.1.1 Primary Food Production.
In  p rim ary  food production  use of new  biotechnological techniques can 
aid  crop and  lifestock production. The initial w ave of research in  p lan t 
biotechnology, driven  by the seed and agrichem ical industries has 
concentrated on 'agronom ic traits' of direct relevance to these 
industries. W ork is directed tow ards the control of insects, w eeds and  
p lan t diseases.4 "Typical goals for crop im provem ents are:
Better F lavour
Longer Shelf Life
Insect resistance
Disease Resistance
H erbicide Resistance
Expanded geographical grow th  range
D rought resistance
M ore nu tritious com position
Increased value com position
M ore rap id  grow th
E arlie r/la te r m atura tion
Better fertiliser u tilisation
These are the same characteristics geneticists have tried  to in troduce 
th rough  selective breeding for m any years. H ow ever use of rD N A  
technology m eans the trad itional h it and  m iss random  and em pirical 
processes of m utation, breeding and  selection have been replaced. N ew  
biotechnological techniques offer m ethods to identify  and directly alter 
specific genes to produce desired characteristics.5 Examples of successful 
application of advanced  biotechnological techniques for construction of 
crop varieties w ith  im proved properties are listed in Table 2.0.
N ew  biotechnological techniques have also a lot to offer those 
involved in  the lifestock industry.
"Successful em bryo transplants are speeding up the genetic 
im provem ent of cattle at low er cost to the farm er. Em bryo 
technology also offers an econom ically viable w ay of transferring  
superior anim al genetics to developing or geographically 
isolated countries. Several superior vaccines to p reven t anim al
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Table 2.0 Successful Application of Advanced Biotechnological Techniques for Construction of Crop Varieties with Improved Properties.
OJ
Product
Fresh market tomatoes with improved taste 
and shelf life
Processing tomatoes with higher solids
Herbicide resistant corn
Virus resistant tomatoes, cantalupes, 
cucumbers
Insect resistant tomatoes, other crops 
Fish
Herbicide tolerant sugar beet 
Canola with modified fatty acid content
Freeze tolerant tomatoes
Foods resistant to spoliage microorganisms
Insect resistant or nutritionally improved corn
Virus resistant potatoes
Cold tolerant crops using fish gene
Hybrid rice (based on genetic sterility system)
Companies Projected Introduction Regulatory Status
Calgene
Calgene
Dekalb
Asgrowseed
(Upjohn)
Monsanto 
other co.s
Several
Plant Gentic 
Systems
Dupont/DNA 
Plant technology 
others
DNA Plant 
Technology
DNA Plant 
Technology
Biotechnica
International
Monsanto
DNA Plant 
Technology
Plant Genetic
1993
1993
mid 1990's 
mid 1990's
Approved for commercialization
Field trials 
Field trials 
Field trials
Early and mid 1990's Field trials
Mid 1990's 
mid 1990's
Field trials 
Status unknown
Early and mid 1990's Commercial products
mid 1990's
mid 1990’s
1996
1996-97 
after 2000
after 2000
Applied for field tests
Applied for fiels tests
Applied for field trials, 1991
Field trials, 1991 
Applied for field trials
Status unknown
Source: The Hale Group/Decision Resources, Inc.(Updated by Food Processing magazine)(1993), "Food Related Biotechnology Products", Food 
Processing, January, p.55.
diseases have been developed th rough  biotechnology. Also 
disease diagnostic techniques are being developed to detect 
anim al diseases, oestrus and pregnancy and  aflatoxin in lifestock 
feed. In  add ition  to controlling anim al diseases, a major 
contribution of genetic engineering will be to increase the 
productiv ity  of farm  animals. For exam ple: Treating cows w ith  
R ecom binant Bovine Som atotropin (rbST), a n a tu ra l pro te in  
horm one m anufactured  th ro u g h  recom binant DNA technology, 
can increase m ilk production  per lactation on  less feed per un it 
of m ilk, thereby reducing m ilk p roduction  costs. Similarly 
adm inistering  recom binantly p roduced  Porcine Som atotropin, a 
natu ra l sw ine pro tein  grow th  horm one to finishing pigs can 
im prove feed efficiency, increase lean m uscling and  reduce fat
deposition".6
2.1.2 Food Processing.
N ew  Biotechnological processes m ay also be applied  after the 
com m odity leaves the farm  gate. One area attracting considerable 
in terest is the genetic im provem ent of food ferm entation 
m icroorganism s. M icroorganism s have been  used  for centuries in  the 
p roduction  of ferm ented foods, such as cheese, sausage, saurkraut, 
w ine and  bread. Genetic engineering provides an alternative to 
classical m utation  and  selection procedures for im proving  m icrobial 
starter cultures w ith  im proved m etabolic processes. Some exam ples of 
how  genetic engineering could be used  to im prove organism s for 
various ferm entation processes are p rov ided  in  the Table 2.1. 
A vailability of such strains w ould  have an  im pact on several aspects of 
ferm entation, including  production  econom ics, shelf life, safety, 
nu tritional content, consum er acceptance and  w aste m anagem ent. 
M icroorganism s are also used in  the p roduction  of ingredients for 
processed foods or enzymes. Enzym es perform  m any valuable 
functions in  food systems. They help control texture appearance and  
nu tritive  value as w ell as the generation of desirable flavours and 
arom as. Im proved  enzym es w ill expand the uses for enzym es in  food 
processing and increase the kinds of raw  m aterials w hich can be
utilised  as food for anim als and hum ans. 7
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Table 2.1 Genetic Improvement of Microorganisms.
Type of 
Fermentation
Nature of 
Improvement
Benefit
Dairy Bacteriophage (virus) resistance Eliminate economic 
losses due to destruction 
by virus infection.
Accelerated ripening of cheese Decreased storage costs
Higher levels of the enzym e Beta- 
Galactosidase
More digestible for 
Lactose - Intolerant 
ind ividuals
Meat Bacteriocin Production 
(natural preservative)
Inhibit pathogenic or 
spoilage organisms.
Addition of cholesterol - 
Reducing enzymes
Reduction of an 
undesirable dietary 
component.
Addition of fat - m odifying  
enzymes
Alteration of the 
saturated to 
unsaturated fat ratio.
Beer Alpha - Amylase production Production of lite or low  
calorie beer.
Source: H arlander S.K., BeMiller J.N. and  Steenson L. (1991), "Impact of 
Biotechnology on  Food and N on-Food Uses of A gricultural Products" 
in  Agricultural Biotechnology, Issues and Choices, B aum gard t B.R. an d  
M artin  M .A., ed.s, P urdue U niversity  A gricultural Experim ent Station, 
W est Lafayette, Indiana.
Experts considering exploitation of these advances m ust be aw are of the 
regu latory  environm ent in  w hich they  exist. The European  regulatory  
approach  places an  em phasis on the techniques as a trigger for 
regu lation  and  does not, as in  the US, em phasise the p roduct itself.
This process has m et w ith  strong criticism  as m any believe it increases 
costs and  regulatory  uncertainty for potential users. In  Europe products 
of biotechnology are assessed th rough  application of safety, quality  and 
efficacy criteria in  conjunction w ith  relevan t horizonta l legislation to 
ensure consum er safety, economic in terests and  perm it pro tection  of
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hum an, anim al and  p lan t health  and  the env ironm ent.8 The EC 
Com m ission has rejected the system atic use of a fourth  criteria in 
addition  to safety, quality and  efficacy for assessm ent (ie the 
socioeconomic im pact of proposals) as proposed  by  the E uropean 
Parliam ent. (Use of socioeconomic criteria in  assessm ent procedures 
has becom e know n as the fourth  hurdle.) H ow ever, it has reserved  the 
righ t to  m ake exceptions and the continuing m ora torium  concerning 
the com m ercialisation of rbST is the exception so far. D raft proposals 
have also been p u t forw ard requiring the labelling of Genetically 
M odified O rganism s, (G.M.O.'s) as such. If labelling does no t guarantee 
acceptance, it at least recognises the righ t of some consum ers no t to 
choose food p roduced  in  this w ay.9
2.2 Price.
The investm ent requ ired  for a po ten tial user to becom e involved  in  
new  biotechnological techniques is enorm ous. A ccording to statistics 
com piled by M ark Dibner the average R&D budget for biotechnology
firm s involved w ith  agriculture is $4.5million.10 Also in  the past 
translation  of scientific findings into com m ercial products has been  a 
slow process and  m any have been d isappoin ted  in  the long lead  tim e to 
com m ercialisation. H ow ever, a few products have b egun  to em erge in  
the food sector and  m any believe the techniques have now  begun  to 
realise their potential.11
W hat are the paybacks to those successful in  bringing  an  innovation  to 
m arket? M arvin  Scher answ ers this question by  considering the case of 
the tom ato. In 1991 the US retail tom ato m arket w as estim ated w o rth  
about $5 billion. This food also records h igh  levels of consum er 
dissatisfaction. A n im proved tom ato  could obviously p rov ide  a 
substantial d ividend. Calgene an A m erican com pany has developed
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such a tom ato w hich boasts superior taste and  is less vulnerable to 
spoilage th an  existing retail varieties. The gene-spliced tom ato is
b randed  and  will be m arketed under the trade m ark Flavr Savr™.12 
It m ust be noted  that under E uropean law  the im proved  tom ato can 
no t be patented , how ever US intellectual p roperty  law  allow s both  
plants and  anim al varieties to be patented . As the holder of a p lan t 
p a ten t for the Flavr Savr™ tom ato, therefore, Calgene can exclusively 
reproduce, sell and  use this tom ato for 17 years. European law
stipulates that patents m ay no t be issued for p lan t or anim al varieties.13 
The perform ance of this p roduct will be closely m onitored  in  order to 
estim ate potential revenues from  fu ture G.M.O.'s. In  general, experts 
assert use of new  biotechnological techniques w ill bring  food costs 
dow n b u t increase farm  incomes because of low er in p u t costs, increased
efficiency and  new  m arkets.14
2.3 Prom otion.
The prom otion  of rD N A  technology adoption  and use has been  
ham pered  by the division in  the public as to the m erit of products 
p roduced  in  this way. O pposition  stem s from  environm ental and 
safety concerns, concerns relating to the possible adverse social and  
econom ic effects of its application and  ethical and  religious concerns. 
Industria l organisations how ever view  science and  thus biotechnology 
as an engine of economic progress. The conflict of attitudes tow ards 
gene-technology produced  food has resu lted  in opposing view s 
presen ted  in  the m edia and  ultim ate confusion for the consum er. 
Because of the prim acy of public perception  issues w ith  regard  to 
adop tion  and diffusion of new  biotechnological techniques a m ore 
com plete discussion of this issue has been  undertaken  later in  the 
chapter. Suffice to note, prom otion  of new  biotechnological techniques 
to date is highly fragm ented and  often deleterious.
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2.4 Place.
The location of new  biotechnological expertise has evolved w ith  the 
techniques. In  the US em erging biotechnology firm s w ere founded  as 
scientists m oved out of academic research laboratories w ith  a vision of
the com m ercial opportunities of their know ledge.15 In  Ireland apart 
from  in  house com pany research m ost biotechnological research is
perform ed in  the universities and  the research institu te .16 D iffering 
levels of involvem ent m ay also be no ted  betw een nations. Foxe has 
indicated  tw o prerequisites for a country to involve and  com pete in  
biotechnology. These are :
(i) A strong research base and
(ii) The industrial capacity to convert the basic research into 
p roducts.17
2.4.1 In te rna tional C om petitiveness in  Biotechnology.
O n the basis of identified prerequisites, it is asserted  th a t the U nited 
States is com prehensively the m ost successful country  in  the 
com m ercialisation of Biotechnology. This is prim arily  due to its strong 
research program s b u t also associated w ith  it's w ell established 
foundations in  pharm aceuticals and  agriculture. It has been estim ated 
th a t of the 2,600 firm s involved w ith  new  biotechnological techniques 
in  1989 , 1,600 w ere US based and  1,000 of these w ere new  biotechnology
firm s.18 O ther factors identified as contributing to the success of new 
biotechnological techniques in  US in d u stry  are extensive ven tu re  
capital and  public m arkets available to provide finance and  US paten t 
law  w hich, as noted, provides generous protection for all k inds of
biotechnology derived  innovations. 19
W estern  Europe controls the next largest w orld  biotechnology m arket. 
In Europe of 700 firms identified as involved w ith  new
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half new  biotechnology firm s .20 It is asserted that particu lar countries 
in Europe do not have the research base or industria l capacity to 
convert basic research into products. Problem s in  Europe also stem  
from  the lack of availability of venture capital for funding , adverse 
public opin ion  and fragm entation of research efforts .21
biotechnological techniques in  1989 half were established firms and
Japan rem ains the other m ajor com petitor in  the area of new  
biotechnological techniques.22 The Japanese have d isp layed  a time 
honoured  excellence in trad itional biotechnology, and  have m ade it a 
national priority  to dom inate the new  biotechnological industry  by the
year 2000.23 The prim ary problem  in  Japan is the lack of strong research 
base w hich has lead com panies to seek access to research and  training 
overseas, particularly in  the US. Experts have also identified 
w eaknesses in  both  Japanese agriculture and  pharm aceutical industries 
w hich  com plicates the process of developing new  innovative products
in  these areas.24 In 1992, 300 Japanese firm s w ere involved w ith  new  
biotechnological techniques the great m ajority (240) of w hich  w ere
established firms.25
2.4.2 Irish Involvem ent w ith  N ew  Biotechnological Techniques.
In  Ireland the first N ational Biotechnology Program  w as announced in 
June 1987 w ith  the objective of developing centres for com m ercially 
o rien ted  biotechnology research  in  Irish  universities.26 Five university  
based  research centres have been  form ed. These include the N ational 
Food Biotechnology Centre a t U niversity  College Cork and  the 
N ational A gricultural and  V eterinary  Biotechnology Centre a t 
U niversity  College Dublin. In  U niversity College Cork research 
in terests include the developm ent of genetically engineered organism s
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for the enhancem ent of bioprocesses, cheese and  m eat biotechnology 
and  natu ra l flavours. The w ork  in  U niversity College D ublin focuses
on  p lan t and anim al biotechnology.27 Incubation com panies have been  
established on the different cam puses and established com panies have 
dem onstra ted  their in terest th ro u g h  involvem ent in  cooperative 
research. This represents an  im portan t partnersh ip  betw een  the 
industria l sector and  academ ic institu tions.28 The w ork of these centres 
of excellence is co-ordinated by a dedicated body, BioResearch Ireland,
also established in  1987.29 O ther Industria l bodies supporting  the 
developm ent of biotechnology in  Ireland include the IDA (supports 
g row th  w ith in  the Irish m anufacturing  and services industries and 
prom otes Ireland as a sound  strategic location for foreign investm ent) 
and  Eolas (The Irish Science Agency w hich develops and  prom otes
science and  technical services to industry .)30 
D ue to the paucity  of research undertaken  to date it is difficult to 
estim ate the num ber of Irish  food firm s involved w ith  new  
biotechnological techniques. Results of a study  undertaken  in  1988 
indicate that in th a t year m ost Irish  food firm s felt enzym e/genetic  
engineering w ould  have a m ajor im pact on food processing 
/d ev e lo p m en t in the years 1995 to 2000. Also, w hen  questioned w ith  
regard  to the relative R&D priority  different technical areas should  be 
given by governm ent agencies, biotechnology was included in  the top
three priority  a re a s .31 In 1990 eleven food and  d rink  com panies w ere 
rep o rted  as involved w ith  biotechnology research and  developm ent in  
an  MBS study, how ever the level of biotechnology use sophistication
w as no t indicated.32
2.4.3 Industrial Policy.
Industria l Policy used  to prom ote the developm ent of biotechnology is 
an  im p o rtan t de term inan t of d ifferent nations' involvem ent and  
success in  exploiting the techniques. Biotechnology policy varies
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trem endously  betw een countries. The US has no biotechnology policy 
b u t bo th  in  Europe and Japan there is a strong governm ent influence 
o n  the w ay  in  w hich  biotechnology is developed and  com m ercialised. 
N ational policies prom oting biotechnology R&D m ay be categorised as 
ta rgeted  or diffuse. Countries like Japan, Singapore and  Taiw an w hich 
have targeted  biotechnology share an em phasis o n  export d riven  
g row th  and  they view  com prehensive governm ent policies strongly 
p rom oting  biotechnology as the key to fu ture  developm ent. In  the US 
and  in  som e areas of Europe w here grow th  prom otion  is less 
p ro m in en t the developm ent of biotechnology is one of m any 
com peting social concerns.33
2.5 Target M arket.
It is necessary to identify  those firms, individuals, research  institutes 
w ho  m igh t potentially  adopt new  biotechnological techniques given 
their characteristics as outlined under the 'four P.s'. W hile it is 
acknow ledged that new  biotechnological expertise has h ad  a strong 
academ ic base in  the past and  rem ains so in  an Irish  context, the focus 
in  th is chapter w ill be on potential adopters in  industry . As outlined, 
the techniques offer applications in  bo th  prim ary  food p roduction  and 
food processing.
2.5.1 Food Processing Sector.
W ith  regard  to the Food processing sector, au thors A ngold, Beech and  
T aggart assert th a t advanced biotechnological techniques are relevant 
p rim arily  to low  volum e p roduction  as in  the m anufacture of flavours 
an d  functional ingredients. These authors describe tw o scales of 
biotechnology practice; Small scale and  Large scale. (Table 2.2) Small 
scale biotechnology practice is associated w ith  h igh  value added  
p roduction , com m ands higher R&D cost and  read ily  em braces 
techniques such as genetic engineering. This level of biotechnology
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practice is associated prim arily  w ith  the pharm aceutical industry.
Large scale biotechnology practice is concerned w ith  low  value added  
production , lower R&D costs and  process engineering  and  
ferm entation  technologies. This type of b iotechnology is used  in the 
food industry  and developm ents have occurred in  this area steadily 
and  undram atically  over the years. Large scale biotechnology practice 
refers to that used in  advance of the developm ents associated w ith  new  
biotechnological techniques.
Table 2.2 Two Scales of Biotechnology Practice.
Small Scale Large Scale
Scale of Plant 100-1000 1 100001
Value added in  Production H igh Low
Type of Product M edical, Pharmaceutical 
H ighly Specialised
Food,
Transformed
Commodity
Main area of R&D Genetic Manipulation Process
Engineering,
Fermentation
technology
R&D Cost H igher Lower
Source: A ngold R., Beech G. and  Taggart J. (1989), Food Biotechnology. 
C am bridge U niversity Press, p.2.
A ngold, Beech and  Taggart offer the follow ing explanations for food 
firm s reticence in  becom ing involved w ith  the less established 
currently  fashionable advances in  biotechnology, includ ing  genetic 
m an ipu lation  and  cloning of p lan t tissue cells.
1. The food industry  operates a large scale com m odity transform ation 
type of biotechnology, characterised as in  all food processing by a low 
pro fit m argin. Cheap raw  m aterials are converted b y  cheap processing
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m ethods to cheap products. The low profit m arg in  of the food 
processing industry  w ould  no t support expensive R&D associated w ith  
sm all scale biotechnology practice in  the pharm aceutical industry.
2. Because of the desirability of advances and  im provem ents in 
healthcare, R&D is often subsidised in  the pharm aceutical industry  by 
governm ents of affluent nations. Also, even w ith o u t subsidies, people 
are often w illing to pay  h igh prices for healthcare products. This gives 
an  econom ic clim ate for the pharm aceutical in d u stry  in  w hich 
expensive R&D m ay be undertaken.
A ngold, Beech and  Taggart a s se r t:
"Generally speaking w here higher cost biotechnology is used  in 
the food industry  it is likely to apply to the production  of 
m aterials used  in sm all volum es such as flavours and 
functional ingredients, low er cost b iotechnology being used 
w here large volum es are involved."34
This w ou ld  indicate that the target m arket for new  biotechnological 
techniques in  the food processing industry  w ou ld  be food ingredient 
suppliers and not necessarily food processors. It m ay be rem em bered 
th a t over the years a large share of new  technologies used  in  the food 
processing industry  have orig inated in  o ther in d u stria l sectors. Stevens 
asserts th a t in ternal R&D in  the food processing in d u stry  is prim arily  
concerned w ith  p roduct innovation.
"The food processing industry  develops a continual stream  of 
new  products, some of w hich are based  on  far reaching 
innovations in  processing and packaging. H ow ever a great deal 
of food industry  R&D is focussed on m inor features of end 
products w hich  are often variations or im itations of existing 
products."35
2.5.2 Primary Food Production.
Sim ilarly, in  the farm  sector com m on sense w o u ld  tell us th a t w hile
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farm ers m ay adop t and  use innovations m ade possible th rough  the use 
of advanced biotechnological techniques they w o u ld  no t be involved 
in  the laboratory in  developm ent. L iterature indicates that one of the 
factors affecting w h at farm ers im plem ent in  their operations includes
the degree of sophistication required for effective u s e .36 The greater the 
level of com plexity associated w ith  any innovation  the less likely it is 
to be adopted inside the farm  gate.
L iterature accessed indicates, therefore, th a t the target m arket for new  
biotechnological techniques are no t prim arily  the farm ers and  the food 
processors bu t suppliers to these sectors. In the food processing 
industry  the sector of greatest potential use is indicated  as those 
involved  in  sm all scale biotechnology, m anufactu ring  flavours and  
functional ingredients. In  p rim ary  food production  the sector of 
greatest potential use is identified as chemical and  seed com panies 
suppling  the inputs to farmers. Farmers and  food processors are 
identified as secondary users.
2.6 Public Perception.
The prim acy of the public perception issue relative to the future 
diffusion and  adop tion  of new  biotechnological techniques is self - 
evident. In dem ocratic nations,
"The rates and  risks of progress are m atters for society to 
decide."37
Public opinion influences the rate and  direction of diffusion of new  
biotechnological techniques th rough  straight fo rw ard  sales and  also 
th ro u g h  the generation of governing regulatory  environm ents. In  the 
follow ing section discussion is focussed u p o n  the public's perception  
of new  biotechnological techniques, the regu latory  and  com m ercial
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environm ents w hich have evolved, directed  by public perception  
issues as well as P.R. strategies undertaken  by proponents of these 
techniques.
2.6.1 Attitudes to Use of N ew  Biotechnological Techniques.
To date public opin ion  has been  d iv ided  as to the m erit of 
biotechnology use. W hile industrial groups often  perceive new  
biotechnological techniques as im portan t determ inan ts of fu ture 
success in  industries as diverse as healthcare and  agriculture, 
opposition stems from  m ultiple concerns relating to use. Lacy, Busch 
and  Lacy have characterised public concern in  term s of nine m ajor 
d im en sio n s .38 These are concerns relating  to the environm ent, health , 
agriculture, science, social justice, econom ic concentration, progress, 
nature and  the sanctity of life.
The perceived risk of biotechnology to the env ironm ent relates 
prim arily  to the release of genetically m odified organism s. O pponents 
of the new  techniques w arn  that G.M.O.s m ay displace existing plants 
and  anim als, d isrup t the functioning of ecosystem s and  reduce 
biological diversity. They highlight the fact that, w hile any given 
in troduction  has only a small chance of becom ing a problem , each is 
characterised as a low  probability, h igh incident risk, w ith  long ru n  
consequences w hich can be enorm ous and  irreversible.
The public also fear negative health  im pacts th ro u g h  exposure to 
genetically engineered food products. Portions of the public believe 
th a t certain genetically engineered p roducts could have un in tended  
negative consequences, for exam ple they m ay contain increased levels 
of toxins or disease causing m icro organism s w hich  are resistan t to 
antibiotics. Concerns have also been  voiced w ith  respect to the 
possible pain  and  suffering to farm  anim als as a consequence of 
genetically engineered changes.
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Use of biotechnology is also seen as another step in  the process of 
reductionism  in  science. Through use of new  biotechnological 
techniques scientists have been able to rearrange the genetic code in  
o rder to produce short-term  commercial gains. This approach perm its 
only the m ost sim plistic understand ing  of the subcellular w orld  and 
de-em phasises a m ore sophisticated understand ing  of complex eco­
system s. The fundam ental issue relating to concerns of social justice is, 
'W ho w ill gain and w ho will lose in  the application  of new  
biotechnological techniques?' This issue is increasingly cited as a 
rationale for m oving cautiously on new  technologies and has lead to 
the generation of the fourth  hurd le in  the EC. O pposition to the 
com m ercialisation and  use of rbST is largely based  on the expected 
negative im pact its in troduction  w ou ld  have on the incom es of 
sm aller farm  families. O n a broader level, there is concern that 
biotechnology w ill continue and accelerate the tren d  tow ards 
increasing concentration of pow er in  the hands of a small num ber of 
corporations. It is predicted  that by  the next century  a small num ber of 
h ighly  diversified, m ultinational corporations w ill likely control m ost 
of the food system. This scenario is quite probable as, increasingly, 
pow erfu l intellectual p roperty  rights, particu larly  in  the US, allow 
ow nersh ip  of genetically m odified organism s.
The seventh  concern relates to our fundam ental concept of progress. 
O pponents of new  biotechnological techniques argue that w e need  to 
redefine progress, extending it beyond term s such as output, utility  and  
efficiency. It is asserted  that a definition of progress should encom pass 
the entire context in  w hich  hu m an  beings live including  all of the 
econom ic, social and  ethical dim ensions. N ew  biotechnological 
techniques then  need  to  be evaluated  in  term s of their contribution to 
progress as redefined. O pponents also question the appropriateness of 
m anipu lation , control and  dom estication of natu re  to serve our 
econom ic purposes. P roponents of this perspective assert tha t natu re
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has an  order, an integrity  and a purpose of its ow n  th a t one should  
respect, no t for our sake bu t for it's sake. Im portan tly  those concerned 
w ith  preserv ing  the integrity of nature are no t posing  the issue strictly 
in  term s of risks and  benefits. Finally, opponents of new  
biotechnological techniques argue that use of these techniques m akes 
any anim al, including  H om o sapiens no different than  a 
m anufacturing  process that can be claim ed as an  invention and 
patented. They argue that the sacredness of life as well as the very 
concept of life are challenged by genetic engineering.3?
2.6.2 A w areness and  Concern.
Research undertaken  in  the US has show n th a t acceptance of 
biotechnology applications are firm ly roo ted  in  the end  objectives of 
each specific use.
Figure 2.0 Levels of A pproval of D ifferen t A pplications of G enetic 
E ngineering
I  Cancer Treatment 
EH Disease Resistance Crops 
HI Frost Resistant Crops 
HI Better Farm Animals 
More Effective Pesticides 
ËÜ Larger Game Fish 
H  Improving Human Traits
n /a  = Comparative data unavailable
No risk to humans No risk to humans and
very remote risk to environment
Source: Office of Technology A ssessm ent, U.S. Congress (1987), New  
Developments in Biotechnology.Public Perceptions of Biotechnology. 
OTA-BP-BA-45 U.S. G overnm ent P rin ting  Office, W ashington  D.C.
In  an  OTA survey in  1987 respondents w ere asked, first, to assum e that 
applications involved neither direct risk  to hum ans nor an 
environm ental risk and  then  to evaluate their approval of d ifferent 
applications of genetic engineering. (Figure 2.0) Seven applications of 
genetic engineering w ere examined: a new  treatm en t for cancer, new  
vaccines, cures for hum an  hereditary  diseases, disease resistan t crops, 
frost resistan t crops, m ore productive farm  anim als and  larger gam e 
fish. A clear m ajority approve of all seven applications of genetic 
engineering. H ow ever, approval ranged  from  a h igh  of 96% for new  
treatm ents of cancer to a low of 66% to p roduce larger gam e fish. The 
results also illustrated  a variation  in  en thusiasm  for financing these 
applications of genetic engineering, w ith  75% strongly approving  of
vaccines and  only 25% strongly approving  of larger gam e fish.40 It is 
in teresting to note that research also undertaken  by  the Office of 
Technology A ssessm ent in  the US indicates that w ith  increasing 
aw areness will likely come increasing concern. In  a study  on 
fam iliarity  and  concern about several environm ental issues levels of 
concern closely paralleled levels of fam iliarity .41
2.6.3 O pposition  G roups.
O pposition  to the use of new  biotechnological techniques is becom ing 
m ore apparen t as public interest groups gain support and  pow er. 
Jerem y Rifkin of the W ashington based  F oundation  on  Economic 
Trends is though t to be biotechnology's m ost im portan t foe. H e and  
his group  are the creators of the Pure Food C am paign, w hich w as set 
u p  w ith  the objective of organising a boycott of genetically engineered 
foods. In  1992 some 1500 US chefs agreed  to d isp lay  the cam paign's 
logo bearing the w ords,
"We do  no t serve genetically engineered  foods." 
on  their m enus. H ow ever the Pure Food C am paign has also targeted
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grow ers, distributors, retailers and  food processors to boycott gene- 
technology foods. The Cam pbell Soup Co. has been  singled o u t for 
special attention. This is because of it's involvem ent w ith  Calgene in  
the developm ent of the Flavr Savr™ tom ato. C am pbell Soup Co. o w n
the righ t to  use Flavr Savr™ tom atos in  their processed products.42 
The Pure Food C am paigners are particularly  incensed as genetically 
engineered food products need no t be labelled as such b y  US law . In 
the US Food and  D rug A dm inistration 's M ay 29 1992, Statement of 
Policy:Food Derived from  New Plant varieties, it w as strongly  
signalled th a t it w ill fall to the p roduct developers to  prove safety and
inform  the  consum er.43
Figure 2.1 Pure Food C am paign Logo.
Source: Vines G.(1992), "Guess w hat's  com ing to dinner", N ew  
Scientist, 14 N ovem ber, pp. 13-14.
In Europe draft proposals have been  p u t fo rw ard  requiring  the 
labelling of genetically m odified organism s as such.44 In the absence of
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labelling, cam paigners believe A m erican consum ers and their children 
w ill become the unw itting  guinea pigs for these radically  new  foods.
In the w ords of Jeremy Rifkin,
"If food producers are so p ro u d  of these brave new  w orld  
products, w hy are they so afraid to label them?" 45
2.6.4 P.R. Strategies of Companies Involved w ith N ew  
Biotechnological Techniques.
M any food experts have come ou t strongly  in  su p p o rt of vo luntary  
labelling. They assert
"...just because the regulators do n 't insist on  labelling 
recom binant foods doesn 't m ean  w e shou ldn 't label them . If w e 
deny  consum ers the know ledge th a t a p ro d u ct is engineered, w e 
deny them  the opportun ity  to choose biotechnology for 
them selves...A nd that is no w ay  to bu ild  a m arket.''46
This approach  is certainly reflected in  Calgene's Public Relations policy
for the Flavr Savr ™ tomato. C arolyn H ayw orth  m anager of public 
relations for Calgene outlined a three p ronged  approach  to the
prom otion  of the Flavr Savr ™ tom ato.
"First she thought there w as a need  to educate food industry  
people about the new  technology and the products. Second, 
Calgene w as planning to label the tom ato and  to provide point 
of purchase brochures explaining the tom ato to the consum er. 
Third, Calgene plans to be com pletely open  to the public w ith  
regard  to inform ation, regu latory  filings etc. The com pany 
position  is th a t inform ed consum ers w ill m ake sound 
decisions."47
Public education  is also asserted to be the corner stone of M onsanto's 
prom otional plans for their gene spliced products.48
Carol Tucker Forem an has h igh ligh ted  the inheren t problem s of 
educational cam paigns in  the prom otion  of gene-technology products.
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She has noted that often,
"there is an  assum ption that if the public can ju st be m ade 
understand , it will open its arm s and  receive biotechnology as 
an  unm itigated  b le ss in g ."49
This ignores the fact that even expert academ ic biotechnologists have 
often adm itted  diam etrically opposed  view s on  the social risks and  
benefits of biotechnology. Also this concept of com m unication leans 
m ore to reassurance than  to a tw o w ay com m unication channel, 
w here the consum er has an opportun ity  to speak, to listen, to be heard , 
to act and  to respond. It m ust be rem em bered th a t the problem s 
associated w ith  biotechnology m ight no t be connected w ith  
com m unication b u t w ith  conflicts of values, (noted previously) w hich 
m ust be resolved in  order to m ove forw ard.
Tucker has also outlined two specific difficulties associated w ith  
educational cam paigns. The first concerns the considerable m istrust 
of scientific advances w hich exists today. Consum ers are influenced by  
the grow ing public dism ay over accidents and  failures of other 
technologies such as the nuclear pow er p lan t at Chernobyl. In  add ition  
it appears consum ers are becom ing increasingly concerned about 
source credibility. The public has lost confidence in  the governm ent 
institu tions it once counted on to resolve questions of safety and 
conflicts betw een  scientific and  social an d  economic view  poin ts.50 A 
s tu d y  u n d ertak en  in 1991 w hich  investigated  E uropean consum er’s 
perceptions w ith  regard  to biotechnology indicated th a t the m ost 
reliable sources of inform ation on b io techno logy /genetic  engineering 
are considered to be, respectively, consum er organisations,
env ironm enta l organisations and schools and  universities.51
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2.6.5 Attitudes of Consumers to Gene-Technology Foods.
D evelopm ent of a successful prom otional cam paign for gene- 
technology products necessitates a com prehensive know ledge of 
existing attitudes of potential consum ers. In the US extensive research 
has been  undertaken  on consum er perceptions of m ilk p roduced  by 
rbST treated  cows. Studies undertaken  in  the state of W isconsin, 
w here consum ers are fam iliar w ith  the concept of rbST indicated that 
71% w ere concerned about the possible ill health  effects of m ilk from  
treated  herds and  77% expressed a preference for m ilk labelled as
com ing from  un treated  herds.52 Further research u n d ertak en  in  N orth  
Carolina indicated that 34% of consum ers are very  concerned and  43%
som ew hat concerned about eating genetically engineered  vegetables.53
N ew  biotechnological techniques and  their applications have n o t been  
the focus of vociferous public debate in  Ireland as in  m any other 
E uropean countries, notably G erm any and  Denm ark. Public interest 
and  know ledge thus of the techniques is naturally  low er here th an  in  
o ther countries w ith  greater involvem ent. In Ire land  research 
undertaken  in  December 1989 indicated  that un d erstan d in g  of the term  
biotechnology is very lim ited am ong Irish  adults. O nly one in  four 
have any spontaneous know ledge of the topic. O ver half of all those 
in terv iew ed h ad  never heard  of it and  only one in  ten  felt they knew  
anyth ing  about it. Research d id  indicate a m ore positive th an  negative 
attitude tow ards biotechnology and  the m ore know ledgeable people 
w ere in  the area the m ore positive their outlook. To a lim ited  extent 
respondents recognised that biotechnology w ould  p lay  a m ore 
im p o rtan t role in  the future of Ireland  than  it does at p resen t and  
agriculture and  health  care w ere the areas of fu tu re  potential im pact 
identified .54 Research undertaken  on  behalf of the D irectorate G eneral, 
Science Research and  D evelopm ent of the E uropean  Com m ission 
indicated  that, in  a ranking of EC countries objective know ledge of
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biotechnology, Ireland came n in th  ou t of twelve. U sing an index of 
objective know ledge score w here seven is com plete know ledge and  
zero is no know ledge Irish respondents scored a m ean of 3.56. Irish 
respondents also indicated h igh  levels of support for Biotechnology
research.55
2.7 Summary.
In  this chapter new  biotechnological techniques w ere review ed 
th ro u g h  use of the m arketing mix fram ework. It w as h oped  th a t use of 
this fram ew ork w ould  allow identification of the salient factors 
affecting adoption, from  the perspective of the potential user.
N ew  biotechnological techniques offer applications to b o th  food 
processing and prim ary  food production  sectors. In  p rim ary  food 
p roduction  use of the techniques can aid  developm ent of im proved  
crops and  m ore productive lifestock. W ith regard  to food processing, 
the techniques m ay be used  to im prove the perform ance of food 
ferm entation m icroorganism s and  enzym es. Due to the expense 
associated w ith  becom ing involved  w ith  new  biotechnological 
techniques and  the h igh  volum e natu re  of food processors' p roduction  
activities, experts assert the techniques are m ost usefully  targeted  at 
food ingredient producers. In  the context of p rim ary  food production, 
use w ould  be anticipated in  agricultural supply  firms.
The US leads the race in  the developm ent and  use of new  
biotechnological techniques follow ed b y  W estern Europe and  Japan. 
Ireland  has b egun  to becom e involved w ith  the techniques th ro u g h  the 
N ational Biotechnology P rogram  in itia ted  in  1987. M ost w ork  is 
centred  in  the universities and  little is know n abou t the involvem ent 
of Irish food firms w ith  the techniques. Strict regulations govern  use 
of the techniques and  experts assert European food firm s face tougher 
regu latory  environm ents th an  those operating in  the US.
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The rate and  direction of diffusion of new  biotechnological techniques 
depends largely o n  consum er response to use of these technologies. To 
date opposition to use of the techniques stem s from  concerns relating 
to environm ent, health , agriculture, science, social justice, econom ic 
concentration, progress, natu re  and  sanctity of life issues.
P roponents of the techniques are experiencing increased public 
relations problem s as opposition  groups continue to gain support and  
m edia attention. H ow ever, although gene-technology foods are not 
requ ired  to be labelled as such, m ost firm s are p u rsu ing  a very  open 
P.R. strategy w ith  genetically engineered foods m arketed. Difficulties 
have been  h ighlighted w ith  regard  to educating consum ers to accept 
genetically engineered foods and  m any feel problem s of consum er 
resistance stem  not from  com m unication difficulties b u t conflicting 
values. Research show s that know ledge of new  biotechnological 
techniques is poor in  Ireland although attitudes to use are m ore 
positive than  negative.
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Chapter 3 Review of the Irish Food and Drink Industry.
3.0 Introduction.
This study  is based in the Irish food and d rink  industry . The p rim ary  
objective is to investigate Irish food and  d rink  firms' response to the 
technological discontinuity  posed by  the em ergence of new  
biotechnological techniques. The pu rpose  of this chapter is to analyse 
the Irish food and d rink  industry  and  review  the context into w hich 
new  biotechnological techniques m ay be adopted . The review  w ill be 
undertaken  th rough  a SWOT analysis as p roposed  by Kotler.1 
O pportunities and threats posed by the external environm ent w ill be 
identified and corresponding strengths and  w eaknesses of the food 
industry  presented. The chapter concludes w ith  a brief review  of State 
p lans for Irish food and drink.
3.1 The Irish Food and Drink Industry.
The food and drink  industry  is very  im portan t to the Irish econom y. In  
total it accounts for 10.5% of GDP, 14.5% of em ploym ent and 25% of 
exports. The industry  is particularly  im portan t because of the low level
of profit repatriation associated w ith  i t .2
Two h u n d red  and seven thousand people are involved w ith  the Irish 
food and drink  industry , 167,000 are producers in  agriculture, forestry 
and  fishing and 40,000 are involved in processing. Food processing is 
largely controlled by  indigenous com panies and  food exports account
for alm ost 40% of foreign exchange earnings.3 In 1989 the C.S.O. 
estim ated there w ere 835 establishm ents em ploying three or m ore
persons in  the food, d rink  and tobacco sector.4
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3.2 The Irish Food Industry: Strengths and Weaknesses, 
Opportunities and Threats
D iscussion in  this section shall be centred on inform ation contained in  
Table 3.0 The Table outlines the m ost im portan t O pportunities and  
Threats posed by the external environm ent to the Irish food industry  
and  corresponding Strengths and W eaknesses. It has been com piled 
th rough  reference to m ultip le texts concerning the Irish food industry .
Table 3.0 The Irish Food Industry: Strengths and Weaknesses, 
Opportunities and Threats.
Strengths
*Green, environmentally clean 
image.
‘ Factor cost advantages. 
‘ Government support.
Opportunities
‘ New Competitive markets. 
‘ Increased value added 
production.
Weaknesses
‘ Over reliance on intervention 
and third country markets 
leading to a narrow products 
range.
‘ Scale.
‘ Seasonality.
Threats
‘ CAP reform.
‘ increased industry concentration 
and consolidation.
‘ consolidation in food retailing.
Source: Com piled th ro u g h  reference to relevant texts.
3.2.1 Strengths.
C entral strengths of the Irish  food industry  are;
*The association of Irish food w ith  a green and  environm entally  
clean im age
^Factor cost advantages enjoyed by  Irish food producers th rough  
grass based p roduction  of m ilk and  beef
^Generous governm ent su p p o rt of the food industry  in  Ireland
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The first and perhaps m ost im portant streng th  is the green and 
environm entally  clean im age of Irish food. This w as h ighlighted  as a 
grow ing source of com petitive advantage by the report of the P.A. 
Consulting G roup to the Industrial Policy review  group in 1992. The 
report h ighlighted the im portance of protecting and  developing this 
advantage by  the establishm ent of tight b u t app ropria te  environm ental
s tan d a rd s .5 Research indicates that the environm entally  clean im age of 
Irish food w ill becom e m ore im portan t in the future. A ccording to a 
repo rt from E urom onitor,
" environm ental awareness, although often difficult to 
docum ent in statistical term s, has becom e an inevitable and 
alm ost ub iquitous aspect of E uropean consum er behaviours in 
the 1990s."6
In relation to food consum ers are w illing to pay  extra for goods w hich 
they perceive to be environm entally  sound - including substantial 
prem ium s for "organic" fruit and vegetables, grow n w ithou t the use of 
artificial pesticides and  fertilisers.7
The second strength  of the Irish food and  d rink  industry  is that it 
possesses factor cost advantages through  grass based production  system s 
for Dairy and Beef products. It is asserted that,
"Given an  efficient processing sector, w e ought to be the low est 
cost E uropean producer of products that su it our raw  m aterial 
production  cycle, which are m ainly com m odity  products".«
Factor cost advantages have also been developed in m ushroom  and 
poultry  sectors.
The rem aining identified strength  of the Irish food ind u stry  is 
governm ent support. Over the years State incentives to the food
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industry  have been generous and seem  to have been prim arily  designed  
to increase the pace of industrial restructuring. Program s have been  
successful in rationalising the industry  and  developing scale. This 
how ever has been achieved at significant cost and  the sector rem ains 
prim arily  a com m odity based industry  w hich is significantly dependen t
on non-com m ercial m arkets.9 Significant su p p o rt for this industry  
seems set to continue. M ost recently the Industria l Policy Review 
G roup highlighted  the food industry  as a sector of national advantage 
and recom m ended policy to develop this sector particu larly  in  the area
of food processing.10
3.2.2 W eaknesses.
Prim ary factors w hich contribute to the uncom petitive na tu re  of the 
Irish food industry  have been identified as;
*The seasonal p attern  of Irish  agriculture particu larly  in  m ilk 
and  beef production.
^Insufficient scale of food com panies for com peting in E uropean  
m arkets.
*An over reliance on com m odity products supported  by  the 
particu lar features of price and  m arket fram ew ork of the 
Com m on A gricultural Policy 11
Pronounced seasonality of p roduction  due to a relatively short grow ing 
season is the price producers pay  for grass based production  system s. 
Recent reports have urged  incentives to ensure year ro u n d  supply  of 
m ilk and  beef. In particular the h ighly  seasonal nature of the beef kill, 
w ith  a large concentration in the fourth  quarter, has contributed  to an
over reliance on in tervention  and  Third w orld  sales.12
Food com panies also need to develop scale if they are to com pete in  the
6 6
European food industry  of the future. W hile a num ber of food based 
PLCs are developing in Ireland, they are still sm all by  European 
standards and  lack the scale to launch brands, m ake m ajor acquisitions 
or invest heavily  in m edium  term  d ev e lo p m en t.13 T rends of 
increasing concentration and  globalisation in  the European  food 
industry  discussed later in this chapter necessitate that food firms 
develop scale in the short rather than  long term  if they are to becom e 
players in the European food m arket of the '90s.
Lim itations due to seasonality and lack of scale, as w ell as other factors, 
have lead to the creation of an food industry  in Ireland w hich is 
heavily  dependen t on in tervention  and  th ird  w orld  m arkets, involved 
w ith  low  levels of value added production. In 1990, 45% of beef ou tpu t, 
55% of bu tte r ou tp u t and 54% of skim  m ilk pow der ou tp u t w ent into 
in terven tion  identifying Ireland as the country  w ith  the h ighest 
dependence on intervention in these com m odities of all EC m em ber
states.14
Value added  levels, while increasing, indicate a h igh  dependence on 
com m odity products. In 1987 value added  as a percentage of gross
o u tp u t for the entire Irish food processing sector w as just 27%.^  Trends 
in  R&D spend ing  w ould no t indicate any short term  change in  the 
value-added  com ponent of production. As a percentage of sales the
average R&D spend for firms in the Irish food sector is 0.3%.16 This 
spend  is low  w hen  com pared w ith  tha t spen t in  a E uropean context. 
The results of a survey conducted on the R&D activities of food firm s 
all over Europe indicated the average spend in 1987 as a percentage of
sales w as 0.8%.17 Com parison of governm ent support policies w ith  
those undertaken  overseas w ou ld  indicate that research and 
developm ent and  new  product developm ent appears to be given a
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higher priority  for the developm ent strategies for the food sectors of 
o ther countries. This has lead to a recom m endation by  the PA 
consulting group that in the future,
"Existing State assistance for the food sector should  be 
reallocated aw ay from  fixed asset investm ent tow ards R & D /new  
p ro d u c t developm ent supports."18
3.2.3 Threats.
W eaknesses identified have increased in im portance in  light of the 
p roposed  dism antling of the C om m on A gricultural Policy. CAP 
reform  m ust be regarded as the p rim ary  threat facing Irish food firms.
It is because the food industry  cannot continue to bu ild  strategies to 
exploit the CAP that a new  direction m ust be found. CAP reform  w ill 
involve a gradual reduction of price and  m arket supports, w hich, it is 
hoped , w ill p u t an end to intensive efficient p roduction  of large 
quantities of unnecessary foodstuffs. This inform ation has lead m any 
including  D avid H edigan, Food and  N atu ral Resources m anager at A n 
Bord Trachtala to recom m end that Irish food com panies, in  spite of 
their w eaknesses, should  endeavour to develop new  com petitive 
m arkets to ensure their fu ture.19
The E uropean food m arket represents a golden opportun ity  for Irish 
food firm s seeking to m ake the transition . This food m arket accounts 
for sales of $600 billion annually  and  services the needs of 320 m illion
consum ers. 20 Features of the burgeoning  food m arketplace how ever, 
m ay m ake success difficult for po ten tia l Irish exporters. Two key issues 
effecting change in this huge ind u stry  w ill pose serious difficulties for 
Irish  food firms. Theses are;
*The trends tow ards, increasing concentration and  globalisation 
of the European food m arket
6 8
*The trend towards consolidation in food retailing 21
Trends of industry  concentration and  globalisation have lead to a 
s ituation  w here pow er in the E uropean m arketplace is increasingly 
concentrated in  the hands of a few giant conglom erates. A num ber of 
factors have contributed to this trend;
1. M any com panies feel that in order to com pete in a pan-European 
m arket they need to achieve a critical size. In o rder for com panies to 
achieve econom ies of scale increased concentration and  globalisation 
w ill continue.
2. M ergers and acquisitions are a cost effective m ethod  of establishing 
positions in both  dom estic and foreign m arkets. They prov ide firms 
w ith  an  established distribution netw ork. This w as reported  to be 
BSN.s m ain  justification for the h igh price it pa id  for H P foods in 1988. 
(Table 3.1)
3. The im portance of established b rands cannot be underestim ated  in 
today 's food m arkets. The cost of bu ild ing  b rands in  foreign m arkets 
can be prohibitively  expensive and  m any com panies are p repared  to 
p ay  a h igh  price for established brands. N estle p a id  £2.5 billion for 
R ow ntree for this reason.
4. Finally harm onisation  of food law  has encouraged com panies to 
expand  their interests outside their dom estic m arkets to exploit the 
to tal EC m arket of 320 m illion c o n s u m e r s .22
As noted  Irish food firms suffer from  lim ited sale of operations, thus 
these trends m ust be regarded  as a significant threat. The enorm ity of 
the problem  is h ighlighted if one considers the case of MD Foods. M D 
Foods dom inate the D airy sector in D enm ark, the com pany enjoys a
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tu rnover of about £1.3 billion. Concerns have been  expressed about the 
ability of this com pany to com pete on a pan-E uropean scale. This 
com pany as other processing giants w ho dom inate the food ind u stry  in 
D enm ark and  other E uropean states are significantly larger than  their 
largest Irish  com petitor.^
Table 3.1 Takeovers b y  E uropean Food G roups, (1988-1989)
Purchaser Purchased Product Range
BSN(France) Birkel(West Germany) 
G albani(Ita ly)
Nabisco European
P asta
D airy
Biscuits
Cadbury Schweppes(UK) Bassett(UK)
Trebor(UK)
Confectionery
Confectionery
DMV(Netherlands) M elkunie(N etherlands) D airy
Douwe Egberts(Netherlands) Van N elle(N etherlands Coffee
Grand Metropolitan(UK) Pillsbury(US)
Burger King and W impy
Various 
Fast food 
chains
J Lyons(UK) Dunkin' Donuts(US) Coffee and 
doughnuts
Nestle(Switz) Rowntree(UK) 
Buitoni Group (Italy)
Confectionery
Pasta,
Confectionery
United Biscuits (UK) Raffinerie Tirlemontoise 
Ross Youngs(UK)
Sugar
Frozen Foods
Source: E urom onitor Pic. (1990), European Food Companies, E u ro p e a n  
Publications, London.
The tren d  tow ards retail concentration has also been  no ted  in  the 
develop ing  European food m arket. This phenom enon  m ust be 
regarded  as a m ixed blessing for food m anufacturers in tend ing  
exporting  to Europe. O n the one h and  few er outlets reduce 
d istribu tion  costs and  facilitate supply . O n the o ther h an d  dependence 
on few er suppliers reduces the bargain ing  pow er of m anufacturers
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especially those m arketing secondary brands. Consequently, 
m anufacturers are under p ressure to provide heavier trade  support
bo th  for existing and new  products.24 This m ay be regarded  as a serious 
th rea t for Irish food firm s w ho have little experience w ith  com m ercial 
end-user products.
3.2.4 Opportunities.
There are tw o prim ary  inter-related opportunities open to Irish  food 
firms. These are to;
^Develop new  com petitive m arkets
’‘M ove into increased value added  production .
As ou tlined  the m ost obvious com petitive m arket for Irish  food 
exporters to target is that of m ainland Europe. In the last section 
problem s posed by features of this developing m arketplace w ere 
discussed. H ow ever, the increasing im portance of environm ental 
issues for consum ers on a pan-E uropean level represents a w indow  of 
opportun ity  for Irish food firms. As Ireland has an internationally  
recognised green and environm entally  clean im age this feature is one 
w hich  Irish  food firms could use to their advantage. 'K errygold' is one
Irish b rand  w hich has already succeeded w ith  this strategy. 2$
V alue-added production  is also supported  by  trends in  the E uropean 
m arketplace. Research indicates that trends influencing the E uropean 
food industry  m ay be sum m arised  as follows;
* G row th in Popularity  of convenience food p roducts
* G row ing aw areness of diet and health
* M ore adven tu rous consum er tastes
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* C hanging consum er food spending patterns.26 
Increasing use of convenience food products is a function of changing 
lifestyles w here m ain occasion, m ultip le person  m eals are becom ing 
obsolete. Experts predict convenience foods are set to increase as a 
p roportion  of total retail food purchases. Volum e sales of m icrow ave 
ovens, predom inantly  used for heating pre-cooked food m ay be used  as 
an indicator of the grow th of this sector of the food m arket. In 1992 
m icrow ave ovens w ere found in  alm ost one th ird  of all W est 
E uropean  households, particu larly  in Finland (53% ow nership) in 
Britain( 48% ow nership) and  in Sw eden (37% ow nership). 27 This sector 
is also predicted to grow to the year 2000. (Table 3.2)
Table 3.2 Microwave Ovens Volume Sales 1990-2000
Thousand Units
1990 2000 %increase
1990-2000
A ustria 140 202 41.2
Belgium 220 331 50.7
Denmark 60 83 51.6
Finland 342 476 38.3
France 1,620 2,304 47.0
Greece 26 37 37.8
Ireland 39 58 49.5
I ta ly 240 351 37.5
Luxemburg 15 29 53.3
N etherlands 190 291 50.1
N orw ay 165 206 50.7
Portugal 40 82 77.8
Spain 280 452 67.6
Sweden 420 604 26.5
Sw itzerland 112 165 40.9
United Kingdom 2,400 3,256 34.0
West Germany 3,100 4,434 54.5
East Germany 388 802 106.7
Source: E urom onitor Pic. (1991), Book of European Forecasts from
N ational Statistical O ffices /U N /E u ro sta t/o th e r.
D ata com piled by 'Europanel' agencies also clearly show s the increasing
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p opu larity  of convenience foods. Table 3.3 com pares penetration  and 
trend  data for frozen ready cooked meals and  a staple product, butter, in  
a num ber of E uropean countries. The data clearly show s that while 
b u tte r  enjoys a greater penetration  in m ost E uropean  countries than  
Frozen Ready Cooked meals its franchise is declining w hile that of 
convenience foods is increasing rapidly. O ther convenience products 
enjoying a surge in  popu larity  include;
Frozen Pizzas - sales increased in '93 by 18% and 14% in  D enm ark and 
Ireland  respectively,
P repared  Salads - M arket grew by 16% in G reat Britain in  '93 
Packet Soups - Sales increased during  '93 by  16% in Austria.28
Table 3.3 Household Trends and Penetration Data - Food Products 
(1992-1993)
Frozen Ready Butter
Cooked Meal
Trend '93/ Penetration Trend '93/ Penetration
'92% '92%
Belgium -5 B -3 A
Denmark +25 B -19 A
France -1 B -1 A
West Germany -1 B -3 A
Great Britain +35 B -3 A
Ireland +7 N /A -2 B
N orw ay +18 B +1 A
Spain +16 B +17 B
Portugal +15 C -5 B
Sw itzerland +12 B +2 A
Turkey +/-0 c +/-0 B
K e y : Trend 93/92%  - Volume
Penetration  -  Quarterly Market 
A  = Over 50%
B = 20-50%
C = Under 20%
Source: The E uropanel In ternational Research C o-ord ination
C entre  (1994), Europanel M arketing Information for Europe, E u ropanel 
EIM, Sw itzerland, pp. 8-9.
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G row ing awareness of health  and diets has also paradoxically lead to an 
increasing dem and for value added  products. Europes' affluent and 
w ell educated populations are becom ing increasingly aw are that the 
food we eat affects our state of health. In 'Europe 2002' author Bengt 
W alstrom  predicts that by 2002 special diets will form  an integral p art
of im m ortality program s to help us live longer.29 The progressive 
ageing of the European population, as in other industrialised  
populations, has also contributed  to this 'healthiness' trend  as an older 
popu la tion  often exhibits a m odel of food consum ption  w ith  less fats 
and  w ith  a total lower calorie intake. In sum  it expresses a greater need 
for nu tritionality .30
Trends tow ards increasing affluence coupled w ith  m ore adventurous 
consum er tastes are also encouraging increased levels of developm ent 
in  the food industry. P roducts like yogurt, also a prim e beneficiary of 
the health  trend, has consolidated its position  in recent years. (Table 
3.4) Yogurt sales are expected to increase steadily in  the next five years.31
Table 3.4 Yogurt: Per Capita Consumption 1985-1990
Kilograms 1985 1990
Belgium 6.6 7.2
Denmark 15.5 14.8
Finland 39.4 39.5*
France 12.7 16.1
West Germany 7.9 10.6
N etherlands 17.5 21.5
Sw itzerland 16.2 16.9
United Kingdom 3,0 4.1*
*Data unavailable for 1990, 1989 data presented
Source: E urom onito r Pic. (1992), The Euromonitor Compendium
of Marketing Information , 1st Edition, Eurom onitor Publications Ltd., 
London, p .177.
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C hanging consum er spending patterns are also leading to increasing 
dem and for value added  food products. Fast food has become 
increasingly popu lar w orldw ide not least so in Europe. (Table 3.5) N ot 
only does fast food fit in better w ith  m odern  lifestyles (shorter w orking 
lunch breaks, etc.,) bu t it also represents an effective response to the 
trad itional com plaint that norm al restau ran t eating is too expensive to 
be affordable as a regular habit.32
Table 3.5 Fast Food: Market Size 1988-1991
Million National Currencies
1988 1989 1990 1991
Belgium 11,400 12,300 13,900 14,600
France 5,9000 6,200 6,600 7,100
Germany 2,200 2,400 2,500 2,700
Ita ly 160,000 153,000 151,000 *
N etherlands 420 460 495 530
Spain 14,000 21,000 31,000 45,000
United Kingdom 3,593 3,960 4,360 X-
* No data available
SourcerE urom onitor Pic. (1992), The Euromonitor Compendium of 
Marketing Information , 1st Edition, Eurom onitor Publications Ltd., 
London p.253.
Increasing use of technology is also noted  at each stage in the food 
p roduction  process. A t farm  level results of a D elphi exercise am ong 
food technologists in  1987 indicated that biotechnology is forecast to 
have a m ajor im pact in this area to the year 2000. Experts feel tha t the 
application of advanced biotechnological m ethods w ill allow the 
developm ent of new  raw  m aterials w ith  im proved processing
characteristics.33 As yet how ever, progress is lim ited. Technologies 
including biotechnology are also having  a significant im pact on food 
processing and preservation. Particular technologies have allow ed 
scientists to develop w hole new  ranges of new  m aterials and
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ingredients to satisfy the needs of industry . In  food preparation  the 
em ergence of the m icrow ave is regarded  of m ajor significance and  has 
aided  developm ent of convenience food m arkets.(Table 3.1)
To sum  up , lim itations of the Irish food industry , linked to problem s of 
scale and  seasonality of p roduction  have created a sector heavily 
dependen t on in tervention  and th ird  country  m arkets. Follow ing the 
reform  of the C om m on A gricultural Policy producers need  to find new  
outlets for their product. The E uropean food m arket is identified as the 
m ost viable alternative. This m arket dem ands vast am ounts of value- 
added  food products and represents a w indow  of opportun ity  for food 
firms. H ow ever, trends of concentration and  globalisation of food 
firm s and  consolidation of retailers on a pan-E uropean  level w ill m ake 
it difficult for Irish food firms to succeed here. They w ill need to build  
heavily  on strengths such as their rep u ta tio n  for environm entally  
friendly food, to m ake an impact. Bearing in  m ind  this short 
in troduction  to the Irish food industry  State p lans for its developm ent 
are p resented  in the next section.
3.3 R eview  of State P lans for the Irish  Food an d  D rin k  industry .
The four m ost recent policy docum ents ou tlin ing  proposed  
governm ent support for the Irish food in d u stry  are "A future in  Food- 
Strategy for the Food and Drink Industry  1988-1992" by IDA Ireland. 
"A griculture and  Food Policy Review" u n d ertak en  by eight officials of 
the D epartm ent of A griculture and  Food, the findings of the 
"Industrial Policy Review Group" p resen ted  in  January  '93 and  the 
report of the expert group on the food industry  p resen ted  in A pril 1993. 
The reports include specific p lans and  ideas for ind iv idual sectors 
w ith in  the food industry , I w ill lim it m y review  to the m ain th ru st of 
their policy proposals .34
The four reports recom m end strategies for increased involvem ent in
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the com petitive food export industry. Control of costs, a culture of 
innovation  and m arketing and a greater involvem ent in h igh  grow th  
sectors like p rep a red /b ran d ed  consum er p roducts and  ingredients are 
central factors of strategies suggested. The reports acknow ledge the 
reality that m ost of the Irish food com panies currently  in existence 
have no t the resources, financial, technical or m arketing  based 
necessary to becom e involved in b randed  consum er m arkets. The IDA 
report identifies several p roduct/custom er linkages possible and 
suggests that m ost Irish food com panies should  aim  for business to 
business involvem ent as a m eans by w hich the Irish  food processing 
industry  can m ove from  being a com m odity p roducer to being a 
p roducer of sem i-processed or consum er foods.(Figure 3.0)
Figure 3.0 Product Consumer Linkage.
Product Category Market Outlet Comments
Low Value 
No Quality Spec
Medium Value 
Medium Quality
Med/High Value 
Limited Security
Low Margin 
Tight Spec
High Value
High Marketing Costs
Source: Industria l D evelopm ent A uthority  (1987), A  Future in Food— 
Strategy for the Food and Drink Industry 1988-1992, In d u stria l 
D evelopm ent A uthority , Dublin, p .10.
This strategy seem s viable in light of Pat O' N eill's (A vonm ore's chief
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"any business setting out to achieve a pre-em inent position as a 
food com pany w ill need as a m inim um  a tw enty  year 
developm ent p lan  w hich w ill have a real vision of the long 
term  fu tu re" .35
The IDA report recom m ends increased m arketing  and  technological 
support for food firm s especially large (ie sales of £500million) to
ensure s u c c e s s .3 6  The report of the expert group how ever, takes a m ore 
optim istic view  and  they recom m end the creation of a substantial 
b rand  p ro d u c t developm ent fund to aid food com panies w ith  a h istory  
of m arketing  culture and expertise to seriously p u rsu e  a b rand
developm ent strategy.37 In this w ay successful b rands can generate the 
price p rem ium  required  to com pensate for extra costs associated w ith  
our peripheral location and make use of the 'Irish im age' in 
continental EC states.
The reports also em phasise the im portance of increasing support to the 
R&D function of food firms. The report undertaken  by  the P.A. 
Consultancy G roup for the Industria l Policy Review G roup 
recom m ends that existing state assistance for the food sector should  be 
reallocated away from  fixed asset investm ent tow ards Research and 
D evelopm ent supports. They also propose that the direction of these 
supports  should  encom pass greater industry  involvem ent. The rep o rt 
of the expert group recom m ends that the share of overall public 
research funds (EC and National) devoted to the food area should  be in 
p roportion  to the im portance of the food sector in  the econom y, w hich  
w ould  m ean  that food should  benefit from  around  23% of overall
public research funds.3« In all reports a distinction is d raw n  betw een 
the needs and possibilities of large scale com pared w ith  sm aller 'niche' 
com panies. It is recom m ended that m any schem es and  support be 
m ade available only to com panies of sufficient scale for com m ercial 
European M arkets.
executive) assertion that,
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3.4 Summary.
The food and  d rink  industry  is very  im portan t to the Irish econom y. 
The industry  is currently  experiencing some difficulties as it grapples 
w ith  the im plications of CAP reform. As prim arily  a p roducer of 
com m odity p roducts for intervention m arkets CAP reform  presents a 
serious threat. H ow ever, the industry  possesses some factor cost 
advantages, enjoys h igh  levels of governm ent support and  has a green, 
environm entally  clean image. O pportun ities for developm ent and  
grow th  are identified as increased value-added production  and 
expansion into new  com petitive m arkets. D ue to problem s of scale and 
lack of experience w ith  branded  products, governm ent policy 
recom m ends a g radual m ove into consum er products, beginning  w ith  
a business to business involvem ent in com m ercial m arkets.
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Chapter 4 M ethodology.
4.0 Introduction.
The p rim ary  objective of this s tudy  w as to investigate the response of 
Irish food firms to the em ergence of new  biotechnological techniques. 
L iterature review ed indicates little is know n of their response. In 
o rder to learn  m ore about food firm s involvem ent or n o n ­
involvem ent w ith  the techniques a three phase p rim ary  research 
m ethodology w as generated. Phase one involved exploratory research 
of expert opinion to assist the developm ent of a research design 
specifically tailored to the unique features of the Irish  food industry  in 
the context of the applications of new  biotechnological techniques.
The second phase involved extensive prim ary  research of identified 
po ten tia l early adopters of new  biotechnological techniques. Pivotal 
response factors investigated were; firms technological capacity to use 
the techniques, strategies used  for involvem ent in  R&D and attitudes 
to the em ergence of the techniques. In  phase three food firms' 
response to the technological d iscontinuity  caused by  the  em ergence of 
new  biotechnological techniques w as inferred th ro u g h  an appreciation 
of their perform ance w ith  regard  to the three response factors 
exam ined in unison. D evelopm ent of a scoring system  allow ed 
in ternational com parison of the technological capacity of firms 
in te rv iew ed .
4.1 Phase One.
The objective of this prelim inary  phase in  the research w as to gain an 
indep th  know ledge of the Irish food industry  in  the context of the 
applications of new  biotechnological techniques to assist the 
developm ent of a pertinent research design. In d ep th  interview s w ere 
undertaken  w ith  a sam ple of experts w orking in  the Irish food 
ind u stry  and  industry  support functions. The sam ple w as chosen to 
represen t inform ed opinion from  all sectors of the  food ind u stry  on
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uses of new  biotechnological techniques. R espondents w ere identified 
experts in  biotechnology use in  the food industry . All w ere higher 
degree scientific graduates and those w orking directly in the Irish food 
industry  w ere R&D m anagers. The judgem ent sam ple achieved 
included  five scientific experts perform ing industry  su p p o rt functions, 
(Experts w ere selected from the N ational Food Centre, Eolas, 
BioResearch and the N ational A gricultural and  V eterinary  
Biotechnology Centre, U.C.D.) and four R&D m anagers w orking  in  the 
Irish food industry.
Table 4.0 Exploratory Interviews - Sample Achieved.
Industry  support functions
No. of Experts
5
The Irish  food industry 4
Total Sample 9
Those selected from  the Irish food industry  w ere representative of the 
diversity  of firms active in this sector. A n R&D m anager was 
in terv iew ed  from  an em erging food biotechnology com pany, one from  
a m ultinational food com pany and tw o from  ind igenous food 
com panies. The chairm an of BioResearch w as am ong those 
in terview ed. Those selected for in terv iew  perform ing  ind u stry  
su p p o rt functions included an expert on the com m ercial applications 
of new  biotechnological techniques and  an  expert on the regulatory  
env ironm ent of new  biotechnological techniques. Two experts w ere 
selected because of their know ledge of the agriculture and  food 
applications of new  biotechnological techniques.
Interview s w ere undertaken  th rough  use of a them e sheet p resen ted  
in  A ppendix  (A). Interview ees w ere allow ed to expand  at length  on 
any particu lar issue of interest. Interview s w ere conducted in the
84
interview ees place of w ork during  sum m er 1992. W here possible 
in terview s w ere recorded and lasted on  average 45 m inutes. Cassette 
transcrip tions and notes were analysed and used  to guide the research 
design for the next stage of the research. Three phases of analysis were 
app lied  to each topic discussed. First O rder analysis involved 
gathering  together responses of all respondents to a particu lar topic. 
Second O rder analysis involved sum m arising and  paraphrasing  w hat 
w as said. In  final analysis regularities and patterns w ere noted  and
conclusions reached for each topic discussed.1
4.1.1 Phase 1: Implications for Research.
Exploratory research highlighted the salience of public perception 
issues w ith  regard to the future use of new  biotechnological techniques 
in the food industry. Respondents indicated an anticipation of 
negative consum er response to food produced in this w ay. Experts 
em phasised  the difficulty of investigating food firm s' response to the 
techniques. They felt that food firms w ould be loathe to report 
involvem ent or in terest for fear of a consum er backlash. The 
im portance sam ple m em bers attached to this issue cannot be 
overem phasised. This finding indicated the necessity of developing a 
research design w hich w ould  allow indirect investigation of food 
firm s' response to the techniques. A suitable research design w as 
generated  and  em ployed in phase two.
Sam ple m em bers also indicated m inim al involvem ent of Irish  food 
firm s w ith  advanced biotechnological techniques. Experts believe that 
the Irish  food industry  continues to avoid new  biotechnological 
techniques prim arily  because of concern regard ing  consum er 
resistance. C onsequently it is likely that conventional m ethods w ill 
continue to be used by the industry. This finding dictated th a t any 
investigation  should  focus only on those firms identified  as actual or
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poten tial early adopters of new  biotechnological techniques. Experts 
asserted  such firms tend to be larger firms w ith  substantial R&D 
spends. As new  biotechnological techniques represen t a new  
technological parad igm  other firms w ould  m ost likely be unaw are of 
their existence. They w ould  no t have an inform ed opin ion  on 
possible fu ture  involvem ent and thus are not of interest.
Finally, experts drew  attention to the suitability of new  
biotechnological techniques to im prove low  volum e h igh  value 
ingred ien t p roduction  (starter cultures, enzym es etc) as opposed to 
h igh  volum e low value food processing. It w as decided thus that any 
investigation should  include such firms in add ition  to D airy firm s also 
identified as an im portan t food sector of impact.
4.2 Phase Two.
Exploratory research undertaken  in  phase one indicated the necessity of 
indirect investigation of food firms' response to new  biotechnological 
techniques due to anticipated negative consum er response. L iterature 
rev iew ed has highlighted the strong consum er resistance tha t proposed  
use of new  biotechnological techniques has encountered  in  m any 
countries. The furore concerning the in troduction  and  use of rbST 
rem ains a case in point. Thus, direct questioning of respondents ' 
detailed  p lans and curren t involvem ent w ith  the techniques w as 
regarded  as an unsuitable form  of enquiry. Experts m ight feel obliged 
to u ndersta te  involvem ent or in terest to avoid consum er d isapproval. 
Food firm s’ response to the technological d iscontinuity  caused by  the 
em ergence of new  biotechnological techniques w as inferred thus from  
a detailed exploration of three factors suggested by  the literature. 
Ind iv idually  and together these three factors are seen as im portan t 
determ inants of food firm s' response to the technological discontinuity  
caused by  the em ergence of new  biotechnological techniques. They are
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described as follows:
4.2.1 Technological Capacity to Use N ew  Biotechnological Techniques.
Literature accessed cited the im portance of 'technological capacity' for 
agents of technological change. It w as asserted that com panies 
involved w ith  technical change w ould  need m ed ium  to h igh  levels of 
com petence in a num ber of technological functions to be successful in 
affecting technical change. As em erging new  biotechnological 
techniques have been  heralded  as a new  technological parad igm  it is 
im perative to investigate the technological capacity of Irish food firm s 
to becom e involved w ith  the techniques.
4.2.2 Strategies U sed for Involvem ent with R&D.
Literature review ed also highlighted the m yriad of d ifferent strategies 
firm s use to becom e involved w ith  new  biotechnological techniques. It 
w as decided thus to investigate Irish food firms' strategies for 
involvem ent w ith  R&D generally. Existing involvem ent w ith  R&D 
w ould  be an im portan t factor dictating strategies for involvem ent w ith  
new  biotechnological techniques.
4.2.3 Attitudes to the Emergence of N ew  Biotechnological Techniques.
Food firms' attitudes to the technological d iscontinuity  caused by the 
em ergence of new  biotechnological techniques also represen t an 
im portan t factor influencing response to these techniques. L iterature 
accessed suggested three m ain areas of investigation; a ttitudes 
regard ing  public perception issues, attitudes regard ing  the regulatory  
env ironm ent and a ttitudes regard ing  the im pact new  biotechnological 
techniques m ight have on the food industry.
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Food firm s response to the technological d iscontinuity  caused by  the 
em ergence of new  biotechnological techniques thus w as to be inferred 
from  a detailed exploration of three factors;
Technological capacity to use the techniques.
R&D Strategies generally.
A ttitudes to the em ergence of new  biotechnological techniques.
4.2.4 The Sample.
In  choosing the sam ple the researcher's objective w as to obtain a 
judgem ental census of actual and potential early adopters of new  
biotechnological techniques w ith in  the food and  d rink  sector only. 
Early and  potential adopters only w ere of interest. As noted, other 
firm s w ould  tend not to have the experience or know ledge relevant to 
the objectives of the research. Academic institu tions w ere not included 
in  the sam ple although it is acknow ledged that new  technologies tend  
to be first adopted in the academic arena. The experiences of industry  
only w as required by the prim ary  objective.
For the purposes of the study, the food and d rink  m anufacturing  sector 
w as defined as firms producing  products defined by NACE codes 411 to 
428 inclusive. (The abbreviation NACE refers to the General 
Industria l Classification of Economic Activities in  the E uropean 
C om m unity  {Nom enclature A ctivité C om m unau té  Europeen} The 
industria l sectors relating to each of these codes are show n below:
411 Vegetable and  A nim al oils and fats
412 Slaughtering, p reparing  and preserving of m eat
413 M anufacture of dairy  products
414 Processing and  preserv ing  of fruit and  vegetables
415 Processing and  preserv ing  of edible fish and o ther sea-food
416 G rain  m illing
417-418 M iscellaneous foodstuffs
419 Bread, biscuits and  flour confectionery
420 M anufacture and  refining of sugar
421 Cocoa, chocolate and sugar confectionery
8 8
422 A nim al and poultry  foods
423 M iscellaneous foodstuffs
424 Spirit D istilling and  com pounding
425-426 M anufacture of w ine, cider and soft drinks 
427 Brewing and m alting 2
The food sector w as also taken to include firms involved w ith  p lan t 
and  anim al breeding services. These firm s w ere included in sam ple 
due to their im portance at the high technology end  of the food sector.
As use of advanced biotechnological techniques is a relatively new  
phenom enon w ith  regard  to Irish food and  d rink  production, it m ay be 
realistically assum ed that few if any of Irish firm s have adopted these 
techniques. In choosing a census of actual and  po ten tia l adopters of 
new  biotechnological techniques the sam ple size w as dictated by the 
level of interest in industry . Firms evidenced in terest a n d /o r  
involvem ent in the techniques th rough  m em bersh ip  of pertinen t lists. 
The list were;
1. Coom bs J. and  A lston Y.R. (1991),The International Biotechnology 
Directory 1991, Products, Companies Research and Organisations, 
M acm illan, London. (This directory lists com panies from  all over the 
w orld  w ith  interests in biotechnology.)
2. Participants on the Labip conference, Cork 1992. (O rganised under 
Bridge "Biotechnology Research for Innovation, D evelopm ent and  
G row th in Europe" The Lactic Acid Bacteria In d u stry  Platform  offers a 
forum  for exchange of view s in relation to Biotechnology of Lactic 
Acid Bacteria Research. The conference w hich took place in Cork in 
M ay 1992 w as attended by  Biotechnology experts from  both industry  
and  academic sectors.)
3. "Top 1200 com panies 1992". Aspect -The Investors Business Journal
,A spect Publications,W icklow. (Com panies listed  in o rder of turnover)
These lists identified food firm s in terested in or involved w ith  new  
biotechnological techniques. They are also the largest firms in term s of 
turnover. (Secondary research indicated new  technology adopters tend
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to be larger firms involved w ith  h igh  levels of R&D.)
Thirty seven firms w ere identified. Thirty five of these w ere 
established incum bent firms and tw o w ere em erging  firm s set up  to 
use biotechnology. The sam ple included D airy firm s and  low volum e 
h igh  value ingredient firms - identified sectors of opportun ity  for new  
biotechnological techniques. O ther sectors of the food industry  w ere 
also represented, nam ely brew ing, fish and  m eat, bakery  and 
m iscellaneous food and  drink. (Table 4.1)
Table 4.1 Judgement Census of Potential Early Adopters - 
Identified and Achieved.
N o. of firms 
id en tified
No. of firms 
achieved
H igh volum e low  value 
food processors
28 21
D airy 14 10
Brewing 4 2
Fish + Meat 3 2
Bakery 3 3
Misc. - general 4 4
Low volum e high value 
supply firms
9 6
Ingredients 7 5
Animal and Plant Breeding 2 1
Total Sample 37 27
Com panies w ere initially self selected from  the list m entioned in 
accordance w ith  their evidenced in terest in  or use of new  
biotechnological techniques. The balance w ere chosen to ensure a 
representative sam ple of food firms in  the context of the applications
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of new  biotechnological techniques. Effective in terview s w ere 
undertaken  w ith  12 firms w ho had  evidenced to the researcher a p rio r 
in terest in new  biotechnological techniques and  15 firm s chosen by- 
v irtue  of their turnover.(Table 4.2)
Table 4.2 Sam ple A chieved by  Basis of Selection: Evidence of 
In te res t / Involvem ent in  N ew  B iotechnological 
T echn iques or Turnover.
Prior
Interest/Involvement
Turnover Total
Dairy 7 3 10
Misc 0 4 4
Brewing 0 2 2
Fish & Meat 1 1 2
Bakery 0 3 3
Ingredients 3 2 5
Anim al & 1 0 1
Plant
Total Sample 12 15 27
A chieved
The sam pling un it was the food and d rink  com pany. One response 
from  each com pany w as sought either from  the Research and  
D evelopm ent D irector, the Technical M anager or the Q uality  C ontrol 
M anager. Secondary research indicated that, in  the absence of a nam ed 
R&D D irector in food firms, the responsibilities of this post are taken 
by  the Technical m anager or the Q uality  C ontrol m anager. In  cases 
w here bo th  Technical m anager and Q uality  C ontrol m anager existed 
w ith in  a responden t firm, response w as sough t from  that p erson  m ost 
involved w ith  R&D m anagem ent in  their firm. For the purposes of
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the research, scientific personnel of this caliber w ere assum ed expert 
w ith  regard  to research and developm ent in their ow n organisations 
and  the food and d rink  industry  in general. In  o rder to elicit all of the 
inform ation needed, the questionnaire m ay on occasion, have been 
addressed  by several persons in an organisation b u t one response per 
question w as recorded.
4.2.5 R esearch M ethod
The study  w as undertaken  through use of a structu red  telephone 
interview . M any of the standard  difficulties associated w ith  telephone 
in terview ing w ere overcom e as respondents on undertak ing  the 
interview  had  had  an opportun ity  to scan the questionnaire and 
responded  w ith  the questionnaire in front of them . In firm  procedure 
dictated that a questionnaire and covering letter w as posted  care of the 
Research and D evelopm ent Director, Q uality  C ontrol M anager or 
Technical M anager to each firm identified. A few days later the 
researcher telephoned the com pany to m ake contact w ith  the relevant 
com pany representative. If unsuccessful a m in im um  of six call backs 
w ere m ade in order to m ake contact and  additional questionnaires 
w ere faxed on if necessary. W hen contact w as m ade the researcher 
arranged  a convenient tim e to undertake the in terview  and at this 
appoin ted  tim e the structured  interview  th rough  use of the 
questionnaire w as undertaken  over the phone. Interview s lasted  on 
average 45 m inutes. A copy of the questionnaire and  covering letter is 
included  in  A ppendix  (B).
It w as decided to undertake interview s over the phone for a num ber of 
reasons.
1. Cost and  tim e constraints p rohib ited  personal interview s w ith  37 
firm s scattered all over the country.
2. G roup in terview ing w as ruled  ou t due to the perceived
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confidentiality of inform ation required.
3. M any questions required  m ore than  one w ord  answ ers and for this 
reason it w as felt a postal study  w ould  no t illicit the full dep th  of 
feelings present.
The interview s w ere undertaken  during  N ovem ber 1992. A response 
rate of 73% w as recorded.
4.3 Description of Measurement Techniques.
As outlined interview s w ere conducted over the phone th rough  use of 
a questionnaire. The questionnaire w as designed to illicit the 
m axim um  inform ation  from  responden ts in  the shortest tim e fram e 
possible. The questionnaire m ay be d iv ided  into three parts 
corresponding to the three m ain  objectives of the study. These are, 
those questions relating  to the investigation of firm s' technological 
capacity to use new  biotechnological techniques, questions w hich 
explored firms' R&D strategies generally and  those questions w hich 
investigated firm s' a ttitudes to the em ergence of new  biotechnological 
techniques.
4.3.1 Investigation of Firms' Technological Capacity to Use N ew  
Biotechnological Techniques.
As outlined agents of technical change need  m edium  to h igh  levels of 
com petence in key functions such as R&D and process technology for 
com petitive success. This is referred to as their 'technological capacity'. 
In Report 8 of the Sectoral D evelopm ent Com m ittee (S.D.C.) (1985) the 
technological capacity of Irish firm s w as assessed in term s of;
(a) C urren t processes and  skills
(b) N ew  product developm ent capability
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(c) Use of state resources for research and development.3
(a) C urren t Processes and Skills.
In the report of the Sectoral D evelopm ent Com m ittee current 
processes and skills w ere m easured th rough  expert assessm ent of the 
International com petitiveness of the hum an  and  physical resources 
used  in m anufacturing. Consideration w as m ade of the relative 
sophistication of processes and  p lan t and  equipm ent in com parison
w ith  in ternational com petitors. H um an  resource skills and  p roduction
system s w ere sim ilarly assessed.4 For the purposes of this piece of 
research identified com panies' processes and skills w ere assessed 
through  investigation of the size and skill profile of their R&D staff 
and th rough  exploration of the relative use sophistication of 
biotechnology in m anufacture and R&D.
The size and skill profile of R&D staff w as explored using a question 
adap ted  from  a study  undertaken by  Cogan and M cGovern. In this 
study  undertaken  in January 1984 firms w ere asked to indicate the size 
and skill profile of their w orkforce at s tartup  and at end  of the last 
trad ing  year.s (A ppendix (C)) The question posed in  this piece of 
research applied  only to the R&D w orkforce and respondents w ere 
required  to indicate size and skill profiles in 1985, 1992 and those 
anticipated in  the year 2000. In this w ay it w as possible to undertake 
analysis of trends in R&D em ploym ent.
Exploration of biotechnology use sophistication in m anufacture and  
R&D w as undertaken  th rough  use of a table indicating the con tinuum  
of progress noted w ith  regard to biotechnology in recent years. 
R espondents w ere required  to self report the level at w hich they w ork  
w ith  biotechnology. The developm ent of a continuum  of progress w as
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particularly  im portan t as literature had  h ighlighted the problem s of 
definition associated w ith  biotechnology and  the m eaningless 
com parisons w hich m ay result from such difficulties. Use of this self 
report m ethod insured results reflected the true biotechnology use 
sophistication of com panies and levels of use of ind iv idual firm s could 
be com pared accurately.
The continuum  of progress w as p repared  w ith  the help of a scientific 
expert in BioResearch and respondents w ere required  to indicate level 
of use of biotechnology in R&D and m anufacture in 1992 and  that 
anticipated in the year 2000. This allow ed tracking of any trends of use. 
The continuum  contained three levels of biotechnology use 
sophistication. Level 1 represented the m ost basic use of 
biotechnology, for exam ple in the p roduction  of w ine and  cheese.
Level 2 corresponded to m ore advanced techniques available p rio r to 
the em ergence of new  biotechnological techniques and  Level 3 
indicated use of new  biotechnological techniques including techniques 
such as genetic engineering. The continuum  is p resen ted  as p art of the 
questionnaire in A ppendix  (B).
(b) N ew  Product D evelopm ent Capability.
Taking direction from the assessm ent of technological capacity 
undertaken  by the S.D.C. R&D spend as a percentage of sales w as also 
used  as the p rim ary  indicator of new  p ro d u ct developm ent capability 
in this study. 6 Respondents w ere asked to indicate approxim ately  the 
percentage of turnover w hich w as spen t on R&D in 1992, 1985 and  that 
anticipated in 2000.
(c) Use of State Resources.
This w as the final factor included to m easure technological capacity of
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Irish firms. The S.D.C. in their assessm ent of the technological capacity 
of Irish firms explored in aggregate the use of State technical resources 
and supports to assist firms undertake p roduct and process research 
and  developm ent.7 As this research w as focussed on the response of a 
sm all group of m ore technically advanced food firms the general use of 
State resources by the food sector w as no t of interest. R espondent firms 
w ere instead  questioned as to their cu rren t or in tended  involvem ent 
w ith  State science and  technology program s. These w ere both  open 
ended questions and in interview  respondents w ere probed  as to the 
details regarding  program s involved and  reasons for non­
in v o lv e m e n t.
4.3.2 Exploration of Firms' R&D Strategies.
Q uestions in this section explored firm s' new  p roduct sourcing 
activities, R&D spend allocation and  in ternal and external strategies 
used to becom e involved in R&D.
The question concerned w ith  sourcing or line im provem ent activities 
of Irish food firms was developed th rough  exploratory interview s and 
background reading. An exhaustive list of new  p roduct sources w as 
generated  and  respondents w ere asked to indicate the percentage of 
products sourced using the different m ethods in 1992 and 2000.
A question w hich explored firm s allocation of R&D spend  w as adap ted  
from  one used in the 1984 Cogan and  M cGovern study.s (A ppendix (C)) 
R espondents w ere required  to indicate their R&D spend allocation in 
1985, 1992 and 2000.
R espondents w ere also questioned specifically about in ternal and 
external strategies used  to becom e involved in R&D. Presentation w as
96
m ade of table adap ted  from  a paper p repared  by M ark Dibner in w hich 
different strategies used to becom e involved w ith  new  biotechnological 
techniques w ere discussed. They w ere than  asked w hich  strategies they
had  used  and w hich they m ight consider using  in  the future.9 
(A ppendix (C)) As w ith  all questions respondents w ere probed for 
m axim um  detail in answ ering.
4.3.3 Exploration of Firms' Attitudes to the Emergence of N ew  
Biotechnological Techniques.
As outlined it w as decided to explore respondents ' a ttitudes w ith  
regard  to public perception issues, the regulatory  environm ent, and the 
possible im pact of new  biotechnological techniques on their industry . 
Four questions w ere generated to explore experts' attitudes w ith  regard  
to public perception issues. All questions dealt specifically w ith  public 
perceptions of gene-technology food and  drink. The first question w as 
open-ended and enquired of respondents how  they felt consum ers 
w ould  react to gene-technology food and drink. A lthough a negative 
reaction w ould  be assum ed from  the research to date the question w as 
designed so as not to bias respondents. The next tw o questions m ay be 
taken  together. Respondents w ere requ ired  to indicate their personal 
num erical risk assessm ent of gene-technology food and  d rink  and 
estim ate the num erical risk assessm ent of consum ers, thereby allow ing 
com parison of the risk scientific experts associate w ith  gene-technology 
foods and their perceptions of consum ers' risk assessm ents of food 
produced  in this way. Use of the num erical scoring system  allow ed 
accurate com parison and contrast. Potential num erical risk 
assessm ents ranged from l(low  risk) to 10 (unacceptably high risk) The 
final question in this section enquired  of respondents how  they felt 
possible adverse consum er reaction to gene-technology foods should  be 
dealt w ith.
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Four questions w ere also generated to explore respondents ' perceptions 
of the im pact new  biotechnological techniques m ight have on their 
industry . Respondents w ere asked about the im pact they felt new  
biotechnological techniques m ight have on the Irish food and drink  
industry  to the year 2000 and w ere asked to predict the sector for w hich 
the techniques w ould have greatest potential. They w ere also asked to 
identify the greatest barriers to use and to give their opinions on 
possible fu ture involvem ent. The question w hich enquired  about 
their in ten tion  to becom e involved w as the final question  included in 
the questionnaire. Two open-ended questions w ere generated to 
explore the issue of the regulatory  environm ent. R espondents w ere 
asked;
1. D id they feel the regulations in Ireland encourage or discourage 
w ork  in the area of genetic engineering?
2. D id they feel genetically engineered food and  drinks should  be 
labelled as such?
Three additional questions w ere also included in the questionnaire.
The first allow ed sector classification of respondents. Two other 
questions w ere generated to explore h igh  volum e low  value food 
processors use of food ingredients. The questions w ere posed; D id the 
food processor purchase ingredients and  w hat w ere the technologies 
used  in the m anufacture of these products? In this w ay  assessm ent 
w as m ade of food firms use of h igh  value, low volum e ingredients and 
their perception of the technologies used  in  the m anufacture of these 
ingredients. These questions w ere no t asked of low  volum e high  value 
ingredient suppliers or p lan t breeders.
4.4 Phase Three.
In  Phase three food firms' response to the technological d iscontinuity  
caused by  the em ergence of new  biotechnological techniques was
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inferred th rough  an appreciation of their perform ance w ith  regard  to 
the three factors exam ined in unison.
A nalysis w as undertaken  in three consecutive, cum ulative 
steps.Follow ing fieldw ork, questionnaires w ere checked and  edited.
The data w as sorted and counted th rough  the construction of frequency 
d istributions of the answ ers to each question. Ind iv idual questions 
w ere initially the focus and results com piled per question. Following 
this results w ere analysed and conclusions d raw n in term s of food 
firm s' perform ance w ith  regard to each of the three response factors 
identified. Finally food firms response to the technological 
d iscontinuity  caused by the em ergence of new  biotechnological 
techniques w as inferred from  analysis of the three factors taken 
together and trends of response com pared and contrasted. Patterns of 
response noted w ere categorised w here possible using both  Daly and 
H am ilton  fram ew orks of strategy and  options available to firms
follow ing a technological d iscontinuity .10 In this w ay trends of 
response w ere m ade available for contrast w ith  the acknow ledged 
response of food firms internationally . An alternative m ethodology 
w as also considered. Using this research m ethod responden t firms 
w ou ld  have been presented  w ith  the options available to them  as 
ou tlined  by Daly and  H am ilton. They could then  self report their 
responses according to these strategic fram ew orks. This alternative 
m ethodology w as abandoned. It w as felt that detailed analysis of the 
indicators of response w ould  give greatest understand ing  of the 
capabilities of Irish food firms and  their response to the em ergence of 
new  biotechnological techniques.
Two objectives w ere generated  in  relation to the analysis of food firms' 
inferred response to the em ergence of new  biotechnological 
techniques. The first w as to determ ine on characteristics, such as firm
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status, food production  activities or any characteristic identified as of 
in terest if any statistically significant relationship exists betw een the 
differentials of these characteristics and trends of response to the 
technological discontinuity caused by the em ergence of new  
biotechnological techniques. This objective allow ed identification of 
differences and sim ilarities in  response to the em ergence of new  
biotechnological techniques by em erging and  established firms and 
firm s involved w ith  low  volum e h igh  value food p rod u ctio n  as w ell 
as those involved in  h igh volum e low value production .
The second objective stem m ed from  the im portance of com m ercial 
E uropean  m arkets for Irish food firms follow ing the dism antling  of the 
C om m on A gricultural Policy. It w as decided to com pare European 
firm s' response to the techniques w ith  that of Irish  identified potential 
early adopters. The response of European and  Irish food firms was 
com pared using technological capacity to use the techniques as the 
p rim ary  indicator of response. A scoring system  described later in the 
chapter w as developed to allow this com parison. C om parative 
inform ation  in the form  of D aly and  H am ilton fram ew orks w as not 
available in a E uropean context.
4.4.1 Analysis of Individual Questions.
As outlined, the first stage of the analysis process involved the 
construction of frequency distributions of the answ ers to each question. 
This w as done th rough  use of the Statistical Package for Social Sciences 
(SPSS). Data obtained was bo th  num erical and literal. In the analysis of 
num erical data use w as m ade of descriptive statistics such as the 
m edian , range, m idm ean  and in terquartile  range. The m edian  
indicates the m iddle value in  a frequency distribution , below  and 
above w hich  lie values w ith  equal total frequencies. Use of the m edian  
allow ed note to be taken  of the activities of the m iddle or m ore usual 
firm. The range allow ed cognisance to be taken of the spread of data 
and  the m idm ean is a m easure of the m ean of the m iddle  50% of
1 0 0
scores. By focusing on the interquartile range or m idd le  50% of firms it 
w as possible to get an idea of w hat the usually  m ore reliable half of 
firm s w ere doing. Using this m ethod the extrem es w hich  m ay bias 
o ther descriptive statistics are ignored. SPSS p roved  a useful tool in 
the generation of these statistics. While use of this package is m ost 
popu larly  associated w ith  the analysis of larger am ounts of data it's use 
in this context aided prom pt production of the necessary statistics.
Literal data  w as content analysed. Content analysis w as undertaken  
using a form at suggested by Jankow icz.11 C ontent analysis of the im pact 
assessm ent question is p resented  to illustrate the fo rm at used. (Table
4.3)
Table 4.3 Content A nalysis Format.
Sample:
Respondents:
Recording Unit:
37 Food Companies 
27 Respondents 
10 respondents unavailable 
Response rate 73%
What was said.
Context Unit: That part of the structured interview where respondents
discussed their opinions on the impact of advanced biotechnological 
techniques with regard to the Food and Drink industry to the year 2000. The 
question was presented as: "What do you think the impact of advanced 
biotechnological techniques such as genetic engineering will have on the 
Irish Food and Drink industry to the year 2000? Whole of reply treated as an 
entry under one category, regardless of the number of utterances.
Data:
Categories:
A transcript of 27 conversations, with the relevant 
part of the interview highlighted, each coded with a 
number 1 to number 6 according to the categories below.
1. No impact
2. Very little impact
3. Some/little impact
4. Major Impact
5. Futuristic - Post year 2000 impact
6. Don't know
D ata w as validated  w here possible using existing available research. 
C rosstabulation w as used to determ ine if any statistically significant
101
relationships existed betw een the differentials of firm  characteristics, 
such as status and production  activities and trends of response.
4.4.2. Analysis of Findings Relating to Individual Determinants of 
Response.
The first step in the analysis of findings relating to ind iv idual 
determ inants of response w as to group together questions relating to 
the exploration of each. Exploration had  been m ade of food firms' 
perform ance w ith  regard  to four indicators of technological capacity. A 
scoring system  w as developed to d raw  together these four indicators. 
This w as a unique m ethodology tailored to the particu lar features of 
'technological capacity' m easurem ent used  in the study . The system  
allow ed presentation  of firms' perform ance w ith  regard  to each of the 
indicators of technological capacity and the relative contribution  of 
each indicator. It also facilitated com parison of the technological 
capacity of food firms w ith  that of firms dedicated to the exploitation of 
new  biotechnological techniques. Use of the system  allow ed 
com parison of the relative technological capacity of food firm s to use 
new  biotechnological techniques in an Irish and E uropean  context.
The system  em ployed a sim ple scoring procedure. Points w ere 
allocated to firms w hich reflected their perceived perform ance on each 
indicator of technological capacity. Each indicator w as w orth  a 
m axim um  of 5 points. All indicators contributed equally  to 
technological capacity thus the m axim um  score possible for strong 
technological capacity w as 20. The unit of com parison on each 
indicator w as the perform ance of firms dedicated to the exploitation of 
new  biotechnological techniques. Points w ere allocated to reflect the 
relative perform ance of firm s investigated as com pared w ith  pub lished  
data pertaining to dedicated firms. Secondary data w as also used  to
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explore the technological capacity of European food firms. It m ay be 
no ted  that points w ere allocated arbitrarily and specific scores m ay be 
open to discussion. H ow ever, the rationale for ind iv idual score 
allocations is presented, each relating directly to secondary or p rim ary  
research presented. The system s strength  lies in its ability to h ighlight 
the ranked perform ance of firms w ith  regard  to technological capacity 
and  the indiv idual indicators investigated. It is a usefu l tool as it distils 
the  m any com ponents of technological capacity into a single score to 
facilitate com parison. Yet the process leading to score generation in 
review  of secondary and prim ary  research insures th a t firms 
perform ance on each facet of every indicator im pacts on the final score 
indicating technological capacity to use new  biotechnological 
techniques.
F indings relating to the rem aining determ inants of response; firm s 
R&D strategies and  attitudes to the em ergence of new  biotechnological 
techniques necessitated a contrasting analysis p rocedure. Q uestions 
generated investigated different aspects of each determ inant. In  
analysis thus the objective w as to uncover a p a tte rn  of response w hile 
retain ing  the detail of ind iv idual issues explored. U sing know ledge 
gained th rough  exploratory research related questions w ere g rouped  
together and significant trends highlighted.
4.4.3 Analysis of Three Identified Determinants of Response Taken 
Together.
Final analysis involved appreciation of food firm s' perform ance w ith  
regard  to the three determ inants exam ined in unison. This allow ed 
food firm s response to the technological d iscontinuity  caused by  the 
em ergence of new  biotechnological techniques be deduced. A nalysis
w as undertaken  using  a synthesis of m ethods suggested by  Griggs.12 
Explanations w ere derived  for firm s' perform ance on ind iv idual
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determ inants and  regularities and  patterns no ted . W ith  increased 
understand ing  specific instances w ere subsum ed into larger patterns. 
Patterns of response w ere then  categorised using bo th  D aly and 
H am ilton  fram ew orks of strategies available to firm s follow ing a
technological discontinuity . 13 In this w ay trends of response could be 
discussed in  an in ternational context.
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Chapter 5 Analysis and Findings.
5.0 Introduction.
A nalysis and findings are presented in tw o parts. In  this chapter 
respondents ' perform ance w ith  regard  to each ind iv idual factor 
identified as im portan t in determ ining food firm s' response to the 
em ergence of new  biotechnological techniques is presented.
C hapter 6 presents findings relating to food firm s' response to new  
biotechnological techniques inferred from  a detailed  exploration of the 
three identified  determ inants exam ined in  unison.
The p rim ary  identified determ inant of food firm s' response to new  
biotechnological techniques w as technological capacity to use the 
techniques. Indicators of technological capacity used  were; 
size and skill profile of R&D staff, 
use of biotechnology in m anufacture and  R&D,
R&D spend as a percentage of sales,
curren t and  in tended involvem ent w ith  State science and  
technology program s.
Findings relating to each indiv idual indicator are p resented  and  scores 
allocated to indicate the relative perform ance of Irish  and E uropean 
firm s on each indicator.
5.1 Size and Skill Profile of Research and D evelopm ent Staff.
In  advance of any detailed exploration of the size and skill profile of 
R&D staffs investigated, it is useful first to note the num ber of form al 
R&D departm ents operated in food firm s in  Ireland. Perhaps the m ost 
strik ing  resu lt w hich em erged from  the investigation of identified 
potential early adopters of new  biotechnological techniques w as the 
h igh  num ber of those w ho do no t operate a form alised R&D 
departm en t in  Ireland. Those w ho do no t operate a form alised R&D 
departm en t are d ivided betw een those w ho are uninvolved  w ith  R&D 
and  those w ho benefit from R&D carried ou t overseas. As m ight be
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expected, those undertak ing  R&D overseas tend to be M N C's w ith  
interests in  other m arkets. (Table 5.1.0)
Table 5.1.0 Respondent Companies Operating a Formal R&D 
Department. (1985,1992, 2000)
1985 1992 2000
N o. % N o . % N o. %
Form al R&D Dept. 16 59 18 67 18 67
R&D Overseas 6 22 5 18.5 5 18.5
U ninvolved  w ith  R&D 5 18.5 4 14.8 4 14.8
T otal
Base: All R espondents
27 100 27 100 27 100
For the purposes of this investigation an R&D departm en t w as deem ed 
to be in  operation  if one or m ore persons w ere em ployed full-tim e 
w ith  research and  developm ent activities. A sim ilar definition w as
used  in the 1991 Eolas Business survey of R&D. H ow ever, for the 
purpose of the Eolas survey it w as also required that a physical space be 
allocated to R&D. The findings of the Eolas survey 1991, indicated  that, 
of the n inety  six technology perform ing com panies identified  in the 
Irish food, drink  and  tobacco sector of that year, forty seven operated 
form al R&D departm ents. Technology perform ing com panies as 
defined by  Eolas are those w hich are involved w ith  either in tram ural 
or ex tram ural expenditures on R&D, joint ven tures, R&D consortia or 
technology licensing. As the tobacco sector is quite sm all in  Ireland it 
m ay be assum ed that the vast m ajority of the forty seven form al R&D 
departm ents h ighlighted are operated  by  food and  d rink  firms.
Thus of the n inety  six technology perform ing food and  d rink  firm s 
identified by  Eolas, 49% operated form al R&D departm ents.1 Results of 
the research undertaken  on potential early adopters of new  
biotechnological techniques indicate th a t 66% of those in terv iew ed
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operate form al R&D departm ents. Early adopters of new  technologies 
in  the industria l sector tend to be firm s w hich  are technologically 
advanced. It is no t surprising thus that in the identification of a 
judgem ental census of Irish food firms though t to be actual or 
potential early  adopters of new  biotechnological techniques that a 
higher p roportion  of these firms w ou ld  operate form al R&D 
departm en ts than  is norm al am ong technology perform ing food 
com panies in general. Taking the results regard ing  low  volum e h igh  
value ingredient supp ly  firms separately it m ay be noted  that only one 
such supp ly  firm indicated that it operated  a form alised R&D 
departm en t in Ireland, two undertake R&D overseas, one is 
un involved  in  R&D and one refused to give details of R&D 
staff.(A ppendix (D )Table 5.1.1)
A dditional secondary data accessed indicates that the num ber of form al 
R&D departm ents operated in food and  d rink  com panies has increased 
rap id ly  since 1982. The Sectoral D evelopm ent Com m ittee reported  
th a t in  1982 eighteen Irish food com panies operated  form al R&D 
departm ents. This study  did no t include the activities of d rink  or 
tobacco com panies. H ow ever, due to the food industries dom inance of 
the food, d rink  and tobacco sector, it is reasonable to assum e the figures 
m ight no t have increased greatly by their inclusion.2 Results of the 
s tudy  u n d er discussion indicate that in 1985 sixteen of the identified 
potential early adopters of new  biotechnological techniques operated  
form al R&D departm ents. It m ust be no ted  th a t w hile the num ber of 
food firm s operating  form al R&D departm ents in  Ireland is increasing 
such firm s rem ain  the exception ra ther than  the rule. This po in t is 
h igh ligh ted  w hen  one considers ou t of 835 food, d rink  and tobacco 
firm s (establishm ents em ploying three or m ore persons) estim ated  in  
existence by  the CSO in 1989,3 Eolas has identified only 47 as operating  
form al R&D departm ents.
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Investigation of the size and skill profile of the R&D w orkforce w as 
lim ited to those firm s w hich operated a form al R&D departm en t in  the 
years of interest. A disappointing response rate w as recorded am ong 
firms, particularly  w ith  regard to details of staff in years 1985 and 2000. 
Experts w ere often unable to supply  inform ation for 1985 and 
unw illing  to m ake estim ates of anticipated staff profiles for 2000.
Details w ere no t recorded of overseas staff profiles.( M ost likely users of 
R&D based  overseas are m ultinational com panies. It m ay be assum ed 
thus tha t as the R&D departm ent of the paren t com pany w ill p rov ide 
R&D services to all countries of operation that this departm en t w ould  
be large and w ell staffed.) Firms uninvolved  w ith  form al R&D 
activities indicated a per project attitude to p roduct developm ent. 
Personnel from  related departm ents w ou ld  come together to solve 
research and  developm ent problem s as required. Form ation of a 
form al R&D departm ent was regarded as unnecessary. Tables 5.1.2, 5.1.3 
and  5.1.4 show  the size and skill profile of R&D staffs in  the years 
investigated  for respondent firms. The response rate w as particu larly  
low for the year 2000. H ow ever, those com panies w ho declined to 
estim ate the size and  skill profile of R&D personnel anticipated in the 
year 2000 w ere united  in their assertion that num bers w ould  rem ain  
constant or increase. U sing the m ost conservative estim ate thus that 
R&D staffs will 'Stay the Same' figures w ere substitu ted  for non­
estim ating com panies to calculate the m edian, range and  in terquartile  
range of total staff num bers anticipated in  the year 2000. This 
inform ation is included in  Table 5.1.5 It m ay be noted that the 
anticipated size of R&D departm ents in the year 2000 is slightly sm aller 
w hen  cu rren t figures are substitu ted  for non-estim ating com panies. 
This is as expected as com panies w ho estim ated norm ally included a 
g row th  factor in  term s of personnel em ployed. H ow ever, in 
substitu ting  curren t figures w e are using the m ost conservative 
estim ate of non-grow th. Also those com panies w ith  larger R&D
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departm ents w ould , by  definition, have m ore form alised p lans than  
their sm aller com petitors. These larger com panies w ould  be m ore able 
to give estim ations of fu ture R&D staffs thus raising the descriptive 
statistics for anticipated R&D personnel in the year 2000.
Table 5.1.2 Size and Skill Profile of R&D Departments. (1985)
Higher Scientific Scientific Scientific Other Total R&D
Degree Staff Degree staff Diplom a staff Scientific staff staff
M edian 0.00 1.00 0.00 0.00 5.00
Range 3.00 5.00 12.00 3.00 20 .00
Qu 1.50 3.00 2.75 0.00 10.00
Ql 0.00 0.00 0.00 0.00 2 .00
Unansw ered 4 4 5 5 2
Base:Companies operating formal R&D departments in Ireland (16) 
Unitj)fM easurgment:Full time research employee.
Table 5.1.3 Size and Skill Profile of R&D Departments. (1992)
Higher Scientific Scientific Scientific Other Total R&D
Degree Staff Degree staff Diplom a staff Scientific staff staff
M edian 0.00 2 .00 1.00 0.00 6 .00
Range 4 .00 20 .00 12.00 3.00 20 .00
Qu 3.00 4.500 2.00 0.00 14 .00
Ql 0.00 1.00 0.00 0.00 4.00
U nanswered 3 2 4 4 1
Base: Companies operating formal R&D departments in Ireland (18) 
Unit of Measurement:Full time research employee.
Table 5.1.4 Anticipated Size and Skill Profile of R&D Departments. 
(2000)
Higher Scientific Scientific Scientific Other Total R&D
Degree Staff Degree staff Diplom a staff Scientific staff staff
Median 1.00 2.00 2.00 0.00 9 .50
Range 5.00 12 .00 12.00 3 .00 23 .00
Qu 2.00 5.00 6.00 0 .50 14 .00
Ql 0.00 2 .00 1.50 0.00 5 .7 5
Unansw ered 7 7 9 8 8
Base:Companies operating formal R&D departments in Ireland (18) 
Unit of Measurement:Full time research employee.
110
Table 5.1.5 Anticipated Size of R&D Departments in the year 2000
(Using Current Figures for Non-Estimating Companies.)
8.00
23.00
14.00
4.00
Base:Companies anticipating operation of a formal R&D department in
Ireland (18)
Unit of Measurement:Full time research employee.
Results indicate a trend  tow ards increased staffing of the R&D 
departm ent. In 1985 the m edian  num ber em ployed in the R&D 
departm ent w as 5, in 1992 this had  risen to 6 and in  the year 2000 the 
m ost conservative estim ate for anticipated staff em ployed w as 8. 
H ow ever, in discussion of these figures the w ide range of size and  skill 
profiles reported m ust be noted. To illustrate: In 1992 the research staff 
em ployed in indiv idual firms ranged from  one to tw enty. By focusing 
on the in terquartile  range or m iddle 50% of firm s an indication 
em erges of w hat the usually  m ore reliable half of firm s are doing. 
U sing this m ethod the extrem es w hich m ay bias o ther descriptive 
statistics are ignored. In 1992 thus, the m iddle 50% of firms em ployed 
betw een 4 and 14 in their R&D departm ents. This figure had  risen 
from  an interquartile range of 2.0 to 10 em ployed in  1985. In the year 
2000 the m ost conservative estim ate w ould  indicate an anticipated 4 to 
14 em ployed in  the R&D departm ents of the m iddle 50% of firms.
In term s of skill profile of R&D staff em ployed, responses rates w ere 
very low. M any respondents again w ere unw illing or unable to give a 
detailed breakdow n of the R&D w orkforce in term s of skills or 
qualifications. H ow ever by ignoring the extrem e responses of the top 
and  bottom  25%s it m ay be noted  that R&D departm ents tend to 
contain betw een  0 and 3 H igher D egree scientific personnel (M aster's 
Qualification plus) betw een 1 and  4.5 Scientific Degree staff, betw een 0
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and  2 Scientific D iplom a staff and  no 'other scientific personnel' 
(helpers, cheese m akers, scientific personnel w ith o u t form al scientific 
qualifications em ployed in  the R&D departm ent). Results indicate that 
increasing num bers of all personnel types have been  em ployed in the 
R&D departm ent since 1985 bu t that at present, D egree level scientific 
staff are m ost popularly  em ployed.
C om parison of R&D staff num bers w ith  total staff num bers m ay be 
m isleading due to the w orldw ide operations of som e firm s and the 
differing m ethods of staff calculation em ployed. This com parison is 
no t included. It m ay be noted how ever, that the em erging firm 
in terview ed em ployed alm ost half of total staff in R&D and the R&D 
departm ents of established firms ranged in size from  1 to 20 in 1992. 
C rosstabulation of evidenced in terest in new  biotechnological 
techniques does not reveal any significant trends. R&D staff sizes are 
spread  across firms w hich have evidenced a prev ious in terest in new  
biotechnological techniques as w ell as those w ho have not.
O n first glance com parison of figures gathered th rough  the 1991 Eolas 
survey w ould  indicate that those firm s identified as potential early 
adopters of new  biotechnological techniques em ploy few er R&D staff 
than  other R&D perform ing food firms. The Eolas survey p resen ted  a 
figure of 499.8 for full tim e equivalent personnel em ployed in the food, 
drink  and  tobacco sector or a m ean of 10.6 R&D staff per food firm.4 
(Figure 5.0) H ow ever, if one subtracts those staff categorised as 'other' - 
skilled and  unskilled labour including clerical and  adm inistrative staff 
w hich w ere no t assigned to the R&D departm ent in  this survey the 
m ean num ber of R&D staff em ployed per R&D perform ing firm  
according to Eolas falls from  10.6 to 7.19. The average num ber of staff 
em ployed in those firms identified as potential early  adopters of new  
Biotechnological techniques in  1992 w as 7.05. Identified  potential early 
adopters thus display sim ilar trends of R&D em ploym ent to o ther Irish
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R&D perform ing food companies.
Figure 5.0 Personnel Engaged in R&D in the Irish Food, Drink and 
Tobacco Sector. (1991)
■  Researchers - 199.2 
B  Technicians - 138.8 
□  Others - 161.8
Total No. Employed 499.8
Source: Science and Technology Evaluation U nit (1992), Business 
Tables for 1990, Eolas, Dublin, p .11
5.1.1 Comparison w ith International Food Firms.
Specific inform ation regarding identified po ten tia l early  adopters of 
new  biotechnological techniques in the in ternational food sector is 
unavailable. Descriptive statistics thus detailing the size and  skill 
profile of R&D departm ents in food related industries w orldw ide are 
u sed  to assess R&D perform ing Irish food com panies scientific 
personnel relative to their in ternational com petitors. D ata p resen ted  
in  Table 5.1.6 indicates that w hile the Irish food industry  accounts for
0.6% of OECD food production it em ploys 0.4% of OECD food related 
RSE personnel. (RSE denotes researchers. The definition of such 
personnel as outlined in the Frascati m anual is,
"Researchers are scientists or engineers engaged in  the 
conception or creation of new  know ledge, p roducts, processes, 
m ethods and system s'^
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E m ploym ent of such personnel is used  as an indicator of the relative 
sophistication of R&D staff profiles in In ternational food com panies.) 
O nly four OECD nations control a significantly greater percentage of 
total OECD food related RSE em ploym ent than OECD food production. 
These nations are Japan, Sweden, the US and the UK. The ratio of 
share of food related RSE em ploym ent to share of food p roduction  in  
the OECD indicates that RSE em ploym ent levels in  Irish  food firms are 
abou t parity  w ith  other European nations. Expressing this another 
w ay; Considering our small share of total OECD food p roduction  our 
share of total OECD food related RSE em ploym ent indicates sim ilar 
R&D staffing levels per un it of food production  to o ther European 
coun tries.
Table 5.1.6 Food Production and Employment of Food Related 
RSEs for Selected OECD Nations. (1985)
% Share of OECD 
Production (adjusted)
%Share of RSE 
Employment
Ratio
A ustralia 1.94 1.32 .68
Austria 1.02 .7 .69
Belgium 1.02 .7 .69
Canada 4.8 2.2 .46
Denmark 1.33 .79 .59
Finland 1.0 .8 .8
France 7.89 3 .38
Germany 6.0 3.2 .38
Greece .5 .07 .14
Iceland 0.04 .02 .5
Ireland 0.6 0.4 .66
Ita ly 4 1.0 .25
Japan 14.75 33.58 2.27
N etherlands 3.07 1.6 .52
N orw ay 0.8 0.13 .16
Portugal 0.4 0.09 .225
Spain 2.76 0.6 .22
Sweden 1.22 1.3 1.06
UK 6.5 7.1 1.09
US 39.56 40.7 1.03
Source: Basic Science and Technology Statistics (1991), OECD, Paris. 
Table 13 and  Stevens C. (1987), "Technology and the Food processing 
In d u stry "  STI Review, Septem ber, no.2, OECD, Paris p .17.
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It should  also be no ted  that in term s of the ratio of food related RSEs 
em ployed to general food related R&D personnel,
("all persons em ployed directly on R&D should  be counted, as 
w ell as those p rov id ing  direct services such as R&D m anagers, 
adm inistrators and  clerical staff's)
the Irish food, d rink  and  tobacco sector com pares w ell to o ther OECD 
countries. We have the highest ratio of food related  RSE's to general 
food related  R&D personnel in all European countries. This indicates 
th a t staff em ployed in  the R&D function of Irish food firm s are w ell 
qualified. (Figure 5.1)
F igure 5.1 Ratio of Food Related RSE Em ployees to T otal Food
R elated R&D Em ployees in  Selected OECD N ations. (1987)
Source: Basic Science and Technology Statistics (1991), OECD, Paris. 
Tables 13 and  12 .
Two poin ts should  be no ted  in the discussion of these finding.
1. Experts assert that for progress in the developm ent and  use of new  
biotechnological techniques "a critical mass" of scientists is necessary, 
along w ith  a good infrastructure and broad  based com m unication 
am ong the specialists w orking  all over the w orld. It has been  po in ted
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out that,
"these basic conditions for successful R&D activity are to be 
found m ainly in  the advanced industria lised  countries and in 
large MNCs and that this is w here biotechnology is going to 
develop fast".7
Thus, although potential early adopters of new  biotechnological 
techniques along w ith  all R&D perform ing Irish  food firm s em ploy in  
relative term s sim ilar num bers of researchers to their E uropean 
counterparts, taken in  absolute figures the opportun ity  to generate the 
'critical m ass' of food scientists in  the Irish food sector is small. Table 
5.1.7 details business enterprise R&D personnel and  RSEs for the food, 
d rink  and tobacco sector in selected OECD countries.
Table 5.1.7Total Business Enterprise R&D Personnel and RSE's, for the 
Food, Drink and Tobacco Sector in Selected OECD Nations. (1985,1986, 
1987)
1985 1986 1987
Total
R&D
staff
RSEs Total
R&D
staff
RSEs Total
R&D
staff
RSEs
B elgium 530 187 592 227 592 230
D enm ark 587 201 A A 707 231
France 2395 762 2739 850 2729 882
G erm any 3296 813 A A 3150 866
Greece A A 48 18 A A
Ireland 276 108 299 147 293 146
Italy 595 276 586 295 689 321
Luxem burg A A A A A A
N eth erlan d s 1850 420 1850 440 1920 440
Portugal A A 69 26 A A
S pain 483 171 616 203 A 213
UK 4900 1800 A A A A
US A 10300 A A A A
Japan 14519 8480 16713 9700 17805 10495
Source: Basic Science and technology Statistics (1991), OECD, Paris. 
Tables 12 and 13.
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In total in 1987 OECD figures indicate the Irish food, d rink  and tobacco 
industry  em ployed 293 persons in R&D generally and  146 RSEs. 
C om pare that figure to D enm ark w hich em ployed 707 persons in  R&D 
and  m ore specifically 231 RSE's.
2. Taken in absolute figures num bers em ployed in  R&D in  Irish food 
firm s are low com pared w ith  our European  com petitors. W hen 
com pared to R&D personnel em ployed by those firm s dedicated to the 
exploitation of new  biotechnological techniques Irish  food firm  R&D 
staff profiles are indicated as very basic. In 1991 the Eolas Business 
survey  indicated there w ere 161.2 full-tim e equivalent R&D personnel
engaged w ith  biotechnology in Ireland.8 In 1986 3,500 technical 
em ployees at g raduate level w ere w orking w ith  novel biotechnology in
the UK.9 Exploration of the qualifications of approxim ately 2000 of 
these is presented in Figure 5.2.
Figure 5.2 Working w ith  N ovel Biotechnology in the UK -
Employment Structure By Q ualification Level.(1986)
Industry Research Centres
Source: Bevan S., Parsons D. and  Pearson R.,(1987) Monitoring the 
Biotechnology labour market. A study  for the B iotechnology 
D irectorate of the Science and  Engineering Research Council. Brighton 
January, p. 17.
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The inform ation clearly show s that for those firm s involved w ith  
advanced  biotechnological techniques the p referred  m inim um  skill 
level is generally the PhD. The m edian num ber of h igher degree 
scientific staff em ployed by Irish food firms identified as potential early 
adopters of new  biotechnological techniques w as zero in  1992. These 
figures w ould indicate that w ithout considerable upg rad ing  of R&D 
personnel in term s of scientific qualifications it w ou ld  be very difficult 
for identified potential early  adopter Irish food firm s to com pete 
against firms currently  involved w ith  new  biotechnological 
techniques. This finding also applies to European food firms w hich 
secondary data accessed indicated had  a low er ratio of food related RSEs 
to general food related R&D personnel than  Irish food firms.
5.1.2 Technological Capacity: Allocation of Scores.
As outlined in chapter 4 a unique scoring system  w as developed w hich 
facilitates direct com parison of the technological capacity of respondent 
firm s to use new  biotechnological techniques w ith  that of dedicated 
firm s w orldw ide and of European food firms. U sing this system  
responden t firms are allocated a score on each ind iv idual indicator of 
technological capacity w hich reflects their perform ance relative to 
dedicated  firms. Each indicator is w orth  a m axim um  of five points.
The sum  of all four scores aw arded  for size and  skill profile of R&D 
staff, use of new  biotechnological techniques, R&D spend  and use of 
State resources reflects their overall perform ance on technological 
capacity. Scores are also allocated to E uropean firm s using the same 
system.
In  this section w e are concerned w ith  the allocation of scores for that 
indicator of technological capacity, size and skill profile of R&D staff. 
A ssum ing those com panies dedicated  to the exploitation of new  
biotechnological techniques have the op tim um  personnel skill profile
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for exploitation of the techniques such a com pany is aw arded  a 
m axim um  of five points.
Irish food firms are aw arded  two points. The rationale for this score is 
as follows: The R&D personnel em ployed by  Irish  food firms is 
underqualified  to com pete in any m eaningful m anner w ith  that 
em ployed by dedicated new  biotechnology firms. H ow ever, Irish food 
firm s are involved in R&D and they do em ploy albeit sm all num bers 
of R&D staff. A dditionally, trends of R&D em ploym ent in the Irish 
food industry  are im proving and  in 1991 they recorded  the highest 
ratio of food related RSEs to general food related  R&D personnel in all 
European countries. Staff em ployed thus are w ell qualified.
Table 5.1.8 Scores Allocated for Size and Skill Profile of R&D Staff.
Firms dedicated to the exploitation of 
new  biotechnological techniques.
5 points
E uropean food firms. 3 points
Irish food firms identified as potential 
early adopters of new  biotechnological 
techniques.
2 points
E uropean food firm s have been aw arded three points. A greater 
num ber of points w ere allocated to this sector to reflect the greater 
absolute num ber w orking  in  R&D in  E uropean  food com panies as 
com pared w ith  the Irish food industry . Reaching a critical m ass of food 
scientists is im portan t to progress w ork  w ith  new  biotechnological 
techniques and  E uropean food firm s are indicated as m ore likely to 
reach this critical m ass than  Irish food firms. H ow ever, sim ilar to the
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Irish  situation, trends of R&D em ploym ent in  the  E uropean  food 
sector are dism al com pared to that of dedicated  new  biotechnology 
firms. Consequently they could no t be aw arded as m any points as 
dedicated firms.(Table 5.1.8)
5.2 Level of Biotechnology Use in Manufacture and R&D.
In  order to track the level of biotechnology use in  food firms 
investigated  a three level continuum  of b iotechnology sophistication 
w as developed. Firm s w ere asked to indicate on  the continuum  w hich 
level best reflected their use of biotechnology in m anufacture and 
R&D. The continuum  is included in A ppendix  (B).
Level 1 and  Level 2 on the continuum  of progress correspond loosely 
to techniques used in advance of the recent developm ents associated 
w ith  new  biotechnological techniques. This type of biotechnology is 
popu larly  used in h igh  volum e low value food production. Level 3 on 
the continuum  of progress corresponds m ore closely w ith  techniques 
such as genetic engineering or small scale biotechnology as defined by
A ngold, Beech and  Taggart.10 Level three indicates use of new  
biotechnological techniques.
Table 5.2.0 Level of Biotechnology Use in Manufacture. (1992, 2000)
Level of Bio Use in 
Manufacture 1992
Level of Bio Use in 
Manufacture 2000
No. of firms % No. of firms %
Level 1 6 22.2 4 14.8
Level 2 11 40.7 11 40.7
Level 3 0 0 0 0
N ot Applicable 3 11 3 11
N o Answer 7 25 9 33
Total
Base: All Companies
27 100 27 100
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Table 5.2.1 Level of Biotechnology Use in R&D. (1992, 2000)
Level of Bio Use in Level of Bio Use in 
R&D 1992 R&D 2000
Level 1 
Level 2 
Level 3
N ot Applicable 
N o Answer
No. of firms % No. of firms %
4 22.2 2 11 
4 22.2 4 22.2 i 
0 0 3 16.6 
3 16.6 3 16.6 
7 40 6 33.3
Total 18 100 18 100 
Base: All Companies operating formal R&D departments in the years 1992, 
2000.
From  the inform ation presented in Table 5.2.0 and  Table 5.2.1 it is 
ev iden t that low  to interm ediate levels of biotechnology use are m ost 
favoured  am ong general food processors as w ell as ingredient suppliers 
in  m anufacture and  R&D to date. N ot one expert anticipated use of 
Level three in  m anufacture in the year 2000.
Three com panies felt that biotechnology w as no t relevant to their 
activities in  food processing. Two of these indicated possible 
involvem ent at field level in the purchase of seeds for better strains of 
crops. The rem aining com pany w hich indicated  that the techniques 
w ere no t applicable to activities is un involved  in  R&D and it's 
m anufacturing  operations are also organised at a very  basic level.
The h igh  num ber of those w ho w ere u n p rep ared  to estim ate fu ture 
involvem ent w ith  the techniques either in  m anufacture or R&D (33% 
respectively) is notew orthy. The refusal to associated w ith  any 
pred iction  is perhaps a reflection of the perceived  uncertainty  
su rro u n d in g  these techniques and their developm ent. M any experts 
from  the general food processing sector asserted  that h igh level/L evel 
Three biotechnology use is irrelevant to activities to date and 
anticipated  in the future. They felt that this level of biotechnology use
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only had  relevance in the food sector in the p roduction  of ingredients, 
enzym es, starter cultures etc. w hich they m ight purchase. They felt 
thus that they m ight be using these advanced techniques 'second 
hand '. This finding is in support of the assertion by  A ngold, Beech and  
Taggart that new  biotechnological techniques have prim ary  application
in  low volum e h igh  value ingredient p roduction .11 In light of this 
finding the response of h igh value, low  volum e ingred ien t firm s w ere 
focused upon. The response rate w as poor and  the results should  be 
treated  w ith  caution. H ow ever, responden t firms indicated 
involvem ent at all levels p redom inantly  at Level 2. O ne of the 
ingred ien t firm s indicated an anticipation of using  Level 3 or m ost 
advanced biotechnological techniques in R&D in the year 2000.(Table 
5.2.2)
Confusion w as indicated am ong food processors as to the exact 
technologies used  in  the p roduction  of h igh  value low  volum e 
ingredients. 86% of the food processing com panies interview ed, 
confirm ed they used  food additives /fo o d  ingredients in m anufacture. 
The host of products w hich w ere m entioned as used  included: yeast 
p roducts, enzym es, em ulsifier, stabilisers, flavourings, colourings, 
rennet, starter cultures and salt. These p roducts are popularly  
purchased  from  Irish ingredient suppliers. Technologies used  in  the 
p roduction  of these products are m ainly centred on dry ing  
technologies and  biotechnology. W hen questioned  respondents w ere 
often u n su re  as to w hether ingredients used  w ere m anufactured  
th ro u g h  use of advanced or basic biotechnological techniques. Two 
experts suggested that rennet used  m ay have been m anufactured  
th ro u g h  use of advanced biotechnological techniques b u t they w ere 
unsure. O ther respondents asserted that ingredients used  by them  
w ere m anufactured  th rough use of s tan d ard  biotechnological 
techniques. Still o thers felt that a lthough  the technologies u sed  m ight 
no t encom pass genetic engineering they w ould  still be classified as
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Table 5.2.2 Level of Biotechnology Use -Low Volume High Value 
Ingredient Firms.
advanced (genetic manipulation).
Level of 
Bio Use in 
Manu 1992
Level of 
Bio Use in 
Manu 2000
Level of 
Bio Use in  
R&D 1992
Level of 
Bio Use in  
R&D 2000
Finn 1 N o answer N o answer R&D else 
-w here
R&D else 
-w here
Finn 2 N o answer N o answer R&D else R&D else
Firm 3 N o Answer N o Answer
Firm 4 N o answer Level 2 Level 1 Level 3
Firm 5 Level 2 Level 2 Level 2 No answer
To m y know ledge there is no secondary research extant detailing the 
level of involvem ent of Irish food com panies w ith  new  
Biotechnological techniques. I feel how ever it is reasonable to assum e 
th a t the com panies in terview ed for the purposes of this research 
represent m ost advanced users of biotechnology in  the Irish food 
industry . C ertainly the sam ple w as chosen to achieve this objective.
5.2.1 Comparison with International Food Firms.
From  the inform ation gained in  the research undertaken  it is clear th a t 
low  to in term ediate levels of biotechnology use are m ost favoured  in  
the Irish food sector. A ngold, Beech and  Taggart have asserted that 
food processors w orld-w ide tend to be involved w ith  biotechnology at
this lev e l.12 They believe that m ore advanced techniques are only used  
by the food sector in the p roduction  of ingredients. The poor response 
from  the ingred ien t sector in  the survey  disallow ed com prehensive 
investigation of this phenom enon in an Irish context. It m ay be no ted  
how ever that those involved w ith  h igh  volum e low value p ro d u c tio n
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asserted that advanced technologies m ay be used  in  the p roduction  of 
ingredients purchased. Also, exploratory research undertaken  
indicated a perception am ong food experts of m ore advanced 
technologies used in the p roduction  of ingredients th an  in  general 
food processing. I feel it is reasonable to assum e thus that use of 
biotechnology is at a m ore sophisticated level in h igh  value low  
volum e ingred ien t p roduction  than  in  low  value h igh  volum e food 
processing. H ow ever, it is im possible to state w ith  any degree of 
accuracy w hether new  biotechnological techniques are used  by Irish 
food ingredient supply  firms.
By definition firms dedicated to the exploitation of new  
biotechnological techniques are involved w ith  the m ost advanced 
biotechnological techniques including technologies such as genetic 
engineering and  hybridom a technology. Results indicate techniques 
used by such firms are very m uch advanced to that used  by  Irish and  
E uropean food firms.
5.2.2 Technological Capacity : Allocation of Scores.
The research undertaken  indicates the m ost popu lar level of 
biotechnology use in  Irish food firm s is Level Two. H ow ever food 
processing firms questioned d id  indicate the possibility that the 
ingredients w hich they purchase m ay be m anufactured  using  m ore 
advanced techniques, thus they m ay be using the techniques second 
hand. Confusion w as evident how ever as to the exact technologies 
used in  ingredient production. L iterature accessed and  exploratory 
research undertaken  also supports  the hypothesis th a t ingred ien t firm s 
m ay be using  biotechnology at a m ore sophisticated level than  that 
used  by large volum e food processing firms. Investigation of 
ingredient firms in this survey w as ham pered  by  a very  poor response 
rate, thus for the purposes of scoring all Irish food firm s are p resum ed
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to display sim ilar use sophistication of biotechnology as food 
processing firms.
The m axim um  of 5 points is allocated to those firm s dedicated to the 
exploitation of new  biotechnological techniques. By definition such 
firm s are involved w ith  the m ost advanced biotechnological 
techniques. Both E uropean and Irish firm s are allocated tw o points. 
They are aw arded  equal scores as according to A ngold, Beech and 
Taggart European  firms are involved w ith  biotechnology as Irish firm s 
at Level Two. Two points are aw arded  as although neither sector is 
involved w ith  new  biotechnological techniques the firm s concerned 
have m oved from  use of the m ost basic techniques to a m odicum  of 
sophistication in application. In fu tu re  years thus use of m ore 
advanced techniques m ay be em braced m ore easily than  if they w ere 
still involved at a prim itive level. The allocation of less than  half the 
m axim um  possible poin ts to E uropean  and  Irish firm s how ever 
reflects the long road ahead of such firm s w ere they to consider 
becom ing involved w ith  the m ost advanced techniques.
Table 5.2.3 Scores Allocated for Level of Biotechnology Use.
Firm s dedicated to the exploitation 
of new  biotechnological techniques.
5 points
E uropean food firms. 2 points
Irish food firms identified as po ten tial 
early adopters of new  biotechnological 
techniques.
2 points
125
5.3 Research and Development Spend.
In  this section results are presented  in tw o parts. Initially analysis is 
un d ertak en  of the R&D spends of those com panies operating  form al 
R&D departm ents.(Table 5.3.0) This is followed by  presentation  of 
inform ation regarding the spend of all R&D perform ing 
com panies.(Table 5.3.1) Those firm s w ho do not operate form al R&D 
departm ents incur expenses on a per project basis and  have often an 
R&D budget as do firms w ho contribute a fixed am ount to R&D 
u ndertaken  overseas. Their R&D spend  thus is of in terest although  
they do no  operate a form al R&D dept. R&D expenses w ere recorded as 
a percentage of turnover.
Table 5.3.0 Research and Development Spend -Companies Operating 
Formal R&D Dept.s. (1985,1992, 2000)
1985 1992 2000
R&D Spend R&D Spend R&D Spend
M edian 0.6% 0.4% 0.75%
Range 100% 30% 30%
Qu 1.50% 1.00% 2%
Q1 0.1% 0.16% 0.33%
Midmean 0.64% 0.49% 0.78%
Unanswered 3 2 3
Formal R&D 16 18 18
Depts.
Base:All Companies with formal R&D Depts. in years 1985, 1992, 2000.
Table 5.3.1 Research and Development Spend-All R&D Performing 
Companies.(1985,1992, 2000)
1985 1992 2000
R&D Spend R&D Spend R&D Spend
M edian 0.2% 0.3% 0.5%
Range 100% 30% 30%
Qu 1.00% 1.00% 1.5%
Q1 0% 0.1% 0.2%
Midmean 0.27% 0.47% 0.57%
Unanswered 3 2 5
Base:All R&D performing companies.
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The results indicate that R&D spend as a percentage of tu rnover is 
consistently higher for those firms operating  form al R&D departm en ts 
com pared w ith  general R&D perform ing com panies. The m edian 
percentage of tu rnover spent for those operating form al R&D 
departm ents w as 00.6%, 00.4% and 00.75% for the years 1985,1992 and 
2000 respectively. The corresponding m edian values taking an 
overview  of all R&D perform ing food com panies are 00.2%, 00.3% and
00.5%. The m idm ean values w hich are perhaps the m ost interesting 
descriptive statistics in this context reveal the m iddle 50% of firms 
operating  R&D departm ents to be spending a m ean of 00.64% in 1985,
00.49% in  1992 and anticipating a spend of 0.78% in 2000. The m edian  
R&D spend fell betw een 1985 and 1992 for those com panies operating  
form al R&D departm ents. The reason for this decline m ay be 
explained by the grow th in num ber of form al R&D departm ents 
operated . As m ore com panies becam e involved the m edian  figure 
decreased, affected by  initially low spends of recently involved firms. 
H ow ever, overall the figures indicate an increasing percentage spend 
on R&D although the spend is low at less than  1% m edian  spend 
anticipated in 2000. M ean calculations w ere no t included as they 
w ould  be a nonsense w hen one notes the fact tha t the R&D spend as a 
percentage of turnover ranges from 0 to 100% in  1985 and 0 to 30% in 
1992 and  2000. The em erging firm included in sam ple spent 100% of 
tu rnover in 1985 on R&D and now  invests 30% of tu rnover in  R&D 
and anticipates to continue investm ent at this level to the year 
2000.The spend  of established firms ranged from  0.1% to 5% of 
turnover. Of the ingredient firms w ho responded  spends indicated 
m irrored  those of established food processors. It should  be noted  that 
all firm s including those w ho declined to offer any concrete estim ates 
of spending , past, present or future indicated an expectation of 
increased R&D spending  w ith in  their ow n com panies and w orldw ide 
in  the future. H ow ever, three com panies in terview ed anticipate 
spend ing  noth ing  on R&D in 2000 as they do no t anticipate becom ing 
involved  in  R&D.
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C rosstabulation of evidence of interest in biotechnology by  R&D spend  
in  1985,1992 and anticipated in 2000 did  no t reveal any trends of any 
significance. Those firms w ho evidenced a previous in terest in 
biotechnology w ere spread over a w ide range of R&D spends as w ere 
those w ho had  not. C om parison of results w ith  secondary data 
detailing  the R&D spend of technology perform ing food firm s in  an 
Irish  and  International context reveals som e in teresting  trends.
Secondary data accessed indicates sim ilar R&D spends am ong those 
Irish food firms identified as potential early adopters of new  
biotechnological techniques as all Irish R&D perform ing food firms. In  
1982 the 40 indigenous food com panies w ho w ere involved w ith  R&D 
spent £4.1 m illion on this activity. This expenditure represen ted  0.2% 
of sales for these companies. It is no tew orthy  that in  the report of the
S.D.C. th is expenditure was highlighted as being exceptionally low  and 
the assertion w as m ade that it should  have been  tw o to three tim es 
higher to equal in ternational s tandards.13 The data  com piled on R&D 
perform ing potential early adopters of new  biotechnological techniques 
also indicated a m edian spend of 0.2% am ong these food firms in 1985. 
The Eolas Business survey of 1991 indicated a sim ilar R&D spend 
m easured  as a percentage of sales am ong general R&D perform ing food 
com panies as those identified as po ten tial early adopters of new  
biotechnological techniques. The Eolas figures indicated a spend of
0.3% of sales for R&D perform ing com panies in the food, d rink  and 
tobacco sector.^ The research undertaken  on identified po ten tia l early  
adopters indicated a m edian spend of 0.3% am ong these firms 
generally although  the m edian spend  of those com panies operating 
form al R&D departm ents w as 0.4% of turnover. It w ould  seem  from  
these descriptive statistics thus that identified potential early adopters 
have sim ilar R&D spending  patterns as all Irish R&D perform ing food 
firm s.
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5.3.1 Comparison with International Food Firms.
In  this section, as in the section w hich contrasted Irish food firms', 
R&D staff, size and skill profiles w ith  those overseas, da ta  relating to 
food related  industries w orldw ide w ill be used for the purposes of 
com parison. The data available detailing the R&D spend  of food 
com panies in  Europe and  elsew here indicates low er spending  patterns 
ev iden t am ong Irish  com panies relative to their In ternational 
com petitors. In the 1980s Angold, Beech and Taggart asserted that the 
follow ing crude rule of R&D spending could be applied  to UK food 
com panies:
1. M ultinational food m anufacturers selling b randed  
consum er goods w ill spend about 1% of sales revenue on R&D.
2.N ational com panies m aking and  selling b ran d ed  consum er 
goods w ill spend about 0.5% of turnover on R&D.
3. C om panies involved in com m odity processing and  trad ing  
w ill spend  about 0.1% of tu rnover on R&D.is
In 1985 the R&D perform ing com panies investigated in  this survey 
w ere spend ing  just 0.2% of tu rnover on  R&D. They w ere in  the m ain 
N ational com panies thus the Sectoral D evelopm ent C om m ittee w ere 
correct in  asserting at least com pared to the UK, R&D spending in
Ireland w as low .16 M ore recent inform ation indicates that in  1992, US 
food com panies spent on average 0.7% of sales on R&D.i? This 
inform ation is balanced by  the finding that of the top US food 
com panies included in the 1991 Food Processing survey, 84% asserted
they spen t less than  1% on R&D. In fact 51% spen t less than  0.5%.^ 
(Figure 5.3) In  the light of this inform ation an average spend  of 0.7% 
reported  by  'Business W eek' seems high. H ow ever, w hatever the 
exact percentage of sales spent on R&D in the US in  1991 and 1992 
secondary data  does indicate that spending  was at least twice as h igh  as 
that spen t by Irish food firms at 0.3% of sales. If one com pares Irish 
food firm s' R&D spend w ith  that of the large European  food firms the
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deficiency noted is larger. R&D expenditures (1987) taken  as a 
percentage of sales for large European com panies are detailed  in Table
5.3.2.
Figure 5.3 R&D Budget as a % of Sales for US Food Companies. 
(1989,1990,1991)
% of Survey Respondents
■  Under 0.5%
■  0.5 - 1.0%
■  1.0 - 1.5% 
El 1.5% - 2.0%
■  2.0 - 2.5% 
[H Over 2.5%
Year 1989 Year 1990 Year 1991
*Note: 30% of respondents include Q A /Q C  in  R&D bu d g et
Source: Sw eintek R.J. (1991),"14th A nnual Survey -Top 100 R&D 
Trends" Food Processing, A ugust, pp38-46.
A nalysis of these figures reveals an average spend of 0.8% am ong the 
largest and  m ost pow erfu l E uropean food com panies. W ith increased 
consolidation of the European food industry , Irish  food firm s can no 
longer afford to ignore the practices of these larger com petitors.
R&D spend ing  in the food industry  relative to the R&D spend  in  other 
industries is higher in  Ireland than  other OECD countries. In  other 
w ords of all OECD countries the percentage of general m anufacturing  
R&D expenditure spen t on food is h ighest in  Ireland. In 1985 14% of 
Irish general m anufacturing  R&D expenditure w as allocated to food 
and  in  1981 the p roportion  w as one fifth. Thus, w hile R&D spending
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in  the  Irish food industry  is inferior to that spen t overseas, in  term s of
general spending on R&D in  Ireland the sector is quite w ell funded .19 
(Table 5.3.3)
Table 5.3.2 R&D Expenditures as a Percentage of Sales for Large 
European Companies. (1987)
R&D expenditure as % of sales
B ahlsen 0.8
Barilla 0.6
BSN 0.6
Cadbury Scheweppes 0.5
F errero 0.3
N estle 1.5
P arm alat 0.5
SME 1.2
U n ilv e r 1.2
U nited  Biscuit 0.4
average spend 0.8
Source: Petroni G.(1991), "New D irections for Food Research" Long 
Range Planning, vol.24, n o .l,  p.43.
C om parison  is also m ade betw een the R&D spend  of food firms 
generally  and  that spent by com panies w hose core of business is 
dedicated  to the exploitation of new  biotechnological techniques. It is 
necessary  first to note the low  level of R&D spending  generally in  the 
food sector com pared w ith  o ther m anufacturing  sectors. To illustrate, 
the da ta  presented in  Business W eek in  1992 indicated  an average R&D 
spend  of 0.7% of sales for food com panies. Com parable figures indicate 
the average R&D spends (taken as a percentage of sales) for healthcare 
firm s w as 9.0%, Office equ ipm ent and  services 8.3% and  Electrical and 
Electronics 5.8%.20 The R&D spends of recognised successful 
biotechnology com panies are in  another league.
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Table 5.3.3 Research and Development Expenditures by OECD Food 
Related Industry. (1988 except where otherwise noted)
million constant $ (1985 prices and ppp-purchasing power parities)
C ountry Total Share of Share of
(m illion) OECD H o m e
US $ Total G eneral
M an u fac tu rin g
R&D.
A ustra lia 52.7 2% 4.8%
A u stria t 12.2 .4% 2.2%
B elg ium 33.3 1.1% 2.4%
Canada 64.1 2.1% 1.9%
D en m ark / 29.6 1% 6%
F in lan d ! 16.3 .5% 3%
France 155.7 5.2% 1.6%
G erm any! 140.1 4.7% 1%
Greece 1.8 .06% 3%
Iceland! .512 .02% 11%
Ireland 18.196 .6% 14%
Italy 43.7 1.4% 1%
Japan 863.0 29% 3%
N eth erlan d s 106.9 3.6% 5%
Spain! 35.1 1.2% 3%
Sw eden! 46.7 1.6% 2%
UK 170.8 5.7% 2%
u s ! 1162.7 40% 1.3%
N orw ay! 5.6 .2% 1%
Sw itzerland* 17.2 .5% 1%
OECD Total 2976.208 100%
* 1981 1 1984 J 1987
Source\Basic Science and Technology Statistics (1991), OECD/Table 9.2. 
In  1991 Business W eek attributed  the following R&D spends as a 
percentage of sales to five such com panies.(Table 5.3.4) W hile it is 
recognised that a long lead tim e to the developm ent of m arketable 
p roducts  w ill have artificially inflated these figures, in term s of the 
percentage of sales allocated to R&D, it m ust be accepted that the R&D 
involvem ent of these com panies is very  m uch advanced  com pared 
w ith  food firms. Statistics taken from  D ibner's 'B iotechnology G uide 
to  the USA' also p resen ted  in Table 5.3.4, indicate the absolute budget
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allocated by these com panies to R&D in 1991. Budgets are m any times 
greater than  turnovers of m any Irish food firms.
Table 5.3.4 R&D Spend for Selected Dedicated Biotechnology
C om panies.
1991 R&D expenses Total R&D
as a % of Sales. Budget (1991)
Centacor 126.7% $60,000,000
C h iro n 115.7% $50,230,000
B iogen 72.1% $35,260,000
Genetics Institu te 55.2% $65,000,000
G enentech 46.3% $173,100,000
Source: A non (1992)/"On a Clear Day you  can see Progress" Business 
Week, June 29, p.55. and  D ibner M. (1991), Biotechnology Guide U SA , 
second edition, M acm illan Publishers Ltd.
P erhaps the m ost telling statistic how ever is that the average R&D 
b u d g e t for biotechnology firms involved w ith  agriculture according to 
M ark D ibner is $4.5 m illion.2i
5.3.2 Technological Capacity : Allocation of Scores.
The rationale for allocation of scores on this th ird  indicator of 
technological capacity is perhaps the sim plest explained. Results 
indicate that the R&D spend of Irish food firms com pared w ith  
ded icated  firms is m iniscule. Yet Irish food firms are involved in 
som e spending  and their expenditure is predicted  to increase, thus they 
deserve recognition of this activity in the scores. European  firm s on 
the o ther hand  are indicated as spending  twice as m uch as Irish  firms 
and  should  receive twice as m any points.
The R&D b u rn  rate of dedicated firms insures they receive the 
m axim um  five points, Irish firm s are allocated a half po in t to reflect 
the d isparity  of their spend and  that of new  biotechnology firms and
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E uropean firms are aw arded  twice that of Irish firms. 
Table 5.3.5 Scores Allocated for R&D Spend.
Firms dedicated to the exploitation 5 points
of new  biotechnological techniques.
E uropean food firms. 1 poin t
Irish food firms identified as potential 0.5 points
early adopters of new  biotechnological
techniques.
5.4 Use of Relevant State Aid Programmes.
Use of relevant State aid program s was the final indicator of 
technological capacity identified and investigated. Results indicate that 
m ore th an  tw o th irds of those firm s in terv iew ed rem ain  un involved  
w ith  science developm ent program s. Those w ho are involved are 
established food firms and  tend  to be larger cooperatives.(Table 5.4.0)
Table 5.4.0 Food Firms' Involvement with Science and Technology 
Programs.
1992 Anticipated for 
Future
No. of Percentage 
respondents
No. of Percentage 
respondents
Involvement with Science and 
Technology Programs 8 30% 12 44%
N o Involvement w ith Science 
and Technology Programs
19 70% 15 56%
Total
Base: All Companies
27 100% 27 100%
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As m any program s as com panies involved w ere m entioned. Reasons 
for non-participation  offered included:
"No com m ercial benefit", (pre-com petitive research)
"N ever approached."
"Lack of funding."
"No involvem ent w ith  R&D."
"No need."
These findings are supported  by  research undertaken  by  Jim Fitzpatrick 
and  Associates in  a report p repared  for the EC C om m ission DGX11.
The rep o rt entitled "Review of the EC R&D Fram ew ork  Program  in
Ire land  1984-1988" presented details of an exploration into the
characteristics and  attitudes of participants and  non-participants in  EC
program s. The program s included "all signed or perform ed DGX11
and  DGV1 Irish contracts betw een 1984 and  1988 and  all Irish Esprit and 
Race contracts from  DGX11 and DGX111 Sprint Irish contracts ."22 
Results of this study  indicated very low levels of participation 
generally  am ong private sector Irish firm s in  EC R&D program s, 
particu larly  am ong m anufacturing  com panies. (Table 5.4.1)
Table 5.4.1 Public and Private Sector Involvem ent in  EC Framework
Program (1984-1988)
Sector Category % of Sector % of Total
Public Gov dept./Agency 32% 23%
Higher Institute 67% 48%
State Commercial Co. 1% 0%
100% 72%
P riva te Manufacturing 32% 9%
Services 68% 19%
100% 28%
TOTAL 100%
Source: J. F itzpatrick and  Associates and  B. W afer and  Associates (1990), 
Review of the EC Framework Program in Ireland 1984-88, A R eport to 
the Com m ission DGX11 Science, Research and  D evelopm ent.p.92.
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Reasons found for non  application and non partic ipa tion  of com panies 
aw are of program s are listed in Table 5.4.2 (The food, d rink  and  tobacco 
sector represented  15% of firms interview ed)
Table 5.4.2 Non-Applicants: Main Reasons for N ot A pplying to
Participate in EC Framework Program (1984-1988)
R easons % of those aw are
No R&D undertaken at the time 2%
R&D is done by parent name 2%
R&D is financed by other sources 2%
Co. R&D does not fall into EC programs 6%
Programs are too specific an d /o r criteria are hard to define 2%
The company is very small 4%
There is a bias in approving companies to take part in program 2%
Application is a slow, bureaucratic, time consuming task 8%
The company does not have the specific information needed to apply 4%
C onfidentiality 2%
There is no benefit/need 2%
O ther 8%
No Response 58%
Total 100%
Source: J. Fitzpatrick and  Associates and B. W afer and  Associates (1990), 
Review of the EC Framework Program in Ireland 1984-88, A Report to 
the Com m ission DGX11 Science, Research and  D evelopm ent,p. 114.
It is interesting to note that in  the Fitzpatrick study  the perceived 
deficiency of pre-com petitive research w as no t cited as a reason for non­
participation. Flowever in  exploration of public and  private sector 
objectives in  undertak ing  R&D, Fitzpatrick found  the m ost im portan t 
overall objectives for Public sector contractors were:
O pen new  scientific areas (65%)
Acquire Basic K now ledge (65%).
O n the other h an d  the m ost im portan t overall R&D objectives for n o n ­
partic ipating  Private sector firms w ere :
Develop new  products (79%).23 
Thus, w hile the issue of the deficiency of pre-com petitive research m ay 
no t have em erged as a specific reason for non-participation  in  the
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Fitzpatrick research, it is reasonable to assum e th a t the needs of pre- 
com petitive research are better serviced th ro u g h  EC program s than  
com petitive. This w ould  explain the predom inance of public sector 
partic ipation  in  such  program s.
Focusing in  m ore detail on  the research u n d ertak en  on  potential early  
adopters of new  biotechnological techniques, the findings w ith  regard  
to in tention  to becom e involved w ith  Science and  Technology 
program s in  the fu tu re  divide the food firm s in terv iew ed  into tw o 
groups. The first group indicated an open m ind  on  the issue and  
asserted any program  w ould  be assessed on a per project basis. The 
second group w ere m ore sceptical and repeated  objections to pre- 
com petitive research and it's lack of relevance to day  to day activities. 
As m ight be an ticipated 71% of those involved w ith  scientific 
program s had  evidenced to the researcher a p rio r in terest in  new  
biotechnological techniques and  66% of those an ticipating fu ture 
involvem ent had  evidenced prior in terest in  new  biotechnological 
techniques.(Table 5.4.3)
Table 5.4.3 Involvem ent w ith  Scientific Program s by  Basis of 
Selection: Evidence of Prior In te rest in  N ew  
B iotechnological T echniques or Turnover.
Evidence T u rn o v e r
In terest
In v o lv e d 71.4% 28.6%
A ntic ipa ted  Involvem ent 66.7% 33.3%
Base: All Com panies.
The Fitzpatrick survey  d id  no t include any investigation of possible 
fu tu re  partic ipa tion  or involvem ent w ith  EC R&D program s.
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H ow ever a secondary finding is of in terest w hich  concerns aw areness 
an  issue unexplored in  this study. The findings of the Fitzpatrick s tu d y  
indicated 49% of non-applicants w ere aw are of EC program s and 25% 
w ere aw are of EC assistance for R&D in  Biotechnology.24
5.4.1 C om parison  w ith  In te rna tional Food Firm s.
The research undertaken  in  addition  to  secondary data  accessed 
indicates low levels of participation am ong Irish  food firms and  the 
private sector generally in  State ru n  science and  technology program s. 
In  this section the purpose  is to m ake in ternational com parisons of the 
level of State su p p o rt for food related industries. H ow ever, the very 
d iversity  of p rogram s undertaken  in  ind iv idual countries m akes 
com parisons and  particu larly  financial com parisons difficult. This 
problem  is exacerbated w hen  trying to m ake com parisons betw een 
countries w here institu tions and statistical practice m ay vary 
enorm ously. In this task thus data p resen ted  by Stevens in 1987 is
used.25 The follow ing table details the am ount of governm ent research  
funds w hich w ere allocated to food related research in  1981 in  selected 
OECD countries. U sing these percentages as a guide, relative support of 
food related industries is highlighted. As m ay be seen from  Table 5.4.4 
governm ent expenditures on R&D in  food related  industries is h ighest 
as a percentage of to tal governm ent expenditure on  R&D in  the 
m anufacturing  sector in  Ireland, D enm ark, Spain and  Iceland. In 
Ire land  8.8% of governm ent financed R&D in  m anufacturing  w as 
allocated to food related  industries in  1981. O n average the OECD 
governm ents only allocated 1% of R&D spend ing  to the food sector
com pared w ith  20-30% to  electronics. H ow ever, this inform ation m ust 
be regarded  in  context. The report of the expert group  on the Irish  food 
industry  asserts tha t the food industry  should  benefit from  a share in  
public research funds in  p roportion  to it's im portance in the econom y. 
They estim ate that the sector should  benefit from  around  23% of public
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research funds.26
Table 5.4.4 Food Sector's Share of Government Financed R&D in  
Selected OECD Countries. (1981)
1981 (%) Share of governm ent financed R&D in  m anufacturing
A ustra lia A
A ustria 5.3%
B elgium 2.4%
Canada 2.9%
D enm ark 15.5%
F in lan d 1.7%
France 0.1%
G erm any 0.4%
Iceland 6.7%
Ireland 8.8%
Italy 0.3%
Japan 0.7%
N eth erlan d s A
N orw ay 0.7%
Spain 6.5%
S w eden 2.2%
UK 0.3%
US 0.1%
OECD Total 0.9%
Source: Stevens C. (1987), "Technology and  the Food Processing 
Industry"S  .T .1. Review , OECD, p.23.
It is also useful to note R&D expenditure in  food related industries by  
source of funds. Data taken from  Basic Science and  Technology 
Statistics 1991 indicates h ighest state involvem ent in  food related  R&D 
in  Ireland, D enm ark and  Italy. (A ppendix D Table 5.4.5) The task  of 
undertak ing  a com parison of State su p p o rt for the biotechnology 
industry  in  an  In ternational context is frau g h t w ith  the same 
difficulties encountered in  the investigation of State support for the 
food industry. Biotechnology policy differs trem endously  betw een  
countries. H ow ever, secondary inform ation  indicates Irish  firm s 
benefit from  sim ilar levels of state su p p o rt for biotechnological 
developm ent as o ther E uropean  nations. W ork aim ed at the
139
exploitation of the benefits associated w ith  new  biotechnological 
techniques is, in  m any areas, at a very prelim inary  stage. Thus it is 
reasonable to assum e that the m ajority of food firms evidenced by  this 
survey  as unconcerned w ith  pre-com petitive research w ould  be in  the 
m ain  unaffected by differing levels of State su p p o rt for biotechnology 
in  a food context.
5.4.2 Technological Capacity: Allocation of Scores.
W ith regard  to the role of State support in  determ ining  the 
technological capacity of food firm s' to use new  biotechnological 
techniques it is necessary to consider State support bo th  for food related  
R&D and support specifically targeted at the exploitation of new  
biotechnological techniques.
As the un it of com parison, dedicated new  biotechnology firms are 
aw arded  the m axim um  five points on this ind icator of technological 
capacity. Results indicate that State support for the food industry  is 
stronger in  Ireland than  other European  nations and  State support for 
biotechnology is about parity  in all E uropean  nations. The support of 
State funding  in  the prom otion of the Irish  food industry  will be an  
im portan t aid  in  the devlopm ent of technological capacity for Irish 
firms. Im portant, because of the poor private sector R&D spend in  
Irish food. The support and  funding  represents an  im portan t s treng th  
for Irish  food firms considering bu ild ing  technological capacity and  for 
this reason  Irish firm s are also allocated the m axim um  five poin ts on  
this indicator of technological capacity. E uropean  food firms gain 
few er points on this indicator of capacity as, although they receive 
sim ilar levels of su p p o rt to the p rogression  of new  biotechnological 
techniques as Irish firms, they do no t benefit from  generous fun d in g  of 
the food sector. (Table 5.4.6)
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Table 5.4.6 Scores Allocated for Involvem ent in State Science and 
Technology Programs.
Firm s dedicated to the exploitation 
of new  biotechnological techniques.
5 points
E uropean  food firms. 3.5 points
Irish  food firms identified as potential 
early adopters of new  biotechnological 
techniques.
5 points
5.5 Technological Capacity to Use N ew  Biotechnological 
Techniques.
Table 5.5 presents the points allocated to  Irish  and  European food firms 
reflecting their perceived perform ance on  each indicator of 
technological capacity. Points have been  aw arded  to Irish and 
E uropean food firm s based on the research (prim ary and  secondary) 
p resen ted  indicating  their perform ance on  in d iv id u al indicators.
N ow , th rough  com parison of the sum  of scores for each firm  type, the 
technological capacity of Irish food firm s to use new  biotechnological 
techniques can be com pared w ith  th a t of dedicated new  biotechnology 
firm  and of E uropean food firms. It m ay  be no ted  that points were 
allocated arbitrarily and specific scores are open  to discussion.
H ow ever, the rationale behind each score allocation has been 
p resen ted  and  the system 's strength  lies in  its ability to,
1. reflect the ranked  perform ance of firm s w ith  regard  to indiv idual 
indicators of technological capacity investigated  as w ell as to
2. com pare in  aggregate their technological capacity to use new  
biotechnological techniques.
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Table 5.5 Technological Capacity of Irish and European Food Firms 
to Use N ew  Biotechnological Techniques.
Size and Skill 
Profile of 
R&D staff
Use of New 
Biotechnol­
ogical 
techniques
R&D
Spend
Use of
State
Resources
Total
Irish Food Firms 2 2 0.5 5 9.5
European Food firms 3 2 1 3.5 9.5
Firms dedicated to 5 
the exploitation of 
new biotechnological 
techniques
5 5 5 20
A llocation of scores indicates that the technological capacity of Irish 
food firms is about parity  w ith  their E uropean com petitors. The size 
and  skill profile of Irish R&D staffs are deficient w hen  com pared w ith  
th a t indicated in a European context as is Irish R&D spend. H ow ever, 
State support for the food industry  in  Ireland is very strong and  m ay 
aid  developm ent of the techniques in  the absence of strong private 
sector com m itm ent. Irish food firm s thus m ay benefit from  research 
u n d ertak en  in  the public sector w ith o u t undertak ing  im portan t 
in ternal technological developm ent. Both E uropean  and  Irish  food 
firms use basic level biotechnology. U sing technological capacity as a 
p rim ary  indicator of response indicates that E uropean food firm s are 
respond ing  sim ilarly to the em ergence of new  biotechnological 
techniques as Irish firms. Both Irish and  European firms rank  a w eak 
second w ith  regard  to technological capacity to use new  
biotechnological techniques as com pared w ith  firm s dedicated to their 
use. Investigation of indiv idual indicators of technological capacity 
revealed  a w eak perform ance from  Irish  and European food firms on 
three of the four indicators as com pared w ith  dedicated new  
biotechnological companies. It is reasonable to assum e that 
considerable upgrad ing  of technological capacity for Irish and  E uropean 
food firm s is necessary for them  to becom e involved w ith  new
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biotechnological techniques.
5.6 Food Firms' Strategies for Involvem ent w ith R&D.
Three aspects of food firm s strategies for involvem ent w ith  R&D w ere 
explored; new  p roduct sourcing activities, allocation of R&D spend  and  
in ternal and  external strategies used  to becom e involved  in  R&D.
5.6.1 Sourcing of N ew  Products.
R espondent firm s' strategies to source new  products w ere investigated 
th ro u g h  use of the question; W hat percentage of p ro d u c t acqu isition / 
line im provem ent is the resu lt of the follow ing activities? The 
inform ation presented  in  Tables 5.6.0 and  5.6.1 w ou ld  indicate th a t the 
m ost popu lar m ethod of sourcing new  products is th ro u g h  applied  
research and  w ill rem ain so to the year 2000. The m iddle 50% of firms 
currently  source betw een 30% and 90% of new  products th rough  
applied  research and  in  the year 2000 betw een 31% and  78% of products 
are anticipated  to be sourced in  this m anner. O ther m ethods of 
sourcing are im portan t for ind iv idual firm s b u t resu lts show  th a t the 
m ajority  of com panies source new  products th rough  applied  research 
com plem ented by low levels of involvem ent w ith  licensing, basic 
research, co.acquisition, contract R&D and  joint ventures. The 
em erging com pany in terview ed d isp layed  sim ilar sourcing m ethods as 
established incum bents, and  com parison of those firm s involved w ith  
h ig h  value low  volum e p roduction  reveals a sim ilar im portance 
attached to applied  research. H ow ever it is notew orthy  that of the six 
firm s anticipating sourcing some new  products th rough  basic research 
in  the year 2000 tw o are h igh  value low volum e ingred ien t supp ly  
firms. (A ppendix (D) Table 5.6.2)
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Table 5.6.0 Sourcing of N ew  Products.(1992)
M edian Range Qu Q1 Unanswered
Licensing .00% 10% .00% .00% 6
Basic Research .00% 100% 2.5% .00% 6
Applied Research 50% 100% 90% 30% 6
Co. Acquisition .00% 70% 7.5% .00% 6
Contract R&D .00% 100% 17.5% .00% 6
Joint Ventures .00% 100% 7.5% .00% 6
Base: All Companies.
Table 5.6.1 Sourcing of N ew  Products.(2000)
M edian Range Qu Qi Unanswered
Licensing .00% 10% .00% .00% 7
Basic Research .00% 100% 13.75% .00% 7
Applied Research 50% 100% 77.5% 30.75% 7
Co. Acquisition .00% 70% 7.5% .00% 7
Contract R&D .00% 50% 10% .00% 7
Joint Ventures .00% 100% 17.5% .00% 7
Base: All Companies.
5.6.2 Allocation of R&D Spend.
Results regard ing  the allocation of R&D spend underline  the 
im portance of in-house developm ent for Irish  food firm s identified  as 
po ten tial early adopters of new  biotechnological techniques. (Tables
5.6.3, 5.6.4, 5.6.5) The interquartile range shows that in  1992 betw een  
50% and  92.5% of the R&D bu d g et w as spent on  in  house developm ent 
for the m iddle  50% of firms. N o other R&D activity w as represen ted  in  
the R&D bu d g e t in  equal im portance. H ow ever, ind iv idual firm s 
allocate large proportions of R&D bu d g e t to activities such as purchase 
of technology, licensing, contract R&D and  jo int program s w ith  firm s 
an d  universities.
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Table 5.6.3 Allocation of R&D Spend.(1985)
In-House Joint Program Purchase of Contract
Development Firm s/U ni Technology R&D
M edian 50% .00% .00% .00%
Range 100% 90% 100% 100%
Qu 92.5% 10% 7.5% 15%
Q1 .00% .00% .00% .00%
Unanswered 1 1 1 1
Base: All R&D Performing Companies.
Table 5.6.4 Allocation of R&D Spend.(1992)
In-House Joint Program Purchase of Contract
Development Firm s/U ni Technology R&D
M edian 80% .00% .00% .00%
Range 100% 50% 100% 100%
Qu 92.5% 7.5% 2.5% 15%
Ql 50% .00% .00% .00%
Unanswered 2 2 2 2
Base: All R&D Performing Companies.
Table 5.6.5 Anticipated Allocation of R&D Spend. (2000)
In-House Joint Program Purchase of Contract
Development Firm s/U ni Technology R&D
M edian 70% .00% .00% .00%
Range 100% 50% 100% 100%
Qu 90% 20% 5% 20%
Ql 50% .00% .00% .00%
Unanswered 4 4 4 4
Base: All R&D Performing Companies.
The em erging firm  investigated  has m oved from  spend ing  100% of the 
R&D b u d g e t o n  in-house developm ent in  1985 to now  d iv id ing  the 
budget, 50% to in-house developm ent and 50% to jo int program s w ith  
o ther firms. A nalysis of those firm s involved w ith  h igh  value low 
volum e ingred ien t p roduction  reveals a variety  of d ifferent activities 
represen ted  in  im portance in  the R&D budget. A lthough in-house 
developm ent is im portan t o ther activities also com m and a h igh  
p roportion  of the R&D budget. Activities h ighlighted  as com m anding
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significant portions of the R&D bu d g e t include, purchase of technology 
and  joint program s w ith  firm s and  universities. (A ppendix  (D) Table 
5.6.6)
5.6.3 Strategies for Involvem ent w ith R&D.
Results indicate that all strategies for involvem ent w ith  R&D are 
popularly  used  w ith  least popular strategies identified  as, firm  
acquisition and  joint program s w ith  o ther firms. The percentage of 
com panies involved or anticipating involvem ent in  the strategies 
ou tlined  are presented in Table 5.6.7 and  Table 5.6.8.
Table 5.6.7 Internal and External Strategies Used to Become Involved  
in R&D.
Internal % External %
Hire new staff 44% Contract R&D 41%
Train staff 56% Joint program  with University 48%
Build facilities 52% Joint program  with firm 30%
Acquire firm 22%
Base: All Companies
Table 5.6.8 Internal and External Strategies Anticipated to Become 
Involved in R&D.
Internal % External %
Hire new staff 30% 
Train staff 48% 
Build facilities 41% 
Acquire firm 15%
Contract R&D 37% 
Joint program  w ith University 37% 
Joint program  with firm 26%
Base: All Companies
It is notew orthy  that in  discussion experts noted the im portance of cost 
as a factor lim iting their involvem ent w ith  different strategies. 
Strategies carried out w ith  universities w ere popu larly  w ith  UCC and 
contract R&D undertaken  w ith  the research staff in  M oorepark. 
C om parison  of strategies used  by those com panies involved w ith  h igh  
value  low volum e ingred ien t p rod u ctio n  does no t reveal any new
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inform ation. Strategies undertaken  and an tic ipated  w ere n o t unlike 
those indicated by established h igh  volum e food com panies. The 
em erging  firm  had  been involved in  some novel strategies to becom e 
involved  in  R&D as it began  life as a cam pus com pany and  developed 
th ro u g h  a joint p rogram  w ith  another firm. From  the inform ation 
p resen ted  it w ould  seem  to be continuing w ith  jo in t type program s.
5.7 A ttitudes to N ew  Biotechnological Techniques.
Investigation of attitudes to the technological d iscontinuity  caused by 
the em ergence of new  biotechnological techniques focused on  three 
central issues, attitudes relating the im pact of new  biotechnological 
techniques on  the Irish  food industry , a ttitudes concerned w ith  the 
regu la to ry  environm ent, an d  a ttitudes regard ing  public perception 
issues.
5.7.1 Im pact of N ew  B iotechnological Techniques.
R espondents opinions w ere explored w ith  reg ard  to the im pact they 
an tic ipated  advanced biotechnological techniques m ight have on their 
industry , the food and d rink  sector of greatest im pact, the greatest 
perceived  barrier to use and  their thoughts or p lans concerning 
possible fu tu re  involvem ent. R espondants opinions varied  w idely  
w ith  regard  to the pred icted  im pact of advanced biotechnological 
techniques on  the Irish food and  d rink  industry  to  the year 2000.(Figure
5.4) O nly 18% of those in terv iew ed felt the techniques w ould  have 
little or no im pact and  66% felt the techniques w ou ld  have an  im pact 
b u t w ere at variance in term s of w h en  and  to w h a t extent. (28% felt the 
techniques w ould  have an  im pact b u t fu turistically  w ell after the year 
2000) N o useful distinction can be m ade betw een  the opinions of those 
involved  w ith  ingredient p rod u ctio n  and  food processors. H ow ever, 
fu rther analysis of the results (Figure 5.5) presents a distinction 
betw een  the opinions of those respondan ts w ho  h ad  evidenced
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prev ious in te rest/in v o lv em en t w ith  biotechnological techniques and  
those w ho had  not. Those w ho had  been selected for interview  
because of their evidenced in terest or involvem ent w ith  new  
biotechnological techniques w ere m ore likely to feel that the im pact of 
these techniques w ould  be felt in  the post 2000 years. The opinions of 
those firm s w ho had  no t evidenced any in terest o r involvem ent to  the 
researcher (selected for interview  due to a h igh  turnover) spanned the 
board. All of those w ho p leaded  insufficient know ledge to make an 
im pact assessm ent w ere also in  the latter category
Figure 5.4 Predicted Impact of Advanced Biotechnological
Techniques on the Irish Food and Drink Industry.
I No Impact 
3 V.Uttle Impact 
^  Some /ltd Impact 
E  Major Impact 
1 Futuristic 
3 Don't know
All Companies
D iscussion of predicted sector of im pact, revealed vary ing  views 
am ong respondents. From  Figure 5.6 it m ay be no ted  that repondents 
feel the im pact will be strongest in  the Dairy, Brewing, Ingredients and  
A nim al & Plant Breeding sectors. It should  be no ted  how ever tha t in  
in terv iew  m any respondents m ade the po in t th a t a lthough  advanced 
biotechnological techniques m ight offer huge po ten tial for any 
particu lar sector the techniques m ight not be dev loped  or even used  in  
th a t sector. The sector of im pact m ight be sim ply using  a product 
m anufactured  and  developed elsewhere. They w ou ld  be using the 
techniques "second hand". The exam ple of genetically enginered 
starter cultures for use in  the Dairy industry  w as often cited. These 
starter cultures w ould  be developed and m anufactured  in  the
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ingredients sector bu t used for p roduction  of yogurt etc in the Dairy 
sector.
Figure 5.5 Predicted Impact of Advanced Biotechnological
Techniques on the Irish Food and Drink Industry by Basis 
of Selection, Evidence of Prior interest or Turnover.
Prior Interest Turnover
I  No Impact 
^  V.Little Impact 
H  Some/ Ltd. Impact 
H  Major Impact 
I  Futuristic 
H  Don't know
It m ay also be noted that the opinions of those w ith  an  evidenced 
in terest in  biotechnology w ere m ore likely to agree w ith  the experts as 
to the sector of greatest potential impact. 38% of those selected because 
of evidenced prior interest in  the techniques identified  the Dairy sector 
as the sector of greatest potential im pact com pared w ith  29% of those 
selected due to a large turnover. It m ay be assum ed tha t those w ho had  
ev idenced  a prior in terest in /in v o lv em en t w ith  advanced 
biotechnological techniques are the m ost know ledgeable w ith  regard to 
their potential.(A ppendix (D) Figure 5.7)
The results from  discussion of suggested barriers to adoption 
illu stra ted  the im portance of consum er resistance as a barrier to the 
con tinued  and  future use of advanced biotechnological techniques in  
the food and drink  industry. Over 50% of all those in terview ed no ted
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consum er resisitance as a barrier to adoption  and  use.(Figure 5.8) 
Figure 5.6 Predicted Food Sector of Impact
40 .0% I  Dairy 
H  Bakery 
H  Brewing 
IH Fish and Meat 
M  Misc. 
iU Ingredients
I !  Plant and Animal Breeding 
0  Don't Know 
Q  None
A n interesting poin t to note about the next m ost popu lar barrier 
m entioned, 'R egulations' is that respondents d iscussed the regu latory  
environm ent as a barrier to the extent that it relates to labelling 
directives, thus underlin ing  the im portance of the public p ercep tio n / 
consum er resisitance question. R espondents felt if p roducts w ere 
labelled  as being genetically engineered then  consum ers m ight not 
accept them. A nother po in t w orth  noting is th a t the consum er issue 
w as no t as im portan t for those com panies invo lved  w ith  h igh  value 
low  volum e p roduction  as it was for those involved  w ith  high 
volum e low value production. The m ost po p u lar barrier to use for 
the form er w as a perceived lack of tangible benefits for the 
m anufacturer inherent in  the techniques. The po in t w as m ade th a t 
firm s w ould  no t adopt these techniques or any new  technique unless 
the new  technology offered a cost saving or o ther such benefit. One 
expert sum m ed u p  the general feeling by  asserting,
"....they (advanced biotechnological techniques) w ill not be
adopted  for the sake of it".
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R espondents were m ost vocal in discussion of this topic, and  only tw o 
of those in terview ed felt there were no barriers to adoption  and  future 
use. (Figure 5.8) As can be seen from Figure 5.9 no distinction can be 
m ade betw een the opinions of those w ho had  evidenced prior in terest 
in  new  biotechnological techniques and those w ho h ad  not. Both 
groups clearly asserted  the im portance of potential consum er resistance 
as an  issue determ ining  the future adoption  and use of advanced 
biotechnological techniques.
Figure 5.8 Perceived Barriers to Adoption of Advanced 
Biotechnological Techniques.
I  Consumer Resistance 
^  Lack of Benefits 
H I Safety 
E  Regulations 
S  No Barriers
T o t a l  Low value High value
High Volume Low Volume
Table 5.7.0 outlines the in tentions of respondents about becom ing 
involved  w ith  advanced biotechnological techniques in  the future. If 
all the 'positive' assertions, 'd o n 't know s' and  'negative' assertions are 
am algam ated  it m ay be seen that the m ajority of firms are keeping an 
o pen  m ind on  the issue.(Figure 5.10) O ver 50% of firm s could 
envisage a scenario arising in  w hich  they w ou ld  becom e involved. 
H ow ever 28% ru led  ou t the possibility altogether.
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Figure 5.9 Barriers to Use of Advanced Biotechnological Techniques 
by Basis for Selection, Prior interest or Turnover.
60
Prior Interest Turnover
Table 5.7.0 Intention to Become Involved w ith Advanced
Biotechnological Techniques w ith Reasons.
Will Become Involved - No Reason Given 4%
If Of Benefit Will Become Involved 42%
Will Become Involved through Seed Developments 8%
Will not become involved - No Resaon Given 20%
Will Not Become Involved - No Need 8%
Don't Know. 16%
As w ould  be expected those w ho had  evidenced to  the researcher a 
p rio r interest or involvem ent w ith  new  biotechnological techniques 
w ere m ost likely to feel they m ight or w ould  becom e involved in  the 
future. ( 69% of those selected for in terview  due  to evidence of prior 
in terest com pared w ith  50% selected due to a large turnover.) (Figure 
5.11)
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Figure 5.10 Intention to Become Involved w ith  Advanced
Biotechnological Techniques.
Tota l
■  NO 
m YES
E l Don't Know
Figure 5.11 Intention to Become Involved by Basis for Selection, 
Evidence of Prior Interest or Turnover.
■ No
n Yes
m Don't know
Prior Interest Turnover
5.7.2 The Regulatory Environment.
It has been  noted that the regulatory  env ironm ent can affect the 
adoption  and  use of any new  technology, no t excepting new, 
biotechnological techniques. It w as necessary th u s  to investigate the 
attitudes of those involved in  food and  d rink  firm s w ith  regard  to the 
regulatory  environm ent in  Ireland. The issue of labelling w as 
suggested for special attention by secondary sources. It has been  noted
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as one of the m ore im portan t regulations affecting the future adop tion  
of advanced biotechnological techniques in  the food and  drink 
industry .
O ver half of the com panies in terv iew ed have no com m ent to m ake 
about the regulatory  environm ent. 58% of those in terv iew ed either 
h a d n 't sufficient know ledge about the regulations to m ake an 
assessm ent, felt the regulations w ere no t relevant to their activities 
and  the general activities of firms in  the food and  drink  sector or h ad  
no comment. (Figure 5.12) The com m on perception  am ong those 
in terv iew ed w as tha t the regulatory  env ironm ent governing the 
dev lopm ent and use of new  biotechnological techniques w as irelevant 
to their w ork  and  involvem ent w ith  biotechnology. In  interview , it 
w as perceived that those w ho expressed a view  as to w hether the 
regulations encouraged or discouraged w ork shared  this view. It m ay 
be inferred  thus from  these findings that the regulatory  env ironm ent 
does not affect the w ork  of the m ajority of firms in  the Irish food and  
d rink  sector. Results analysed in  term s of those w ho had  evidenced to 
the researcher some p rio r in terest in  biotechnology or new  
biotechnological techniques and  those w ho h ad  no t d id  no t yield any 
new  finding
Figure 5.12 Perceived Affect of Regulations on D evelopm ent and Use 
of N ew  Biotechnological Techniques.
■  N e ith e r Encourage o r D iscourage 
^  Encourage 
Ü  D iscourage  
HI D on 't know
T o ta l
O U .U  /o
5 0 . 0 %
4 0 . 0 %
3 0 . 0 %
20 .0%
10 .0 %
0 .0%
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From  Figure 5.13 it m ay be seen tha t there is a clear divide am ong the 
experts in  the food and  drink sector as to w hether genetically 
engineered food and  drink should be labelled as such.
Figure 5.13 Opinions with regard to Labelling of Gene -Technology 
Foods.
I  yes- consumer right 
no cause confusion 
HI don't know 
EH yes - same/irradiated 
S  no G.E. Product same 
ID if novel yes if not no 
§  Yes - no reason 
□  No - no reason
A lthough the greatest percentage of respondents favour labelling as a 
consum er right, (26%) other reasons are given in  su p p o rt of non  
labelling such as the assertion th a t labelling m ight cause confusion 
am ong consum ers. If those in  favour are com pared  w ith  those 
opposed  d isregarding  the 'don 't know s' the figures favour labelling. 
(59% v 33%) N o useful distinction m ay  be d raw n  betw een  the 
opin ions of those involved w ith  h igh  value low  volum e p roduction  
an d  those involved w ith  low volum e h igh  value production .
The results from  further analysis show  th a t those w ith  a p rio r in terest 
in  advanced biotechnological techniques w ere the m ost likely to feel it 
w as a consum er righ t that genetically engineered goods should  be 
labelled as such. (46%) In total 85% of those selected for interview  due 
to  a p rio r in terest in  advanced biotechnological techniques w ere in 
favour of labelling, if for different reasons. H ow ever, the opinions of 
those w ith  no evidenced prior in terst w ere m ore dispersed, roughly  
half of these (43%) opposed  labelling 49% w ere in  favour and  8% gave
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no opinion.(Figure 5.14)
Figure 5.14 Opinions with regard to Labelling of Gene-Technology 
Foods by Basis for Selection, Evidence of Prior Interest or 
Turnover.
Prior Interest Turnover
|  In Favour of Labelling 
Ü  Opposed to Labelling 
H  Don't Know
5.7.3 Public Perception of Gene-Technology Food and Drink.
Four questions w ere generated in  o rder to  investigate this topic. The 
questions explored experts' perceptions of consum ers risk  assessm ent 
of food and  d rink  produced th rough  use of advanced biotechnological 
m ethods and  by  com parison their ow n  assessm ent of food and  drink  
produced  in  this way. Exploration w as also m ade of expert opinion 
w ith  regard  to expected consumer reaction to genetically engineered 
food and  d rink  and  contingency plans to deal w ith  possible adverse 
reactions.
R espondents w ere asked to indicate on  a scale of 1 to 10 (w ith l= no  
risk, up  to 10= very high risk) b o th  their ow n num erical risk 
assessm ent of food and drink p roduced  th ro u g h  advanced 
biotechnological techniques including  genetic engineering and  th a t of 
consum ers. Tw o ingredient supply  firm s refused to  give a risk 
assessm ent on  the grounds that each new  food w ould  necessitate
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ind iv idual assessm ent. H ow ever, the results show  a consensus 
em erging am ong those w ho did  respond. All save tw o estim ated the 
consum er risk  assessm ent as higher than  their ow n. Risk assessm ent 
scores are presented  in  Figure 5.15. R espondents' m ore ususal 
num erical risk  assessm ent of food and  d rink  p roduced  th rough  
advanced biotechnological m ethods w as 2(low risk) and  their estim ate 
of the consum ers' risk assessm ent w as 8 (high risk). Use of the 
in terquartile  range indicates that the m iddle 50% of firms num erical 
risk  assessm ent of gene-technoloy foods w as betw een 2 and  5 and  their 
estim ate of consum ers' risk assessm ent w as betw een 5.5 and  8. The 
findings here further support the argum ent that experts w orking  in  the 
food industry  anticipate adverse cosum er reaction to  gene-technology 
food and  drinks. C om parison of the risk assessm ents of those involved 
w ith  low  value h igh  volum e p roduction  and those involved w ith  
h igh  value low  volum e p roduction  does no t reveal any significant 
findings.
Figure 5.15 Respondent Risk Assessment of Gene-Technology Foods 
and Estimates of Consumer Risk Assessment.
R espondent O w n A ssessm ent 
R espondent Estim ate of C onsum er A ssessm ent
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A lm ost com plete agreem ent am ong those in terv iew ed w as noted  as to 
the expected adverse reaction consum ers will have to genetically 
engineered  food and  drink. 78% of those in terv iew ed anticipated 
fu tu re  adverse consum er reaction. Six experts how ever felt that 
consum ers m ight not have an  adverse reaction an d  their opinions 
w ere variously:
"If the custom er is ok (following consum ption) then  the 
response w ill be ok., it w ill find its place."
"C onsum er reaction is lead by press reaction..."
"If it's  cheap enough they w ill eat it"
"If it is properly  advertised and  prom oted  then  no problem "
D ue the the overw helm ing response indicating an  expected negative 
consum er response some of the com m ents are p resen ted  below.
"w ith  m istrust if presented as such"
"B ru ta l"
"W ith  D oubt"
"C onservatively"
"Slow to accept... trad itional consum ers"
"W ith  confusion"
"Strong bias against initially... if realised"
"....ignorance...sceptical"
"Poorly"
"Badly"
"C autiously"
"H ard  to say...adverse reaction"
"Badly ..lack of understand ing  .. genetically engineering w hips 
u p  em otion bu t if explained....no difficulty"
"C onsum er m ight not realise, additives m ight be a b igger 
problem ... w ary, this is a w orldw ide phenom enon."
"U nless parcelled properly  ...will find objection"
"N ot G reat" (sarcastically)
Ingred ien t supply  firms w ere not as likely to anticipate an  adverse 
consum er reaction to gene-technology food and  drinks as h igh  volum e 
food processors. (Figure 5.16) Analysis of the responses in  term s of 
those w ho had  evidenced prior in terest in  biotechnology and  those 
w ho h ad  not, show ed that a negative reaction was predicted  equally by  
bo th  groups.
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Figure 5.16 Anticipateci Consumer Response to Gene Technology 
Foods.
H  N e g a tiv e  R e s p o n s e  
^  P o s it iv e  R e s p o n s e
T o ta l L o w  V a lu e  H igh  V a lu e  
H igh V o lum e Low  V o lum e
The m ost popular rem edy suggested to com bat possible adverse 
consum er reaction to genetically engineered food and  d rink  w as 
consum er education. (Figure 5.17) 60% of the total sam ple suggested 
this general rem edy, and  another 23% focused on  particu lar aspects of 
consum er education such as balanced m edia debates, p roof of safety 
and  com m unicating this proof and  the im portance of food and  d rink  
firm s becom ing open abou t their developm ent activitities. It is 
no tew orthy  how ever th a t tw o respondents felt th a t the s ituation  could 
not be rem edied  th rough  education, rather they felt the techniques 
should  be dropped. Also, another tw o experts notably in  the ingredient 
supply  sam ple felt that adverse consum er reaction had  n o t b een  noted  
and  and  should  not be expected. As one respondent asserted;
"If it's  no t broken d o n 't fix it".
A nalysis of responses by  basis for selection, evidence of p rio r in terest 
new  biotechnological techniques or large tu rnover d id  no t y ield  any 
new  inform ation. The response of b o th  groups w ere broad ly  similar.
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Figure 5.17 Suggested Remedies to Anticipated Adverse Consumer 
Reaction.
I  Consumer Education 
^  Don't use genetic methods 
0  Don't presuppose neg. reaction 
EH Firms open about activities 
H  Balanced media debate 
H  No Comment
1 !  Prove safety + communicate it 
T o t a l
5.8 Trends of Response Relating to Each Identified Determinant.
Findings indicated tha t the technological capacity of Irish firm s w as 
about parity  w ith  their European com petitors. The technological 
capacity of Irish and  European food firms to use new  biotechnological 
techniques w as indicated as deficient com pared w ith  dedicated 
com panies. The scoring system  used  to d raw  together the four 
indicators of technological capacity resulted  in  the allocation of 9.5 
poin ts to identified potential adop ting  Irish food firms and  E uropean 
food firm s respectively. Com panies created to exploit the potential of 
new  biotechnological techniques w ere allocated a m axim um  of 20 
points. U sing technological capacity as a prim ary indicator of response 
it m ay be assum ed E uropean  firm s as Irish firm s investigated have n o t 
yet responded  in  any m eaningful m anner.
Exploration of the strategies u sed  to  becom e involved in R&D revealed  
an  em phasis on in-house app lied  research  am ong com panies 
interview ed. O ther strategies w ere used  b u t only to com plem ent this 
general th rust of R&D effort. Results of the exploration of a ttitudes to
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the em ergence of new  biotechnological techniques m ay be presented in  
th ree parts. W ith regard  to the investigation of perceived  future 
im pact new  biotechnological techniques m ight have on  the food 
ind u stry  respondents w ere divided. Those w ho h ad  evidenced to the 
researcher a prior in terest in  the techniques w ere m ost likely to feel the 
techniques w ould  have an  im pact b u t futuristically - post 2000 and  that 
the sector of greatest potential im pact was the Dairy sector. These 
experts w ere also m ost likely to assert they could envisage a scenario 
em erging w hich  m ight result in  them  becom ing involved. The 
opinions of those w ho had  not evidenced any p rio r in terest w ere less 
defined and a consensus w as not reached on any aspect of impact.
Public perception issues w ere indicated as of p aram o u n t im portance to 
the fu tu re  adoption  and  use of new  biotechnological techniques and an 
overw helm ing m ajority anticipated adverse consum er reaction to gene- 
technology food and  drinks. The regulatory  env ironm ent w as 
indicated  as of im portance solely as it related to possible com pulsary 
labelling of gene-technology food and  drinks.
P receding results sum m arize the findings for the total sam ple in 
aggregate. O bviously indiv idual firm s and groups of firm s perform ed 
differently  on ind iv idual and  all determ inants of response.
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Chapter 6 Patterns of Response Inferred.
6.0 Introduction.
In  this chapter trends of response to the technological discontinuity- 
caused by the em ergence of new  biotechnological techniques are 
inferred th rough  an appreciation of the three identified  determ inants 
of response:
Technological capacity to use new  biotechnological techniques. 
Strategies used to becom e involved in R&D.
A ttitudes to the em ergence of new  biotechnological techniques.
Trends of response inferred  are p resented  in  the follow ing m anner. To 
begin, the general response noted of all potential early adopters of new  
biotechnological techniques interview ed is presented . A nalysis is then  
m ade of the differences and sim ilarities no ted  in the responses of;
Established incum bent firms investigated and  the em erging firm  
investigated ,
Firm s involved w ith  h igh  volum e low value p roduction  and 
firms involved w ith  low  volum e h igh  value food p roduction , 
and
Firm s selected for interview  due to evidenced p rio r in terest in  
new  biotechnological techniques and  those selected because of a 
large turnover.
6.1 General Pattern of Response Inferred for all Firms Investigated.
Thirty seven potential early  adopters of new  biotechnological 
techniques w ere identified in the Irish food industry . 73% of those 
identified responded  to the investigation. These firm s included 
established firms, and  an  em erging firm , firm s involved w ith  h igh  
value low  volum e production , and  those involved  w ith  h igh  vo lum e 
low  value production , firm s w ho had  evidenced to the researcher a 
p rio r in terest in  new  biotechnological techniques and  som e w ho had  
not. They represented Dairy, Fish and  M eat, Bakery, Brewing,
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M iscellaneous food production , Ingredients an d  A nim al and Plant 
Breeding sectors of the Irish food industry . The aggregate response of 
these firm s to the technological d iscontinuity  caused by the em ergence 
of new  biotechnological techniques is inferred th ro u g h  an appreciation 
of their perform ance on the three identified determ inan ts of response.
6.1.1 Analysis of Determinants of Response.
(i) Technological Capacity to use techniques: A nalysis of firms' capacity 
to use new  biotechnological techniques is included  in C hapter 5.
Results indicated tha t the capacity of firms in terv iew ed to use new  
biotechnological techniques w as deficient w hen  com pared w ith  firm s 
dedicated  to their use. Taking each indicator separately:
R&D staffs em ployed, although better qualified th an  those present in 
E uropean food firms w ere not of the sam e stan d ard  academ ically as 
those em ployed by firm s dedicated to the exploitation of new  
biotechnological techniques. D octorate level staff, m ost popularly  
em ployed by such firms are barely represen ted  in  the R&D departm ents 
of firms interview ed. R&D spends taken as a percentage of sales and  in 
absolute figures w ere also indicated as deficient com pared w ith  that 
spen t by dedicated firms. Results indicated use and  in tended use of 
biotechnology w as at a basic level and  d id  no t include the exploitation 
of advanced biotechnological techniques. Use sophistication w as 
indicated  as in-line w ith  that norm ally  used  by  h igh  volum e low value 
food processors internationally. The single factor w hich  indicated a 
possible fu ture increase in technological capacity to use new  
biotechnological techniques is the significant governm ent support 
w hich  the Irish food industry  enjoys.
In order to appreciate the w ide chasm  betw een  the technological 
capacity of firms interview ed and those dedicated  to the use of new  
biotechnological techniques it is useful to note th a t the scoring system  
developed to d raw  together the four indicators of technological capacity 
resulted  in  the allocation of 9.5 points to Irish  food firm s com pared
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w ith  a m axim um  of 20 points allocated to firms dedicated  to their use. 
Results did indicate how ever that the technological capacity of Irish 
food firms interview ed is com parable to that of their E uropean 
com petitors. Both groups of firms w ere allocated 9.5 points 
respectively.
(ii) Strategies for involvem ent in R&D: Strategies for involvem ent 
w ith  R&D indicated an overw helm ing concentration on  in-house 
applied  research. O ther strategies and  m ethods to source new  products 
and  further research and developm ent are used  b u t only to 
com plem ent this general th rust of R&D effort.
(iii) A ttitudes to the em ergence of new  biotechnological techniques: 
Investigation of a ttitudes to the em ergence of new  biotechnological 
techniques revealed tw o im portan t beliefs of firm s interview ed.
O n the one hand  experts acknow ledged and appreciated the potential 
offered by new  biotechnological techniques to the food industry . 59% of 
those in terview ed could envisage a scenario evolving w hich m ight 
resu lt in them  becom ing involved, and  sectors of greatest po ten tial 
im pact w ere identified as Dairy, Brewing, Ingredients and  A nim al and  
P lant breeding. O n the other hand  experts indicated that possible 
consum er rejection of gene-technology food and  drinks represen ted  a 
m ajor deterrent to use. The salience of this issue for experts 
interview ed m ay no t be over em phasised. The regulatory  
environm ent w as discussed as a problem  only as it related to possible 
com pulsory labelling of gene-technology foods. Experts estim ated 
consum er risk assessm ents of gene-technology foods as m uch higher 
than  their ow n and an adverse consum er reaction to food produced  
th rough  advanced biotechnological m ethods w as anticipated by alm ost 
all respondents.
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6.1.2 Inferred Response.
A nalysis of the three determ inants of response w ould  not indicate any 
significant involvem ent of potential early adop ters in terview ed w ith  
new  biotechnological techniques. The p rim ary  indicator of response 
investigated was technological capacity and results indicate firms 
interview ed have not the capacity to use the techniques, nor are any 
significant increases in  technological capacity anticipated  in the future. 
Strategies for involvem ent in R&D are centred on in-house applied  
research. Involvem ent w ith  basic research, critical for the 
developm ent of em erging technologies is m inim al to zero. A ttitudes 
reflect an appreciation of the techniques potential b u t also a realisation 
of public perception problem s possible th rough  use. Using Daly's 
description of options available to firms follow ing a technological 
discontinuity, firms interview ed are indicated  as availing of options,
" Do N othing  or 
M onitor only."1
Analysis of identified determ inants of response d id  no t indicate any 
first hand  involvem ent w ith  the techniques thus supporting  the 
hypothesis that firm s in terview ed follow ing the technological 
discontinuity  caused by  the em ergence of new  biotechnological 
techniques are 'doing nothing '. H ow ever approxim ately  half of those 
in terview ed w ere included in the judgem ental census of potential early  
adopters of new  biotechnological techniques because they had  
evidenced to the researcher a previous in terest in  new  biotechnological 
techniques. (Table 4.2) It is reasonable therefore to assum e that som e 
firm s a lthough  rem aining  un involved  w ith  the techniques are 
undertak ing  a m onitoring strategy. U sing H am ilton 's typology of 
strategy available follow ing a technological discontinuity  firms 
in terview ed m ay be categorised as using  the 'O pening W indow s' 
s tra tegy .2 This involves m onitoring and identification of im portan t 
technologies.
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The inferred  'Do nothing ' or 'M onitor only' response to the em ergence 
of new  biotechnological techniques contrasts w ith  research u n d ertak en  
in 1990 w hich indicated 11 Irish food and  d rink  firm s w ere involved 
w ith  biotechnology R&D. These com panies w ere in  the Dairy, 
Ingredients and  Alcoholic Beverage sectors. H ow ever the definition of 
biotechnology used  in that piece of research w as very  broad and  d id  no t 
necessarily encom pass new  biotechnological techniques.(A ppendix (E)) 
The screening criteria required only tha t the com pany be actively 
involved in  biotechnology research and  developm ent in Ireland as a 
m eans tow ards innovation, either th rough  in-house or contracted
R&D ac tiv itie s .3
The rationale suggested for potential early adopters of new  
biotechnological techniques in terv iew ed availing  of identified options 
and  strategies following the em ergence of new  biotechnological 
techniques is as follows:
1. A factor identified as im portant, by  the literature accessed, in the 
process of diffusion of a new  technology in ind u stry  is the perceived 
risk associated w ith  adoption.4 For firm s in terview ed, results show  the 
risk associated w ith  adoption of new  biotechnological techniques is 
enorm ous. Food firm s highlighted the salience of public perception 
issues as affecting adoption. They po in ted  out they do not w ish  to be 
associated w ith  any technology how ever pow erfu l if consum ers regard  
the p roducts possible th rough use as potentially  harm ful. Perceived 
risk associated w ith  adoption and  use thus has resulted  in firms 
rem ain ing  un invo lved  and  in  som e cases 'm onito ring  only'.
2. M ansfield has noted  the probability  of diffusion and adoption  of an
innovation  is a decreasing function of the size of investm ent requ ired .5 
C om parison of the technological capacity of potential early adopters 
in terview ed w ith  that of firms dedicated to use of the techniques has 
h igh ligh ted  the huge investm ent necessary for firm s in terview ed to
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becom e involved. This is another factor w hich has lead firms 
in terv iew ed  to 'Do nothing ' or 'M onitor only'.
3. W ebster has indicated that a factor w hich tends to retard  diffusion 
includes the degree to w hich increased technical skills are required  to
use the innovation .6 Analysis of the size and skill profile of R&D 
w orkforces of firms interview ed h ighlighted the considerable 
upgrad ing  necessary for firms to use new  biotechnological techniques. 
This has also supported  the continuing non-involvem ent strategy of 
firm s in terv iew ed.
4. Finally, literature accessed indicated that the relative advantage 
afforded by an  innovation has been identified as a p rim ary  determ inant
of w hether it is adopted  in an industrial m arket.7 For firms 
in terview ed results indicate the relative advantage to be gained 
th rough  use of new  biotechnological techniques is no t clear. The 
techniques as noted in literature accessed have been slow  to realise 
their po ten tial and as yet it is difficult to identify in  a food context an 
im m ediate relative advantage afforded th rough  use. In sum  
exam ination of results w ould indicate firms in terv iew ed are 
responding  to the em ergence of new  biotechnological techniques by 
'D oing no th ing ' or 'M onitoring only'.
6.2 The In ferred  Response of E stablished and  Em erging Firms.
The distinction betw een established and  em erging firms is an 
im portan t one in the developm ent of a new  technology. In this survey 
the judgem ental census of food firms identified as potential early 
adopters of new  biotechnological techniques included tw o em erging 
firms and  th irty  five established incum bents. This sam ple reflected 
trends of in terest in new  biotechnological techniques noted  in the Irish 
food industry . The sam ple achieved contained one em erging firm  and 
tw enty  six established incum bents.
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Table 6.0 Sample Achieved - Emerging and Established Firms.
Em erging firm s 
Established Incum bents
No. of firms 
1 
26
Total 27
The bu lk  of firms interview ed thus w ere established incum bents. Such 
firm s as defined by  H am ilton have positions in a particu lar industry  or
m arket to w hich applications of a new  technology m ay be directed.» In 
this survey established incum bents in terview ed included food co­
operatives, brew ing, baking, and m iscellaneous food firm s as w ell as 
food ingredient firms. For all of these firm s new  biotechnological 
techniques represent another, albeit pow erful, tool w hich m ay or m ay 
not be adopted  for use in m anufacture a n d /o r  research and  
developm ent w ork. A n em erging firm  how ever is defined as one
"created to exploit a new  technology."9
For the purposes of this survey the em erging firm  identified and 
interview ed w as a h igh  technology p lan t breeder. D etailed 
exam ination of findings how ever raised  the question w hether th is firm  
w as m is-classified as an em erging new  biotechnology firm  b u t ra ther is 
an  em erging firm  based on biotechnological techniques available p rio r 
to the advances referred to as new  biotechnological techniques.
6.2.1 Analysis of Determinants of Response.
A nalysis of results revealed the response of established incum bent 
firms, due to their dom inance in sam ple reflected the aggregate 
response of all po tential early adopters interview ed. H ow ever, a 
slightly different p a tte rn  of response w as indicated from  exam ination
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of findings relating to the em erging firm  interview ed. Focus on the 
results relating to the perform ance of the em erging firm  reveals the 
follow ing trends:
(i) Technological Capacity to use techniques: The p rim ary  factor of note 
w as the prim acy of the R&D departm ent and R&D activities to the 
general functioning of the em erging firm  as com pared w ith  established 
incum bents. A lm ost half of those em ployed in the em erging firm  w ere 
em ployed in the R&D departm ent and  half of these w ere educated  to 
h igher degree level. Trends of R&D staff em ploym ent thus w ere 
sim ilar to R&D staff em ployed in all dedicated new  biotechnological 
firms. Degree level staff w ere m ost popularly  em ployed in the R&D 
departm ents of established incum bents. R&D spend as a percentage of 
sales for the em erging firm w as also indicated as h igh at 30% in 1992 
and anticipated to rem ain so. The percentage had  form ally been 100%. 
Secondary data accessed indicated that R&D spend taken as a percentage 
of sales is norm ally h igh  for dedicated companies. The R&D spend as a 
percentage of sales for established incum bents w as popu larly  indicated 
as betw een 0.1% and 5%.
In term s of use sophistication of biotechnology the results w ere perhaps 
surprising. The em erging firm  in terv iew ed asserted that it u sed  Level 
1 or m ost basic biotechnology in m anufacture and  R&D and in tended  
to continue use at this level into the  future. The m ost po p u lar level of 
use for established incum bents w as Level 2 in m anufacture and  R&D. 
Similar to established incum bents the em erging firm  benefits from  
significant governm ent support of the Irish food industry , although  
results indicate it had  no t been involved w ith  State science and 
technology program s in the past.
O verall the technological capacity of the em erging firm w as indicated  as 
superior to that established incum bents. Results indicated it undertook
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sim ilar trends of R&D em ploym ent to dedicated  firm s and  also spen t 
sim ilar am ounts taken as a percentage of sales as such firms. H ow ever, 
it d id  no t use biotechnology at an advanced level and  it is for this 
reason th a t this firm 's classification as an  em erging firm, created to 
exploit new  biotechnological techniques, is questioned. It's staff, size 
and  skill profile and  R&D spend w ould  indicate it is such a firm. 
H ow ever, it does no t use biotechnology at an advanced level and  is no t 
involved w ith  State science and technology p rogram s directed tow ards 
the developm ent of these em erging technologies. Because of this the 
firm  perhaps m ight be m ore correctly classified as a h igh  technology 
firm  based  on use of biotechnology in general ra ther than  new  
biotechnological techniques.
(ii) Strategies for involvem ent in R&D: Strategies used  to becom e 
involved in R&D w ere very sim ilar to those reported  used  by 
established incum bents. A pplied in-house research and developm ent 
w as indicated  as im portant, although novel strategies had  been used  in  
previous years. The com pany started  life as a cam pus com pany and 
used  classic strategic alliances to com bine it's core technical assets w ith  
innovation-specific com plem entary assets of an established firm  to 
develop new  p lan t products.
(iii) A ttitudes to the em ergence of new  biotechnological techniques: 
A ttitudes to the em ergence of new  biotechnological techniques w ere 
very  sim ilar to those expressed by  established incum bents. The 
em erging firm  appreciated the po ten tial of advanced  biotechnological 
techniques b u t em phasised the salience of public perception  issues in 
dictating their use and  adoption  in the food industry .
6.2.2 In ferred  Response.
Results indicate that the response of established incum bent firm s is 
very  sim ilar to the aggregate response of all firm s interview ed. It m ay
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be assum ed thus that following the technological d iscontinuity  caused 
by  the em ergence of new  biotechnological techniques these firm s are 
'D oing nothing ' or 'M onitoring only'. A nalysis of resu lts regard ing  the 
identified em erging firm  how ever indicated  a firm  w ith  a superior 
technological capacity to use the techniques to th a t of established 
incum bents bu t yet not as advanced as dedicated com panies. Strategies 
used  to becom e involved in R&D w ere sim ilar to those used  by  
established incum bents, if form ally m ore novel, as w ere attitudes.
If w e accept that this com pany has been m isclassified as an  em erging 
com pany as defined by H am ilton - created to exploit new  
biotechnological techniques, and is m ore correctly defined as a h igh 
technology com pany based on biotechnology (for reasons outlined in 
the preceding section) it is easier to analyse it's response to the 
em ergence of new  biotechnological techniques. The firm is no t yet 
involved w ith  new  biotechnological techniques, yet it has the 
technological capacity to use them , it has used  novel strategies in the 
p ast to becom e involved in R&D and  expresses sim ilar attitudes to the 
em ergence of new  biotechnological techniques as established 
incum bents. From this inform ation it is reasonable to assum e that this 
firm  is also m onitoring the techniques follow ing their em ergence and  
m ay or m ay not becom e involved in  the future. If how ever a decision 
w as m ade to become involved adoption  m ight be m ore expedient in  
this firm  com pared w ith  established incum bents due  to it's superio r 
technological capacity. Results show  the com pany can envisage a 
scenario em erging w here it m ight becom e involved if the technologies 
afforded advantage to activities.
6.3 The Inferred Response of Firms Involved w ith H igh Volum e 
Low Value Production and those Involved w ith  Low V olum e  
H igh Value Production.
Literature accessed has h ighlighted the applicability of new  
biotechnological techniques to the w ork  of low volum e h igh  value
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food ingredient suppliers as com pared w ith  h igh  volum e low value 
food processors w ho m ay use the techniques second h and  in the 
purchase of genetically engineered ingredients for use. In  the 
judgem ental census of food firms identified as po ten tial early  adopters 
of new  biotechnological techniques, 28 h igh volum e low  value food 
processors w ere identified and 9 low volum e h igh  value ingredient 
supp ly  firms. The sam ple achieved included 6 low  volum e h igh  value 
supp ly  firm s and 21 h igh volum e low  value food processors.
Table 6.1 Sam ple A chieved - H igh  V olum e Low V alue Food
Processors and  Low V olum e H igh  V alue S upp ly  Firm s.
No. of Firm s
H igh volum e Low  value Food Processors 21
Dairy 10
B rew ing 2
Fish and  M eat 2
Bakery 3
M iscellaneous 4
L ow  Volume, High Value Supply Firms 6
Ingred ien ts 5
P lant breeding 1
T otal 27
6.3.1 A nalysis of D eterm inants of Response.
In this section presentation is m ade of the sim ilarities and  differences 
no ted  in  the trends of response of firm s involved w ith  h igh  volum e 
low  value p roduction  and  those involved  w ith  h igh  value low 
volum e production. A nalysis of resu lts perta in ing  to the latter is 
h am pered  due to the poor response rate am ong such com panies and  
findings should  be treated  w ith  caution.
(i) Technological capacity to use techniques: C rosstabulation analysis
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revealed the technological capacity of high volum e low  value food 
processors w as not significantly different to that indicated  by  all firms 
in terview ed. On the other hand  only tw o h igh  value low  volum e 
ingred ien t firms indicated that they operate a form alised R&D 
d epartm en t in Ireland, tw o undertake R&D overseas, one is 
un involved  in R&D and one refused to give details of R&D staff. 
(A ppendix (D) Table 5.1.1) Those w ho operated  R&D departm ents in 
Ire land  em ployed sim ilar num bers of scientific staff as h igh  volum e 
low  value processors. Staff w ere indicated to be m ore academ ically 
qualified  in  the R&D departm ents of h igh value low  volum e 
ingred ien t firms. Details w ere not recorded of overseas R&D 
departm en ts although, as noted respondents indicated  overseas 
departm ents tended to be large and well staffed. L iterature has indicated 
the applicability of new  biotechnological techniques or Level 3 use to 
such firms. Findings indicated how ever, sim ilar use sophistication 
am ong h igh  value low  volum e supply  firms as h igh  volum e low 
value food processors. (Level 2) No difference w as no ted  betw een the 
R&D spend  of high volum e low value processors and  h igh  value low 
volum e supply  firms. Both groups benefit from  governm ent support to 
the Irish  food industry . Results show  supply  firm s rem ain  uninvolved  
w ith  State science and  technology program s w hereas considerable 
involvem ent was indicated  am ong high volum e low  value processors.
The technological capacity of h igh  value low volum e supply  firm s w as 
indicated  thus as very  sim ilar to that of h igh  volum e low  value 
processors. The form er tended  to em ploy a greater p roportion  of m ore 
academ ically qualified staff b u t indicated less involvem ent w ith  State 
science and  technology program s to the latter.
(ii) Strategies for involvem ent in R&D: Findings indicated  high 
volum e low  value supp ly  firm s used  slightly m ore novel strategies for 
invo lvem ent in R&D than  h igh  volum e low  value food processors.
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Supply firms tended  to indicate m ore involvem ent w ith  strategies such 
as purchase of technology and joint program s w ith  firms and 
universities. H igh  value low  volum e supp ly  firm s also represented  
one th ird  of those w ho anticipated sourcing future p roducts th rough  
basic research.
(iii) A ttitudes to the em ergence of new  biotechnological techniques: It 
w as in the exploration of this the last identified determ inant of food 
firm s' response to the technological d iscontinuity  caused by  the 
em ergence of new  biotechnological techniques that the greatest 
differences w ere no ted  betw een the response of h igh  volum e low value 
processors and h igh  value low volum e ingred ien t supp ly  firms. Low 
volum e high value supp ly  firms d id  not attach the equal im portance to 
the public perception issues dictating fu ture adoption  and  use of new  
biotechnological techniques as h igh  volum e low  value processors.
This difference in a ttitude w as particu larly  ev iden t in the exploration 
of attitudes w ith  regard to the greatest perceived barrier to use of new  
biotechnological techniques and suggestions for rem edies to possible 
adverse consum er reaction to gene-technology foods. For supply  
com panies the greatest barrier to use w as no t as indicated for processors 
the possible adverse reaction of consum ers to gene-technology foods 
b u t ra ther the perceived lack of benefits inherent in  the techniques use. 
Also w hen  asked for suggestions to possible adverse consum er reaction 
supp ly  firms gave answ ers such as
"if its not broken don 't fix it."
Two h igh  value low  volum e supp ly  firm s m aintained  th a t adverse 
consum er reaction h ad  no t been  noted and  should  no t be anticipated. 
A nalysis of findings w ould  indicate that the attitudes of h igh value low 
volum e supply  firm s tow ards the em ergence of new  biotechnological 
techniques tend  to stem  from  the functional aspects of these 
technologies and the relative advantages of use. The po ten tia l of the
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techniques w as appreciated as by high volum e low value processors b u t 
a com parable em phasis no t attached to public perception  issues 
affecting adoption.
6.3.2 Inferred Response.
Inferring a response to the technological d iscontinuity  caused by the 
em ergence of new  biotechnological techniques th ro u g h  an appreciation  
of the three identified determ inants of response is difficult for h igh 
value low  volum e supply  firm s due to the poor response rate to 
questions posed. In particu lar the response to questions concerned 
w ith  m easurem ent of technological capacity w as poor. H ow ever, the 
findings indicate responden t firms, have sim ilar technological capacity 
to h igh  volum e low value processors, use slightly  m ore novel 
strategies for involvem ent in  R&D and are m ore involved  w ith  basic 
research than  processors. Such firms also express a m ore functional 
attitude to new  biotechnological techniques and  do no t attach equal 
im portance to public perception issues as d ictating use. W ithout 
fu rther investigation of the technological capacity of such firm s it is 
difficult to state conclusively their response to the em ergence of new  
biotechnological techniques. In  particular research needs to conducted 
on  the capacity of R&D departm ents overseas to use new  
biotechnological techniques as m any firms indicated they benefit from  
the w ork  of these departm ents.
W ith  the lim ited inform ation  available it is hypothesised  h igh  value 
low  volum e supp ly  firm s have m ore involvem ent w ith  new  
biotechnological techniques than  food processors. The determ inants of 
response indicate such firm s are involved w ith  basic research an 
im portan t prerequisite  for the developm ent of an  em erging 
technology, R&D personnel tend to be m ore academ ically qualified 
then  those em ployed by processors, the perceived risk associated w ith  
involvem ent is no t as great for these firms as processors due to the
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lack of im portance attached to issues of public perception  and finally 
results presented earlier indicated m any food processors believe 
ingred ien t supply  firms are using advanced gene-technologies. U sing 
D aly's fram ew ork of options available to firm s follow ing a 
technological d iscontinuity  it m ay be hypothesised  th a t low  volum e 
h igh  value ingredient supply  firm s are m oving from  a strategy of 
'M onitoring only' to 'Participation in som e m anner'. H ow ever, in  the 
absence of m ore detailed  inform ation it is im possible to state w hat 
level of partic ipation ind iv idual firms are pursu ing . A nalysis of results 
perta in ing  to h igh  volum e low  value processors indicates a sim ilar 
response to that no ted  for all firms interview ed. U sing Daly's options 
such  firms m ay be categorised as 'Doing nothing ' or 'M onitoring only'. 
It is interesting to note that m any high volum e low value processors 
indicated  they felt they m ight be using new  biotechnological techniques 
second hand  in ingredients purchased. In total 86% of processors 
asserted  that they purchase h igh  value low  volum e ingredients, thus 
the response of such supply  firm s w ill directly affect the response of 
low  value h igh  volum e processors.
6.4 The Inferred  R esponse of Those Selected for In terv iew  Because 
of Evidenced Prior In terest and  Those Selected D ue to a Large 
T u rn o v er.
The researcher's objective in choosing the sam ple w as to obtain a 
judgem ental census of potential early adopters of new  biotechnological 
techniques in the Irish food industry . To achieve this the sam ple w as 
chosen using  three lists. Two of the lists identified food firms w ith  a 
p rev ious in terest in  new  biotechnological techniques, the th ird  
identified food firms in  decreasing order of turnover. In  this section 
p resen tation  is m ade of the differences and  sim ilarities in the inferred  
response noted betw een firm s w ho had  evidenced to the researcher a 
p rio r in terest in new  biotechnological techniques and  those chosen for 
in terv iew  solely by  v irtue  of a large turnover. The sam ple achieved
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included 12 firms w ho had  evidenced to the researcher a p rio r in terest 
in new  biotechnological techniques and  15 firms chosen solely by 
v irtue  of turnover.(Table 4.2)
6.4.1 Analysis of Determinants of Response.
(i) Technological capacity to use techniques: C rosstabulation of 
evidence of in terest in new  biotechnological techniques by the various 
indicators of technological capacity reveals few significant findings. 
Those w ho had evidenced to the researcher a p rio r in terest in the 
techniques indicated sim ilar R&D staffs em ployed, sim ilar use 
sophistication of biotechnology and sim ilar R&D spends as those w ho 
w ere chosen for interview  solely by v irtue of their tu rnover. H ow ever, 
in  analysis of firms' curren t and in tended  involvem ent w ith  State 
science and  technology program s, results indicated, as m ight be 
anticipated, firms m ost involved w ere those w ho h ad  evidenced an 
in terest in the techniques. 71% of those involved in  State science and 
technology program s had  evidenced a p rio r in terest in  new  
biotechnological techniques and  these firm s represen ted  66% of those 
w ho anticipated fu tu re  involvem ent. A part from  increased 
involvem ent in science and technology p rogram s no ted  w ith  regard  to 
those firms w ho had  evidenced a p rio r in terest in new  biotechnological 
techniques, a relationship w as no t indicated betw een  evidence of 
interest in the techniques and  technological capacity to use them.
(ii) Strategies for involvem ent in R&D: A nalysis of strategies for 
involvem ent in R&D by evidence of in terest in new  biotechnological 
techniques d id  not reveal any new  findings. Sim ilar strategies, 
sourcing m ethods and R&D spend allocations w ere indicated by bo th  
groups of respondent firms.
(iii) A ttitudes to the em ergence of new  biotechnological techniques: 
A nalysis of firms attitudes to the em ergence of new  biotechnological 
techniques did  reveal some interesting findings w ith  regard  to the
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differences of opinion held  by those w ho h ad  evidenced a prior in terest 
in new  biotechnological techniques and those w ho h ad  not. As noted  
in C hapter 5 those com panies w ho had  evidenced to the researcher a 
p rio r in terest in new  biotechnological techniques w ere m ore likely to 
feel that; advanced biotechnological techniques w ill im pact on the food 
industry  b u t futuristically (post 2000), the sector of greatest potential 
im pact will be the D airy sector and that gene-technology food and 
drinks should  be labelled as such. (85%) O n the o ther hand  com panies 
identified as potential early adopters b u t w hich h ad  no t evidenced a 
p rio r interest in new  biotechnological techniques d id  no t reach a 
consensus as to the predicted im pact of advanced biotechnological 
techniques on the food industry , did not identify  a single m ost 
im portan t sector of im pact and w ere d iv ided  as to the m erit of 
labelling gene-technology foods. Those w ho had  evidenced a prior 
interest w ere also m ost likely to envisage a scenario presenting itself 
w hich m ight result in them  becom ing involved w ith  the techniques 
(76%) com pared w ith  50% of those chosen for in terview  solely by 
v irtue of a large turnover. If one assum es th a t those w ho evidenced to 
the researcher a p rio r in terest in new  biotechnological techniques are 
the m ost know ledgeable it is evident that the inform ed view  is that 
new  biotechnological techniques w ill have an  im pact on the Irish food 
industry  b u t futuristically - post 2000, that the sector of greatest 
potential im pact is the D airy sector and gene-technology food and 
drinks should  be labelled as such. C rosstabulation of evidence of 
interest in new  biotechnological techniques by  o ther attitudes 
m easured  d id  not reveal any new  findings. Similar attitudes w ere 
expressed by  bo th  groups.
6.4.2 Inferred Response.
A nalysis of determ inants of response to the technological d iscontinuity  
caused by  the em ergence of new  biotechnological techniques revealed 
significant differences in the response of firm s w ho had  evidenced a 
p rio r in terest in  the techniques and those w ho h ad  not. Results
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show ed th a t those w ho had evidenced a prior interest w ere m ost likely 
to be involved w ith  State science and technology program s and w ere 
m ost likely to agree as a group that the techniques w ould  im pact on the 
food industry  bu t futuristically - post 2000, that the sector of greatest 
potential im pact w ill be the Dairy sector and that gene-technology food 
an drinks should  be labelled as such. These firm s w ere also indicated 
as m ost likely to becom e involved in the future. Those chosen for 
interview  solely by v irtue of tu rnover on the other hand  w ere unlikely 
to be involved in State science and technology program s and could no t 
reach a consensus regard ing  any issue concerned w ith  the fu ture use of 
new  biotechnological techniques in the food industry . Using Daly's 
series of options available to firms following a technological 
d iscontinuity  it is reasonable to assum e firms w ho had  evidenced to 
the researcher a p rio r interest in new  biotechnological techniques are 
'M onitoring only'. They are m ost know ledgeable about the techniques 
and  have becom e involved in State science and  technology program s. 
Those firm s chosen for interview  by  v irtue of tu rnover are indicated as 
'D oing nothing '. Results indicate these firm s are less know ledgeable 
about the techniques and  rem ain un involved  in basic state sponsored  
science and  technology program s.
6.4 Summary of Findings.
Findings indicate th a t the aggregate response of all identified potential 
early adopters in terview ed to the technological discontinuity  caused b y  
the em ergence of new  biotechnological techniques m ay be inferred as 
'D oing no th ing ' or 'M onitoring only'. Explanations for food firm s' 
continuing  un invo lvem ent w ith  the techniques w ere taken from  the 
literature accessed. Research has show n adoption  and  diffusion of new  
technologies in industry  is a decreasing function of the perceived risk 
of involvem ent, the size of investm ent requ ired  for involvem ent and  
the increased technical skills necessary for use. Findings indicated all of 
the above factors have contributed to retarded  diffusion of new  
biotechnological techniques in the Irish food industry . Findings also
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indicated the relative advantage afforded th rough  use of new  
biotechnological techniques w as no t apparen t to food firms 
in terview ed and this had  also contributed to re tarded  diffusion and  
adoption  of the techniques. Analysis of the response of established 
incum bents and the em erging firm  in terview ed resu lted  in the 
recategorisation of the em erging firm  as a h igh  technology com pany. 
D etailed exploration of this firm 's technological capacity to use the 
techniques highlighted the fact that it could no t be accurately described 
as an em erging firm as defined by H am ilton - created to exploit new  
biotechnological techniques. The inferred response of established 
incum bents w as 'Do nothing ' or 'M onitor only ' and  the h igh 
technology com pany interview ed w as indicated as 'M onitoring 
only'.
Exploration of the response of h igh value low  volum e supply  firm s 
w as ham pered  due to the poor response rate to questions posed. 
H ow ever, th rough  an appreciation of the determ inants of response, 
and  other background inform ation it w as hypothesised tha t such firm s 
m ay be m oving from  a m onitoring strategy to 'Participation in  som e 
m anner'. The response of h igh  volum e low value food processors w as 
indicated as 'Do noth ing ' or 'M onitoring only'. F indings h igh ligh ted  
the fact tha t 86% of such com panies use high value low  volum e 
ingredients in m anufacture, therefore the response of low volum e, 
h igh  value ingredient supp ly  firms has a direct im pact on the response 
of processors. Analysis of the difference and  sim ilarities in  the 
responses of those w ho had  evidenced to the researcher a p rio r in terest 
in  new  biotechnological techniques and  those w ho h ad  no t indicated 
that those w ho had  evidenced an in terest w ere m ost correctly 
categorised as 'M onitoring only'. Those chosen for in terview  solely by 
v irtue of a large tu rnover w ere m ost accurately categorised as 'D oing 
n o th in g '.
182
References.
1. D aly P. (1985), The Biotechnology Business - A  Strategic Analysis, 
Frances Pinter Ltd., London, p p .107-108.
2. H am ilton W.F. (1990), "The D ynam ics of Technology and  Strategy", 
European Journal o f Operational Research, vo l.47,p p .141-152.
3. M ullen  D. (1990),Innovation through biotechnology in Healthcare 
and Food and Drink companies in Ireland, (u n p u b lish ed  MBS thesis 
D ublin City University.)
4. W ebster jr. F.E. (1969), "New P roduct A doption  in Industria l M arkets 
- A Fram ew ork for Analysis", Journal of Marketing, vol.33., no.3, July, 
pp  .35-39.
5. M ansfield E. (1968), Industrial Research and Technological 
Innovation:An Econometric Analysis. Longm an, G reen & Co.,
London, p .204.
6. W ebster, op.cit., p .35-39.
7. U tterback J.M. (1974), "Innovation in  Industry  and the D iffusion of 
technology", Science, vol.183, February 15, p p .620-626.
8. H am ilton, op.cit., p .141-152.
9. ibid.
183
Chapter 7 Conclusions and Recom mendations.
7.0 Introduction.
C onclusions and recom m endations are p resen ted  u n d er four headings. 
Initially conclusions are presented  specific to each of the three 
determ inants investigated; technological capacity to use new  
biotechnological techniques, strategies for involvem ent w ith  R&D, 
and a ttitudes to the em ergence of new  biotechnological techniques. 
Finally, conclusions and recom m endations are presented  relating to 
responses inferred  for firms interview ed.
In analysing the following conclusions it m ust be acknow ledged that 
they w ere reached through  the investigation of firms identified as 
potential early adopters of new  biotechnological techniques. The 
extent to w hich the conclusions can be generalised or said to apply  to 
the 800 rem aining firms in the Irish  food sector is unknow n. 
R espondents represent the leading edge and  are identified potential 
innovators w ith  regard  to use of new  biotechnological techniques in 
the Irish food sector. O ther firm s particu larly  non-technology 
perform ing com panies m ight perform  very differently  in response to 
the em ergence of new  biotechnological techniques.
It is recom m ended that non-technology perform ing firms be included 
in  any fu tu re  investigations. As ingredients p roduced  through 
advanced  biotechnological techniques becom e increasingly available 
the techniques' im pact will no longer be confined to technology 
perform ing  com panies. Firms w ill no t have to use the techniques to 
becom e involved. Technology and  non-technology perform ing 
com panies alike will be obliged to m ake a decision regard ing  inclusion 
of genetically engineered com ponents in  their food products. Research 
is recom m ended to investigate possible sim ilarities and  differences in
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the decision processes of those considering involvem ent th rough  use 
and , alternatively , those considering involvem ent th rough  inclusion 
of genetically engineered ingredients in production . Technology 
perform ing firms identified as potential early  adopters th rough  use 
w ere the focus of this research.
7.1 Technological Capacity to Use N ew  Biotechnological 
Techniques.
Technological capacity was identified as the p rim ary  determ inant of 
response. Food firms' perform ance on this determ inan t indicated 
their ability to use the techniques. Indicators of technological capacity 
used  in the study were; size and skill profile of R&D staff, use 
sophistication of biotechnology in m anufacture and  R&D, R&D spend  
as a percentage of sales and current and  in tended  involvem ent w ith  
State science and technology program s. From  the investigation of size 
and  skill profile of R&D departm ents it m ay be concluded:
Identified potential early adopters of new  biotechnological 
techniques have sim ilar R&D staff profiles as all technology 
perform ing Irish food firms.
R&D staffing levels per un it of p roduction  are sim ilar in Irish 
food firms as European food firms.
Taken in absolute figures Irish food firms do no t em ploy 
sufficient R&D personnel to create a 'critical m ass' necessary for 
the developm ent of new  biotechnological techniques.
R&D personnel em ployed by Irish and  E uropean food firm s are 
severely underqualified  com pared w ith  those em ployed by 
dedicated new  biotechnology firms.
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Use of the scoring system  revealed that Irish identified early 
adopters w ere ranked th ird  on this indicator of technological 
capacity. (Table 7.0)
The size and skill profile of R&D staffs em ployed by  Irish food 
firm s are insufficient to use advanced biotechnological 
techniques.
Table 7.0 Performance Rankings on First Indicator of
Technological Capacity: R&D Staff, Size and Skill 
Profile.
1. Firm s dedicated to the exploitation of 
new  biotechnological techniques.
5 points
2. E uropean food firms. 3 points
3. Irish  food firms identified as potential
early  adopters of new  biotechnological 2 points.
techniques.
Conclusions relating to the investigation of use sophistication of new  
biotechnological techniques are as follows:
The m ost popular level of b iotechnology use in m anufacture 
am ong Irish food firms identified as potential early  adopters of 
new  biotechnological techniques is Level 2. This level of use 
corresponds loosely to techniques available in advance of the 
developm ents associated w ith  new  biotechnological techniques.
The m ajority of firms in terv iew ed anticipate using  Level 2 in 
m anufacture to the year 2000. Use of m ore advanced techniques 
is no t anticipated.
Level 2 is m ost com m only used  in m anufacture by the
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International food processing sector.
Level 1 (use of basic or classical biotechnological techniques) 
and  Level 2 use is m ost favoured in R&D although  three firm s 
anticipate using Level 3 or advanced biotechnological techniques 
in  R&D in  the year 2000.
A belief exists in the food industry  that selected ingredients 
purchased  m ay be produced using  advanced biotechnological 
m ethods or Level 3.
Firm s dedicated to the exploitation of new  biotechnological 
techniques are by  definition using advanced biotechnological 
techniques or Level 3 in m anufacture and  R&D.
Biotechnology use sophistication of Irish and  E uropean food 
firm s is equal although basic com pared w ith  that used by new  
biotechnology firms.(Table 7.1)
Table 7.1 Performance Rankings on Second Indicator of 
Technological Capacity: Use Sophistication of 
Biotechnology.
1.Firm s dedicated to the exploitation 
of new  biotechnological techniques.
5 points
2.E uropean food firms. 2 points
2.1rish food firms identified as potential
early adopters of new  biotechnological 2 points
techniques.
From  the investigation of R&D spend  it m ay be concluded:
The m edian R&D spend for Irish firms is 0.3% taken as a 
percentage of sales.
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The R&D spend of European food firms is indicated as twice 
that of Irish food firms.
The R&D spend for dedicated new  biotechnological com panies 
ranges from  46.3% to 126.7% taken as a percentage of sales.
The R&D spend of Irish firms identified as potential early 
adopters is low com pared w ith  European  firm s b u t m inim al 
com pared w ith  dedicated new  biotechnology firms.(Table 
7.2)
Table 7.2 Perform ance R ankings on T h ird  Ind icator of 
Technological Capacity: R&D Spend.
1. Firm s dedicated to the exploitation 5 points
of new  biotechnological techniques.
2. European  food firms. 1 po in t
3. Irish food firms identified as potential
early adopters of new  biotechnological 0.5 points.
techniques.
The follow ing conclusions em erged from  investigation  of firms' 
cu rren t and  in tended  involvem ent w ith  State science and  technology 
program s:
State support for the Irish food industry  is h igh  com pared w ith  
o ther European  countries.
Low  levels of partic ipation  are indicated am ong food firm s in  
particu lar and the Irish private sector in general w ith  State 
science and  technology program s.
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Irish  firms benefit from  sim ilar levels of State su p p o rt for the 
developm ent of new  biotechnological techniques as their 
E uropean  com petitors.
G enerous governm ent su p p o rt of the Irish food industry  
coupled  w ith  uniform  E uropean support to the developm ent of 
new  biotechnological techniques resu lted  in  the  m axim um  
allocation of 5 points to identified potential early  adopters on 
this indicator of technological capacity.(Table 7.3)
State support is an im portan t factor contributing to increased 
technological capacity for potential early adopters of new  
biotechnological techniques in the Irish food industry .
Table 7.3 Perform ance R ankings on F ourth  Ind icator of
Technological Capacity: Use of State Science and  
Technology Program s.
1. Firm s dedicated to the exploitation 
of new  biotechnological techniques.
5 points
1. Irish food firms identified as potential
early  adopters of new  biotechnological 5 points.
techniques.
2. E uropean food firms. 3.5 p o in t
It is recom m ended th a t research should  be undertaken  to explore 
m ethods of increasing the partic ipation  rate of p riva te  com panies in 
State science and technology program s. In  the p rogression  of new  
biotechnological techniques, involvem ent in State science and  
technology program s could be an invaluable asset for food firms. 
Research w hich  identified m ethods of increasing partic ipa tion  and 
satisfaction w ith  State run  program s m ay be instrum ental in  the fu ture 
developm ent and use of new  biotechnological techniques. For the
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p urposes of com parison partic ipation rates in  State science and 
technology program s w ere assum ed equal am ong E uropean  and  Irish 
food firms.
A ssim ilation of scores and rankings on ind iv idual indicators p resen ted  
in  Table 7.4 lead to the following overall conclusions regard ing  
technological capacity:
Table 7.4 Technological Capacity of Irish and European Food Firms 
to Use N ew  Biotechnological Techniques.
Size and Skill Use of 
Profile of N ew  
R&D staff Biotechnological 
techniques
R&D
Spend
Use of 
State
Resources
Total
Irish food firms. 2 2 0.5 5 9.5
European food firms. 3 2 1 3.5 9.5
Firms dedicated to 
the exploitation of
new  biotechnological 
techniques.
5 5 5 5 20
European food firms com m and sim ilar technological capacity 
to use new  biotechnology firm s as Irish food firm s identified as 
potential early adopters of the techniques.
E uropean and  Irish food firm s need considerable up g rad in g  of 
their respective capacities in  order to use new  biotechnological 
techniques.
D edicated new  biotechnological firms record far superior 
perform ance on three of the four indicators of technological 
capacity as com pared w ith  Irish  and E uropean food firms.
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In  using technological capacity as a p rim ary  indicator of 
response, it m ay be concluded that both  Irish and  E uropean food 
firm s are incapable of using the techniques and  have no t yet 
responded in any positive sense.
That E uropean firm s are sim ilarly indicated as incapable of using the 
techniques implies that an opportun ity  exists for Irish firm s to bu ild  
technological capacity in tandem , if not in advance, of such firm s and 
perhaps benefit from  first m over advantages. H ow ever, results 
indicate a significant increase in technological capacity is not 
anticipated by firms interview ed thus it m ay be p resum ed  identified 
potential early adopters do no t anticipate using the techniques in the 
future. O n the other hand  factors w hich m ay influence their decision 
on possible fu ture direct involvem ent, or m ore probable indirect 
involvem ent include the regu latory  env ironm ent and  public 
perception  issues. Conclusions reached relating to the investigation of 
these issues are p resented  in the following sections.
F u ture  research is recom m ended to involve prim ary  investigation of 
identified potential early adopters of new  biotechnological techniques 
in  the European food industry. Secondary data used  in  this study  
w hich  described the activities of E uropean food related industries in 
general m ay have d ilu ted  the perform ance of potential early adop ter 
E uropean food firms on ind iv idual indicators.
7.2 Strategies for Involvem ent w ith R&D.
The second identified determ inant of response investigated w as 
strategies for involvem ent w ith  R&D. The follow ing conclusions 
em erged:
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The m ost popu lar m ethod of sourcing new  products is applied  
research and  will rem ain so to the year 2000.
The vast m ajority of the research b u d g e t is spen t on in-house 
d ev e lo p m en t.
A diverse range of strategies have been used  and  are anticipated 
to becom e involved w ith  R&D.
Strategies ou tlined  for involvem ent w ith  R&D indicate an  em phasis 
on in-house applied  research w hich precludes any involvem ent w ith  
advanced biotechnological techniques. R&D u n d ertak en  owes m ore to 
p ro d u ct testing procedures than  fundam ental or basic research w ith  
food. Strategies explored in this study w ere those used  to become 
involved w ith  R&D generally. L iterature ou tlined  the particular 
strategy patterns associated w ith  involvem ent w ith  new  
biotechnological techniques. It is recom m ended th a t fu ture research is 
un d ertak en  w hich investigates this phenom enon  in  an Irish context. 
A nticipated  adverse consum er reaction how ever m ay  create difficulties 
in  the recruitm ent of firms w illing to speak about strategies specific to 
po ten tia l involvem ent w ith  new  biotechnological techniques.
7.3 A ttitudes to the Em ergence of N ew  B iotechnological 
Techniques.
This w as the final determ inant of response investigated , conclusions 
are p resen ted  below.
66% of respondents felt new  biotechnological techniques w ould  
have an im pact on the food industry  b u t w ere at variance in 
term s of w hen  and  to w hat extent. 28% felt the techniques 
w ou ld  have no im pact on their industry .
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Sectors of greatest potential im pact w ere identified as Dairy, 
Brewing, Ingredients and A nim al and  P lant breeding.
The greatest barrier to use was identified as anticipated 
consum er resistance.
54% of respondents could envisage a scenario arising in  w hich 
they w ould becom e involved w ith  the techniques. 28% ru led  
o u t the possibility of becom ing involved.
The regu latory  environm ent governing  developm ent and use 
of new  biotechnological techniques w as indicated  as irrelevant 
to the w ork of Irish food firms.
Respondents w ere d ivided as to the m erit of labelling gene - 
technology foods. 58% w ere in favour, 33% against.
R espondents indicated a num erical risk assessm ent of food and  
drink  produced  th rough advanced biotechnological techniques 
as 2 (low risk) and  their estim ate of consum ers' risk assessm ent 
w as 8 (high risk).
78% of those in terview ed anticipated an adverse consum er 
reaction to gene-technology food and  drink.
The m ost popu lar rem edy suggested to com bat possible adverse 
reaction w as education.
R espondents appreciate the po ten tia l of new  biotechnological 
techniques for their industry  bu t are also aw are of the possible 
public perception problem s use of the techniques m ight incur.
Investigation of a ttitudes indicated the uncertain ty  w hich su rrounds
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fu tu re  use of new  biotechnological techniques. Research is 
recom m ended to track consum er attitudes to gene-technology food and  
d rink  into the future. This is of particular im portance as products 
becom e m ore available and the public is m ade m ore aw are of the 
im plications of use. Research will indicate w hether experts' 
anticipation of adverse reaction is accurate. C onsum er response to 
gene-technology food and drinks is of equal im portance both  to those 
firm s considering involvem ent th rough  use and  those considering 
indirect involvem ent by  purchase of gene-technology ingredients. 
Research is also recom m ended to investigate consum er attitudes to 
labelling of gene-technology foods. Experts are d iv ided  as to the m erits 
of labelling. D etailed exploration of consum ers view s m ay aid 
generation of appropriate  regulations.
L iterature accessed indicated that w ith  increasing aw areness of new  
technologies comes increasing concern.i In 1989 aw areness of 
b iotechnology w as found to be very low am ong Irish  adults.2 In the 
absence of w idespread  m edia debate it is reasonable to assum e this 
level of aw areness rem ains. Ireland thus is the perfect setting in  w hich 
to investigate this phenom enon th rough  the  im plem entation  of a 
long itud inal s tudy  tracking aw areness and  concern into the future.
A final recom m endation  for research stem s from  an  identified 
s treng th  of the Irish  food industry; our green and  environm entally  
clean im age.3 Research is recom m ended to investigate w hether fu ture 
involvem ent w ith  new  biotechnological techniques m ight enhance or 
discredit this perception of Irish produced food and  drinks. The results 
of this research w ould  be of particular in terest to food firms developing 
into new  com petitive m arkets and increased value-added  production . 
A lthough, literature accessed indicated the existence of a trend  tow ards
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increased technological inpu t in food p roducts 4 the m erits of the 
techniques' use m ust be w eighed against possible a ttendan t public 
perception problem s. It is recom m ended that responsibility  for this 
research m ight be taken by the State and results used  to develop a 
com prehensive policy for fu ture industry -w ide involvem ent w ith  new  
biotechnological techniques. An agreed policy regard ing  involvem ent, 
w hether th rough  use or second hand th rough  ingredients purchased, 
m ust be p u t in place if the green and environm entally  clean im age of 
Irish products is in  any danger. The pace w ith  w hich products are being 
developed th rough  use of new  biotechnological techniques necessitates 
that this research be undertaken  as soon as possible. Decisions on the 
inclusion of genetically engineered com ponents in  food products 
w hich m ay have far reaching consum er percep tion  consequences are 
been  taken in the p resen t tim e dim ension.
7.4 Responses Inferred.
Through an appreciation of firms' perform ance w ith  regard  to the 
three identified determ inants of response exam ined a p attern  of 
response w as inferred for those firms in terview ed. Patterns of 
response w ere categorised according to Daly and H am ilton fram ew orks
of strategy available following a technological discontinuity .5 It m ay be 
concluded:
The general response of food firms in terview ed to the
em ergence of new  biotechnological techniques has been to 'Do
N othing ' or 'M onitor only'.
Firms have not the technological capacity to use the techniques and 
use applied  research for involvem ent in R&D. A lthough  they are 
aw are of the potential of new  biotechnological techniques for their 
industry , anticipation of adverse public reaction discourages 
involvem ent. Factors identified as re ta rd ing  involvem ent and use are
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the perceived risk associated w ith adoption  due to anticipated adverse 
consum er reaction, the size of investm ent requ ired  to build  
technological capacity to use new  biotechnological techniques, and  the 
fact that relative advantage afforded th rough  use for m any is as yet 
unclear.
Particular groups of firm s w ere identified as p u rsu ing  slight 
m odifications on this general p attern  of response. Evidence of p rio r 
interest in the techniques w as indicated as an im portan t factor 
d iscrim inating  betw een  'M onitoring' or 'Do no th ing ' strategies.
Results indicated  those w ho had  evidenced a p rio r in terest w ere m ore 
know ledgeable about the techniques and also m ost likely to be 
involved in  State science and technology program s thus indicating a 
'M onitoring' strategy. O n the other h and  those w ho had  no t 
evidenced any prio r interest in the techniques tended  to be 
un involved  w ith  State science and technology program s and w ere 
often confused regard ing  the potential applications of new  
biotechnological techniques in the food sector. Such firm s w ere 
indicated thus as 'Doing nothing'. It m ay be concluded thus:
Firm s w ho had  evidenced to the researcher a p rio r in terest in 
the techniques are pu rsu ing  a 'M onitoring' strategy and  those 
w ho had  no t are 'Doing nothing '.
P roduction  activities w ere also hypothesised  as a discrim inating factor 
d ictating response. Findings indicate h igh  value low  volum e supp ly  
firm s have sim ilar technological capacity as h igh  volum e low  value 
processors, use slightly  m ore novel strategies for involvem ent w ith  
R&D and  are m ore involved w ith  basic research than processors. M ost 
im portan tly  how ever, they express a m ore functional a ttitude to new  
biotechnological techniques than  processors and do not attach equal 
im portance to public perception issues discouraging use. D ue to the
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poor response rate am ong this sector it is im possible to state w ith  any 
degree of accuracy their response to new  biotechnological techniques. 
H ow ever it is hypothesised that these firms are m oving from  a 
'M onitoring' strategy  to 'Participation in som e m anner'. The 
follow ing indicators of increasing involvem ent form  the basis for this 
hypothesis:
(i) Processors feel such firms m ay be involved.
(ii) The techniques have prim ary application in the ingredient sector.
(iii) R&D personnel em ployed in low volum e h igh  value firm s tend  to 
be m ore skilled than  those em ployed in o ther Irish food firms.
(iv) F indings indicated m ore involvem ent w ith  basic research 
necessary for the developm ent of an em erging technology and  less 
im portance attached to public perception issues discouraging use 
am ong these firms. It is hypothesised thus that:
H igh  value low volum e ingred ien t supply  firm s are 
m oving from  m onitoring to a strategy of 'Participation in  som e 
m anner'. Low value high volum e processors are indicated as 
'D oing noth ing ' or 'M onitoring only'.
Firm  status w as not indicated as a discrim inating factor dictating 
response. Established incum bents w ere indicated as involved w ith  
'M onitoring 'and  'D oing no th ing1 strategies and the em erging  firm  
based on  technologies available in  advance of new  biotechnological 
techniques w as indicated  as ’M onitoring’. Research is recom m ended 
to identify an em erging new  biotechnology firm  in  the Irish food 
industry  and  to track it’s developm ent.
Established incum bent firm s are undertak ing  'M onitoring ' or 
'Do nothing ' strategies and  the em erging firm  in terv iew ed 
although better qualified to use the techniques than  established 
firm s is also involved in  a 'M onitoring ' strategy.
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It m ay be concluded thus responses of identified potential early 
adopting food firms m ay be divided in to three b road  categories. Those 
w ho are 'Doing nothing ' in  response to the techniques, those w ho are 
'M onitoring only' and  those w hich are hypothesised  as m oving from  a 
'M onitoring' s trategy  to 'Participation in  som e m anner'.
Conclusions indicate that for m ost potential early adopters identified 
in  the Irish food industry  use of new  biotechnological techniques is 
neither anticipated nor desired. Such firm s only anticipate possible 
fu ture involvem ent 'second hand ' th ro u g h  the use of genetically 
engineered ingredients. The sole group for w hich possible fu ture  
direct use was indicated w ere h igh value low  volum e ingredient 
supply  firms. It is recom m ended that fu ture research studies are 
tailored to the ind iv idual requirem ents of direct or indirect use. The 
research requirem ents of direct users w hich  include h igh  value low  
volum e ingredient suppliers are estim ated as greater than  those 
anticipating indirect involvem ent. In add ition  to consum er reaction 
to gene-technology food and  drinks w hich  m ay influence their derived  
dem and curve, such firms need to be aw are of the optim um  strategies 
to becom e involved w ith  new  biotechnological techniques and  
m ethods to increase technological capacity. In an  Irish  context research 
is recom m ended to investigate the po ten tial m arket for gene- 
technology ingredients. Recently the report of the expert food group 
highlighted  the po ten tia l of the ingredient industry  for the Irish  food 
sector.6 D etailed exploration of this m arket characterised by derived  
dem and m ay indicate the profitability  of involvem ent w ith  and  use of 
new  biotechnological techniques for such firms. Subject to a finding 
indicating grow ing dem and for gene-technology ingredients research is 
recom m ended to undertake a detailed  investigation of the 
technological capacity of low  volum e h igh  value ingredient firm s and 
their strategies to becom e involved in  R&D com pared w ith  dedicated  
firm s and  sim ilar firm s active overseas. Exploration of technological
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capacity and  optim um  strategies used  to becom e involved w ith  new  
biotechnological techniques w ould  also be of interest to em erging new  
biotechnology firms.
The research interests of indirect users how ever are m ore basic as these 
firm s are prim arily  concerned w ith  consum er reaction to food p roducts 
containing genetically engineered com ponents. Relevant research 
studies have been recom m ended previously  and  include 
investigations of consum er aw areness and  response and the 
im plications for the perceived im age of Irish produced  food products.
Research undertaken  in this s tudy  outlined an  industry  to w hich new  
biotechnological techniques m ay be applied. It m ay be concluded that, if 
the products of biotechnology are to be used in this industry  they w ill 
be p roduced  elsewhere. Possible fu ture direct involvem ent is only 
anticipated  by  low volum e, h igh  value ingredient firms. The m ajority 
of Irish food firm s rem ain un involved  w ith  the techniques and  do not 
foresee direct involvem ent in  the future. Irish food firm s are 
indicated  as m arket rather than  technology driven.
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Appendices.
Appendix (A)
Theme Sheet.
Topic 1. Current use of advanced biotechnological techniques in 
the Irish food industry.
Probes: Use in  food processing.
Use in  p rim ary  food production  - anim al & plant.
O w n C om pany involvem ent.
Specific instances of use know n.
Industry  u se /u se  in  industry  support lab.s.
Topic 2. Potential of new biotechnological techniques for the Irish 
food industry.
Probes: Time fram e of potential use.
Sector's of greatest potential.
(i) Food ingredients.
(ii) P rim ary food production.
(iii) Food processing sectors.
Potential for industry .
Potential for industry  support lab.s.
O w n com pany potential use.
Topic 3. Consumer issues.
Probes: Food com panies m arket or technology driven.
Im portance of consum er issues.
Labelling.
M ethods to com bat adverse reaction.
Issues involved w ith  m edical and  food use.
Ethical issues.
Topic 4. Regulatory environm ent.
Probes: Directives 219/220.
Im portance of regulations for developm ent and  use. 
Labelling.
Intellectual p roperty  law  (Europe and  the US).
Topic 5. Food industry personnel
Probes: Skills and  education  profile of scientific staff.
(i) in  industry
(ii) in  industry  su p p o rt lab.s
M otivation of scientific staff in  industry  and  in  industry  
support lab.s.
A vailability of h ighly  skilled scientific personnel.
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Probes: Industry R&D facilities.
State support R&D facilities.
Spending on  R&D in food industry.
Industry involvement in State science and technology 
programs.
Importance of R&D for food industry.
State funding of basic and applied research.
Industry use of State support R&D facilities.
Topic 6. Research and development activities.
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Appendix (B)
Strategic Research & Development
college of marketing & design, dublin 1. phone (01) 363000 ext. 65.
FOR THE ATTENTION OF THE R&D DIRECTOR, THE QUALITY CONTROL 
M ANAGER OR THE TECHNICAL MANAGER.
address
08:10:1992
D ear Mr. X,
The food sector is very im portan t to Irish industry. This fact has recently been 
publicly recognised by the Industrial Policy Review G roup headed  by Mr. Jim 
Culliton. For food firms to retain the N atural A dvantage they now  possess 
m any experts recom m end g row th  through technology developm ent, 
particu larly  in the area of food science and  technology.
A survey is proposed. The objective of this survey w ill be to assess leading 
food firm s current involvem ent w ith  Technology D evelopm ent and  their 
fu ture p lans if any, to becom e involved. I w ish  to invite you  to participate in 
this research. Learning of your experiences w ith , and  opinions on technology 
developm ent w ould  greatly  benefit m y studies. The investigation w ill be 
und ertak en  th rough  use of a telephone survey. The topics for discussion are 
detailed  in  the questionnaire enclosed. I w ou ld  appreciate if you could scan 
this docum ent, in  p reperation  for m y call.
The inform ation  w hich you p rov ide w ill be treated  as confidential and  no 
effort w ill be m ade to trace details to particu lar respondents. Trend data only 
w ill be recorded. Participating firms w ill be fo rw arded  a copy of the results 
w hen  available. The research w ill be p resen ted  in  fu lfillm ent of the 
requ irem ents of an  M.B.S. degree.
I look fo rw ard  to speaking to you. Please expect a telephone call from  me in  
the next few days.
Yours sincerely,
C lare K avanagh
Post-Graduate Research Room, C.O.M.A.D., Mountjoy Sq., Dublin 1.
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QUESTIONNAIRE.
SECTION 1. PRODUCTS AND R&D
Q ue.l In the food sector, what products and/or services do you produce? 
Dairy Foods 
Meat and Fish Products 
Bakery Products j
Brewed and Distilled Products 
Confectionary and Other Food Products 1
Que. 2 H ow  do you normally source your products? Please indicate the percentage of 
product acquisition /  line improvement which is currently the result of each of the 
follow ing activities. Please also record, in the space provided, the expected situation  
in the year 2000.
1. licensing
NOW YEAR 2000
2.Basic Research
3.Applied Research
4.Company Acquisition
5.Contract R&D
6.Joint Ventures
Que. 3 Please complete the following table indicating an approximate of the 
percentage of turn-over which is currently spent on Resesarch and Development, the 
proposed spend in 2000 and the spend in 1985.
1985 N ow  2000
% of Turnover
3
Que. 4 Please divide this R&D spend, in terms of the proportion allocated to In-House 
Development, Joint programs with Firms or Universities, Purchase of Technology 
/licensing and Contract R&D.
In-House Development
1985 Now 2000
Joint Program with Firms/Universities
Purchase of Technology/licensing
Contract R&D
Que.5 Please complete the following table indicating the size and skill profile of 
your Irish R&D work force now, in 1985 and in the year 2000.
Base Country NUMBERS
R&D DEPT. 1985 NOW 2000
SCIENTIFIC HIGHER DEGREE 
GRADUATES
MARKETING GRADUATES
SCIENTIFIC DEGREE GRADUATES
CHEESE MAKERS -( SKILLED)
SCIENTIFIC DIPLOMA GRADUATES
TOTAL R&D STAFF
TOTAL COM PANY STAFF NUMBERS.
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Que.6 The following two tables list internal and external corporate strategies that 
you may have used in order to become involved in R&D. Please indicate those with  
which you have been involved and those which you intend becoming involved and 
your reasons for selection of these strategies.
INTERNAL STRATEGIES:
Strategies undertaken Intended Strategies
HIRE NEW STAFF
TRAIN EXISTING STAFF
BUILD FACILITIES
ACQUIRE FIRM
OTHER
F.XTF.RN AT STRATFGTFS:
Strategies Undertaken Intended Strategies
CONTRACT R&D
JOINT
PROGRAMME
WITH ACADEMIC
LAB.
JOINT
PROGRAMME
WITH OTHER
FIRM
Que.7 Have you ever been involved in any Science Developm ent programs?
YES - Give Details - (State Agency involved, Benefit - monetary or otherwise) 
N o - Give Reasons.
Que.8 Do you intend becoming involved in any Science Developm ent Programs in the 
future?
Give Details.
Que.9 Do you purchase food additives or ingredients for manufacture?
YES goto Que.10 
N O  gotoQ u e.ll
Que.10 What technologies are used in the production of these products?
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SECTION 2. BIOTECHNOLOGY
Que. 11 Thinking of the advances made in biotechnology recently, w hat level of this 
technology are you currently using in manufacture and in  research and development, (if 
any) and where do you envisage working in the year 2,000.
I have divided the continum  of progress into three general areas. Please tick the boxes 
which you feel best describe the level at which you w ork w ith biotechnology.
MANUFACTURE R &D(if any)
NOW  YEAR NOW YEAR 
2000 2000
1 .TRADITIONAL BIOTECHNOLOGY:BREW ING  
W INE, YOGURT, FERMENTED MILKS, CHEESES [  
BIOYOGURTS(USE OF PROBIOTICS) COTTAGE  
CHEESES A N D  ORGANIC FOODS. BASICALLY, 
BIOTECHNOLOGICAL TECHNIQUES FOR 
DEVELOPING USEFUL PRODUCTS BY TAKING  
A D V A N TA G E  OF NATUR AL BIOLOGICAL 
ACTIVITIES
2 .FUN CTIO NA L FOO D INGREDIENTS
-  U SING  CHARACTERISED INGREDIENTS 
TO CONTROL PROPERTIES OF FOOD  
PRODUCT eg flavours, fat substitutes, low  calorie 
options.etc ALSO IN C LU D ED  HERE ARE 
TRADITIONAL PRODUCTS W HICH ARE 
PRO DU CED  W ITH A  BETTER 
U N D E R ST A N D IN G  N O W  OF THE PROCESS 
OF M A NU AC TU R E ESPECIALLY 
FERM ENTATION TECHNIQ UES A N D  
D O W N STR E A M  PRO CESSING.
3 .M O D ER N  BIOTECHNOLOGY W H ICH  W ITH  
THE DISCOVERY OF RECOM BINANT D N A  
TECHNIQUES A N D  OF CELL FUSION H A S  
LEAD TO A  RADICAL ACCELERATION OF 
PROGRESS A N D  TO A  MULTIPLICATION OF 
BOTH TOOLS A N D  APPLICATIONS.
TECHNIQ UES USED HERE MIGHT BE:
(I) .GENETIC ENG INEERING
(II) .HYBRIDOM A TECHNOLOGY-CELL FU SIO N  
(IE).BIOPROCESS TECHNOLO GY
(IV) .PROTEIN ENGINEERING
(V ).BIO INFO RM A TICS  
EXAMPLES INCLUDE THE USE OF 
BIOLOGICAL PRIODUCTS A S NATURAL  
FOO D PRESERVATIVES (BACTERIOCINS), 
DIAG NO STICS FOR C O N TA M IN A N TS A N D  
FOO D SPOILAGE O R G A N ISM S,- THESE C A N  
BE D N A  PROBE BASED OR M ONOCLONAL  
A NTIBO DY BASED-, GENETIC ENGINEERING  
FOR STRAIN IM PROVEM ENT A N D  PRO DU CTIO N  
OF CROPS W ITH N EW  CHARACTERISTICS-
eg  bruise resistant tom atoes.
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SECTION 3. ATTITUDES
Que. 12 W hat do you think the impact of advanced biotechnological techniques such 
as genetic engineering will have on the Irish food and Drink industry to the year 2000?
Que.13 O n which sector in the Food and Drink industry will the impact of these 
techniques be the strongest?
Que. 14 In terms of the barriers preventing the continued and future use of genetically 
engineered food and drink, what for you would be the most im portant barriers?
Que. 15 Do you feel the regulations in Ireland encourage or disencourage work in this 
area?
Que. 16 How do you feel consumers will react to genetically engineered food and drink 
products?
Que.17 On a scale of one to te n , where one denotes no risk and ten denotes unacceptably 
high risk please indicate your risk assessment of food and drink produced through 
advanced biotechnological methods, including genetic engineering.
Que. 18 On the same scale of risk, using your experience in the marketplace please 
estimate consumers risk assessment of food and drink produced through advanced 
biotechnological techniques.
Que. 19 Do you feel genetically engineered food and drink products should be labelled 
as such?
Que. 20 How do you feel possible adverse consumer reaction to genetically 
manufactured food and drinks should be dealt with?
Que. 21 Do you intend becoming involved with genetically engineered food and drink in 
the future?
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Appendix (C)
Questions taken from Cogan&McGovern study. (1984)
Que. 5. Indicate the size and skill profile of your workforce at startup and at 
the end of your last trading year.
Start.- up, Present
Professional
Technical 
Non Technical
Technician
Production
Other
Que. 7. Indicate the expenditure that has been made (in man years/£) in the 
development of high technology based products/services.*
Year 1 Year 2 Year 3 Year 4
In house product 
developm ent
In house process 
developm ent
Purchase of technology
Other
*Give approximate proportions if absolute values are not available.
Que. 8. Indicate revenues derived from high technology based 
products/services.*
Year 1 Year 2 Year 3 Year 4
In house product 
developm ent
In house process 
development
Purchase of technology
Other
*Give approximate proportions if absolute values are not available
Source: C ogan D.J. and  M cG overn B. (1984), The Nature and Needs of 
High Technology Industry. E ducation, Innovation  and  
E n trep reneursh ip  Research Program m e, Dublin.
1
List of Strategies for Involvem ent w ith  Biotechnology 
com piled by  Dibner.(1987)
TABLE 1 - THE PROS AND CONS 
OF VARIOUS CORPORATE STRATEGIES
Strategy
A. In ternal
1. H ire new  staff
2. Train existing staff
3. Build facilities
4. A cquire b iotech firm
B External
1. Joint p rogram  w ith  
academ ic lab
2.Joint p rogram  w ith  
biotech firm  
("partnering")
Pros
Gets expertise in-house 
Fam iliar w ith  
co rporation  
Necessary step for 
in terna l developm ent. 
Gets expertise in-house
Gets patent rights; 
T rain ing :Inexpensive
M ultip le partners; 
Project focus;Products to 
m arket;Shared  risk
Cons
S low
M ay not be easy to 
tra in ; slow 
Costly; slow
V ery costly;lim ited 
to firm 's focus
Key people can 
leave. P roprietary  
risk
Lim it to profits; 
L im it to 
agreem ents
Source: D ibner M.D. (1987) "Corporate Strategies for involvem ent w ith  
B iotechnology", Biofutur, Juillet, A out, p .47.
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Appendix (D)
Table 5.1.1 Type of Company by Number of Persons Employed in R&D 
Department. (1992)
STAFF NUMBERS
1 2 4 5 6 8 10 12 16 20 R& D N O N O TOTAL
ELSE R&D A N S
WHERE
FIRM TYPE
ESTABLISHED 1 2 3 1 1 1 1 1 2 2 3 3 21
FIRM S 4.8% 9.5% 143% 4.8% 4.8% 4.8% 48% 4.8% 95% 9.5% 143% 143% 77.8%
50% 50% 60% 75%
EMERGING 1 1
FIRM S 100% 4%
50%
INGREDIENT 1 2 1 1 5
FIRM S 20% 40% 20% 20% 18.5%
50% 40% 25% 100%
Table 5.4.5 R&D Expenditure in Food Related Industries by Source of 
Funds. (1987)
Business G overnm ent Other Funds Total
Enterprise National From
Abroad
Belgium 1480.5(96%) 58.6(4%) A A 1539.1
Denmark 293.0(92%) 14.0(4%) 6.9(3%) 4.2(2%) 318
France 1019.2(87%) 33.5(3%) 4.1 (.5%) 118.0(10%) 1174.8
Germany 322.0(97%) 11.0(3%) A A 333
Greece 215.8(99%) 1.8(1%) A A 217.6
Ireland 12.411(89%) 1.490(11%) .002(0%) .027(0%) 13.93
Italy 60427.0(94%) 3691.0(6%) A A 64118
Japan 192248(99%) 1028.0(1%) A A 193276
Spain 3796.4(99%) 31.0(1%) A A 3827.4
UK(1985) 109.9(89%) 4.1(3%) A 9.2(8%) 123.2
Source: Basic Science and Tecnologi/ Statistics (1991), OECD.
Table 5.6.2 Sourcing of new  Products - Companies involved with High Value Low Volume
Production. (1992, 2000)
Licensing Basic Research Applied Research Contract R&D Joint Venture
1992 2000 1992 2000 1992 2000 1992 2000 1992 2000
Firm 1 No R&D currently or anticipated in the year 2000
Firm 2 100% 100%
Firm 3 R&D currently and anticipated overseas.
Firm 4 15% 15% 70% 50% 15% 35%
Firm 5 100% 70% 10% 20%
Firm 6 20% 100% 80%
Base: All Companies involved with high value low volume production.
Table 5.6.6 Allocation of R&D spend - Companies involved with High Value Low Volume
Production. (1985,1992, 2000)
In-House Joint Program Purchase of Contract
Development Firm /Uni Technology R&D
1985 1992 2000a 1985 1992 2000a 1985 1992 2000A 1985 1992 2000a
Firm 1 No R&D currently or anticpated in the year 2000.
Firm 2 o o o o Vp 0^ O o 0^ >
(overseas)
Firm 3 R&D currently and anticipated overseas.
Firm 4 10% 100% 70%A
<1OCOoON
Firm 5 100% 50% 50%A 50% 50%A
Firm ò 100% 100% 100%A
BaseiAll Companies involved with high value low volume production.
Figure 5.7 Predicted Food Sector of Impact by Basis for Selection,
Evidence of Interest in New Biotechnological 
Techniques or Turnover.
None 
Don't know 
Plant&Animal 
Ingredients 
Misc 
Fish&Meat 
Brewing 
Bakery 
Dairy
r0 1 0  2 0 3 0
Prior Interest 
Turnover
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"Biotechnology refers to the application of scientific and engineering 
principles to the processing of materials by biological agents to provide 
goods and services. This term is understood to exclude biomedicine 
and agriculture excepting those areas which now involve the 
application of cellular or molecular biology."
Definition of biotechnology used in, Mullen D. (I990)lnnovation 
through biotechnology in Healthcare and Food and Drink companies 
in Ireland, (unpublished MBS thesis, Dublin City University.)
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